

WORLD WITHOUT CANCER

New edition
Revised and
updated



Actual
Laetrile
crystal

The Story of Vitamin B₁₇

by G. Edward Griffin

ADDITIONAL COPIES OF THIS BOOK

Single copy: \$17.50*

For shipping and insured US delivery add \$5.50

2 to 11 copies: \$14.00 each*

For shipping and insured US delivery add \$7.50 for 2 copies or \$8.50 for 3 copies. We pay shipping on 4 to 11 copies.

Case purchases, 20 books per case:

\$210.00 per case (\$10.50 per book)

For shipping and insured US delivery add \$18.70 per case.

California residents add 7 ¼ % sales tax.

Outside the US: Call for shipping charges.

Place your order with

AMERICAN MEDIA

Post Office Box 4646

Westlake Village, CA 91359-1646

For immediate service, order by phone.

Call toll-free: (800) 595-6596

Orders may also be placed over the Internet at
www.realityzone.com

***These prices are guaranteed through December 31, 1999.
After that date, please contact us for verification.**

WARNING!

The purpose of this book is to marshal the evidence that cancer is a nutritional-deficiency disease. It is not caused by a bacterium, virus or mysterious toxin but by the *absence* of a substance that modern man has removed from his diet. If that analysis is correct, then the cure and prevention of cancer is simple. All that needs to be done is to restore that easily obtained and inexpensive food factor to our daily meals.

This is an exciting theory. It holds the promise for a world without cancer *now*, not at some distant point in the future, and it would mean that the billions of dollars spent each year on research and medical treatment could be redirected to more happy pursuits. Of course, it also would mean that the million-or-so professionals now gainfully employed in the cancer-research, cancer-therapy, and fund-raising industries would rapidly be out of work. This is where the plot becomes interesting, because these are the same people to whom we have turned for expert opinion regarding the validity of Laetrile, nutritional therapy.

It should not be surprising that these experts have rejected the vitamin-deficiency concept of cancer. There is nothing in it for them. Not only would a world without cancer lead to pay-check shock, it also would represent a blow to professional prestige. Imagine: a cure for cancer found in the seeds of fruits, not in research laboratories, and discovered by people without government grants or prestigious diplomas hanging on their walls!

Organized medicine has spoken. Laetrile is quackery, it says, and is derided as an "unproven" cancer treatment. However, let us take a closer look at that word. For most people, *unproven* means simply that there is no proof. But what is proof? It is not an absolute concept. In the strict sense, there is no such thing as proof; there is only evidence. If evidence is convincing to the observer, then it is said to be proof, and the thesis which it supports is viewed as "proven." If a second observer finds the same evidence to be *unconvincing*, then it is *not* proof, and the thesis is "unproven" to that observer.

As we shall see in the pages that follow, there is a great deal of evidence supporting the nutritional-deficiency concept of cancer—more than enough to convince most people that the thesis is proven. But the word *proven*, when used by the FDA, has an entirely different meaning. It is a technical definition. When the

FDA says a therapy is *proven*, it means only that its promoters have complied with the testing protocols set by the agency to demonstrate safety and effectiveness. It is important to know, however, that the successful completion of those tests does not mean, as the terminology implies, that the therapy is safe and effective. It merely means that tests have been conducted, the results have been evaluated, and the FDA has given its approval for marketing, often *in spite of* the dismal results.

If cancer patients undergoing these FDA-*proven* therapies were to read the actual laboratory reports, they would recoil in horror. They show neither safety nor effectiveness and, in fact, they are not intended to do so. Their purpose is to establish the lethal dose—the point at which the therapy will kill 50% of the patients—and also to establish the ratio between those who are benefited and those who are not. That ratio often is in the range of only eight or nine people out of a hundred. Furthermore, “benefited” can mean any slight improvement such as a temporary reduction in tumor size. It almost never means a complete cure. If anything is “proven” by these studies, it is that most FDA-approved cancer therapies are both *unsafe* and *ineffective*.

Then there is the question of money. The testing protocols established by the FDA are costly. The promoters of a new therapy must assign a large staff of technicians and compile many thousands of statistical pages. The complete reports often weigh hundreds of pounds and stack over six feet in height. The process can take years and consume over two-hundred-million dollars per study.

Only the large pharmaceutical companies can play that game. (Although they publicly complain about this expense, they privately approve, because it prevents competition from smaller companies.) The potential reward of getting a new product into the world market is well worth the investment. But who would be willing to spend that kind of money on developing a product that cannot be patented? *Substances found in nature cannot be patented*; only those which are invented by man. If a company were to spend two-hundred-million dollars to obtain FDA approval for a natural substance, its competitors then would be able to market the product, and the developer could never recover the investment.

Therefore—and mark this well—as long as the present laws remain, the only substances that ever will be “approved” for cancer therapy will be proprietary. No substance from nature will

ever be legally available for cancer or *any other* disease unless its source can be monopolized or its processing can be patented. No matter how safe and effective it may be, and no matter how many people are benefited, it will forever be relegated to the category of "unproven" therapies. As such, freely available cures from nature will always be illegal to prescribe, to promote, and in many cases even to use.

It is partly for these reasons that the following warning and disclaimer is offered. But even without that background, it is only common sense that cancer victims should be encouraged to exercise great caution when selecting their therapy. Be advised, therefore, that *Laetrile is, officially, an unproven cancer treatment. The author of this book is a researcher and writer, not a physician. The facts presented in the following pages are offered as information only, not medical advice. Their purpose is to create the basis for informed consent. Although there is much that each of us can do in the area of prevention, self-treatment for clinical cancer is not advised. The administration of any cancer therapy, including nutritional therapy, should be under the supervision of health-care professionals who are specialists in their fields.*

WORLD WITHOUT CANCER

The Story of Vitamin B₁₇

Second Edition

by G. Edward Griffin

American Media

Fourteenth printing: April 1999
Thirteenth printing: April 1998
Twelfth printing: January 1997
Eleventh printing: August 1980
Tenth printing: July 1978
Ninth printing: July 1977
Eighth printing: December 1976
Seventh printing (hardbound) June 1976
Sixth printing: June 1976
Fifth printing: May 1976
Fourth printing: January 1976
Third printing: June 1975
Second printing: March 1975
First printing: December 1974

Second edition: January 1997
First edition: December 1974

Copyright © 1997 and 1974 by G. Edward Griffin
All rights reserved

Published by American Media
Post Office Box 4646
Westlake Village, California 91359-1646

Library of Congress Catalog Card Number: 96-84094

International Standard Book Number
(ISBN): 0-912986-19-0

Printed in The United States of America

DEDICATION

This book is dedicated to the memory of Dr. Ernst T. Krebs, Jr., and John A. Richardson, M.D. When confronted by the power and malice of entrenched scientific error, they did not flinch. While others scampered for protective shelter, they moved to the front line of battle. May the telling of their deeds help to arouse an indignant public which, alone, can break the continuing hold of their enemies over our lives and our health.

A NOTE OF APPRECIATION AND GRATITUDE

The material in this volume could not have been assembled without the help and guidance of many others. I am indebted to the late Dr. John Richardson for his persistent hammering away on the significance of vitamin therapy until it finally began to penetrate into this thick skull; and to my wife, Patricia, who, for several months prior, had attempted to arouse my curiosity on the subject. I will always be indebted to the late Dr. Ernst T. Krebs, Jr., for his patience and thoroughness in explaining and re-explaining so many scientific matters. I am grateful to Bruce Buchbinder, Ralph Bowman, Malvina Cassese, Frank Cortese, George Ham, Grace Hamilton, Jim Foley, Mac and Idell Hays, Pokie Korsgaard, Sanford Kraemer, Dr. J. Milton Hoffman, Maurice LeCover, Bob Lee, Betty Lee Morales, Beverly Newkirk, John Pursely, Julie Richardson, Bob Riddel, Lorraine Rosenthal, Alice Tucker, Lloyd Wallace, M.P. Wehling, Kimo Welch, Melinda Wiman, Ann Yalian, and others too numerous to mention for their strong encouragement, endless patience, and tangible support.

TABLE OF CONTENTS

PART ONE THE SCIENCE OF CANCER THERAPY

FOREWORD	15
--------------------	----

Chapter 1. THE WATERGATE SYNDROME	21
---	----

Examples of dishonesty and corruption in the field of drug research; a close look at the first major study which declared Laetrile (vitamin B₁₇) "of no value;" proof that the study was fraudulent; the FDA's ruling against the use of Laetrile because it had not been tested; and the refusal then to allow anyone (except its opponents) to test it.

Chapter 2. GENOCIDE IN MANHATTAN	37
--	----

Continued attempts by the cancer industry to prove that Laetrile is worthless; the suppressed lab reports from the Sloan-Kettering Institute which proved that Laetrile does work; the Rockefeller connection to the pharmaceutical industry; the story of how a group of employees at Sloan-Kettering leaked the truth to the outside world.

Chapter 3. AN APPLE A DAY	53
-------------------------------------	----

A review of entrenched scientific error in history; the vitamin-deficiency concept of cancer as advanced in 1952 by Dr. Ernst T. Krebs, Jr.; and a survey of the evidence both in nature and in history to support that concept.

Chapter 4. THE ULTIMATE TEST	63
--	----

A look at the many cultures around the world that are, or have been, free from cancer; and an analysis of their native foods.

Chapter 5. CANCER: THE ONRUSH OF LIFE	75
---	----

An explanation of the trophoblast thesis of cancer; a description of a simple urine test for cancer; an appraisal of BCG vaccine as an anti-cancer agent; and a review of the vital role played by the pancreas in the control of cancer.

Chapter 6. THE TOTAL MECHANISM 85

The nutritional factor as a back-up mechanism to the enzyme factor; a biographical sketch of Dr. Ernst T. Krebs, Jr., and his development of Laetrile; the beneficial secondary effects of vitamin B17 on a wide range of human disorders; and an appraisal of the complexity of nature's total natural anti-cancer mechanism.

Chapter 7. THE CYANIDE SCARE 95

A newspaper account of a couple who reportedly were poisoned by eating apricot kernels; a close look at the facts in this case; an evaluation of the toxic potential of seeds containing B17; and the clinical evidence that Laetrile is less toxic than sugar.

Chapter 8. THE LAETRILE "QUACKS" 105

The names, professional standings, medical achievements, and clinical findings of some of the more prominent doctors who endorse Laetrile; the beneficial side-effects produced by its use; a suggested anti-cancer diet; and a brief description of vitamin B15.

Chapter 9. "UNPROVEN" CANCER CURES 115

Clinical evidence in support of the trophoblast thesis; laboratory experiments showing that Laetrile kills cancer cells; and case histories of terminal cancer patients who attribute their recovery to the effect of Laetrile.

Chapter 10. "PROVEN" CANCER CURES 137

The effects of surgery and radiation in the treatment of cancer patients; a comparison showing that those who receive no treatment at all live just as long, if not longer, than those who are treated.

Chapter 11. A NEW DIMENSION OF MURDER 151

Anti-cancer drugs shown to be ineffective and cancer-causing; FDA-approved experiments on humans resulting in death from drugs rather than from cancer.

Chapter 12. A STATISTICAL COMPARISON 165

The inherent weaknesses of all cancer statistics; the need for statistical comparisons in spite of those weaknesses; a comparison of the results obtained by orthodox and Laetrile physicians; and the consequences of consensus medicine.

PART TWO

THE POLITICS OF CANCER THERAPY

Chapter 13. CARTELS—ESCAPE FROM COMPETITION 177

A review of the science of cancer therapy; a summary of the politics of cancer therapy; the early history of the I.G. Farben chemical and pharmaceutical cartel; the cartel's early success in the United States; and its "marriage" with DuPont, Standard Oil, and Ford.

Chapter 14. THE ULTIMATE MONOPOLY 193

Early examples of cartel support for totalitarian regimes; I.G. Farben's role in lifting Hitler out of political oblivion and converting the Nazi state into an instrument of cartel power.

Chapter 15. WAR GAMES 203

Germany's industrial preparations for World War II; the continued support by American industrialists given to Farben and to the Nazi regime during this period; and the profitable role played by Ford and ITT in war production for both Nazi Germany and the United States.

Chapter 16. CONSPIRACY 211

Efforts to camouflage Farben ownership of firms in America; the assistance rendered by Rockefeller interests; penetration into the U.S. government by agents of the cartel; and the final disposition of the Farben case.

Chapter 17. THE ROCKEFELLER GROUP 227

A biographical sketch of John D. Rockefeller, Sr., and his crusade against free-enterprise; the beginning of Standard Oil; the entry of the Rockefellers into investment banking; their influence in the pharmaceutical industry and international politics.

Chapter 18. THE CHARITY PRESCRIPTION 247

The drug cartel's influence over the nation's medical schools; the drug-oriented training given to all medical students; and the use of philanthropic foundations to obtain control over educational institutions.

Chapter 19. HE WHO PAYS THE PIPER 261

The low state of medical education in the U.S. prior to 1910; the role of the Flexner Report in dramatizing the need for reform; the role played by the Rockefeller and Carnegie foundations in implementing the Flexner Report; and the use of foundation funding as a means of gaining control over American medical schools.

Chapter 20. HE WHO CALLS THE TUNE 269

AMA influence over the practice of medicine in America; how the leadership of the AMA keeps control away from its members; AMA funding by the drug industry; and examples of interlock between the two.

Chapter 21. THE PROTECTION RACKET 277

Cartel agents in the FDA and other agencies of government; the CFR as a control structure over U.S. foreign policy; scientific ineptitude at the FDA; and the growth of FDA power.

Chapter 22. THE ARSENAL OF COMPLIANCE 293

Government harassment of the nutrition and vitamin industry; the role played by the media in discrediting Laetrile in the public mind; and a comparison of the cost of Laetrile therapy with that of orthodox cancer treatments.

Chapter 23. THE DOUBLE STANDARD 303

An analysis of the FDA's double standard in which harmless non-drug materials such as vitamins and food supplements are burdened with restrictions in excess of those applied to toxic and dangerous drugs.

Chapter 24. TO WALK THE HIGHEST WIRE 315

How doctors are intimidated into not using Laetrile; why the pharmaceutical industry seeks a patentable substitute for Laetrile; and the courageous stand against the FDA and AMA by Laetrile doctors.

Chapter 25. A QUESTION OF MOTIVES 329

What has motivated opposition to Laetrile therapy; the "limited" vs. "total" conspiracy theories; and the grass-roots backlash as a force for change.

Chapter 26. A WORLD WITHOUT CANCER 349

Areas of need for further research with vitamin B₁₇; how the Laetrile controversy differs from medical controversies of the past; an analogy of biological and political cancer; and a scenario in which both will be conquered together.

First Photo Section 129–136

Second Photo Section 239–246

Bibliography 359

Index 362

FOREWORD

A great deal of drama has been enacted on the cancer stage since the first edition of this book was published. While it is true that many of the original actors have been replaced by their understudies, the plot of the play has not changed. This is the outline of that drama.

Each year, thousands of Americans travel to Mexico and Germany to receive Laetrile therapy. They do this because it has been suppressed in the United States. Most of these patients have been told that their cancer is terminal and they have but a few months to live. Yet, an incredible percentage of them have recovered and are living normal lives. However, the FDA, the AMA, the American Cancer Society, and the cancer research centers continue to pronounce that Laetrile is quackery. The recovered patients, they say, either had "spontaneous remissions" or never had cancer in the first place.

If any of these people ultimately die after seeking Laetrile, spokesmen for orthodox medicine are quick to proclaim: "You see? Laetrile doesn't work!" Meanwhile, hundreds of thousands of patients die each year after undergoing surgery, radiation, or chemotherapy, but those treatments continue to be touted as "safe and effective."

The average cancer patient undergoing Laetrile therapy will spend between \$5,000 and \$25,000 for treatment. That is a lot of money, but it is peanuts compared to the astronomical bills charged by conventional medicine. Yet they never tire of complaining that Laetrile doctors are greedy quacks and charlatans who profiteer from the sick and the frightened.

That is a classic case of accusing your opponent of exactly what you yourself are doing. It is common today for an elderly couple to give their entire life savings to a medical center and a battery of attending physicians and technicians, all in the vain hope of saving the husband or wife from cancer. Even their house may have to be sold to pay the bills. And the maddening part is that, in most cases, the doctors *know* there is no chance of long-term success. But the surviving spouse is seldom told that.

The next time you hear a spokesman for orthodox medicine condemn those greedy, money-grubbing Laetrile doctors, watch him as he goes to the parking lot. Chances are, he'll drive off in his new Jaguar.

The only real difference between the controversy today and when it began in the 1970s is that the media has lost interest in it. The sparsity of coverage has created the false impression that Laetrile has fallen into disfavor, but nothing could be further from the truth. The number of patients using Laetrile today continues to run in the thousands.

It has been suggested that the mass media have decided to ignore Laetrile because, when it did receive national publicity, it became popular. People decided to give it a try in spite of the negative press. If they had been told they were going to die anyway, why not? And the clinics in Mexico thrived. Another reason may be that, although the controversy continues, there is nothing *of substance* that is really new. Each unfolding event is merely an extension of forces and arguments that have preceded.

For example, in 1977, the parents of Chad Green kidnapped their own son and took him to Mexico to avoid being forced by officials in Massachusetts into giving him chemotherapy for his leukemia. They preferred nutritional therapy instead. This is part of the heavy price we pay for allowing government the power to decide what is best for us and our families. When special-interest groups become politically strong enough to write the laws, then it is *those groups* that tell us what to do—all in the name of protecting us, of course. The Chad Green story made big headlines but, unfortunately, the same thing involving other children has happened numerous times since then but with only minor news coverage.

In 1980, movie actor Steve McQueen also made news when he went to Mexico for Laetrile and other unorthodox therapies. When he died following surgery four months later, the press had a heyday telling the American people that Laetrile didn't work. What they failed to report is that McQueen's cancer was, indeed, apparently cured by Laetrile, and that only a non-cancerous tumor remained in his abdomen. (Most tumors are composed of a mixture of cancer and non-cancerous tissue.) McQueen was feeling great and decided to have the bulge removed for cosmetic reasons only. It was a complication of *that* surgery, not cancer, which caused his death. Not a word of his prior recovery was to

be found in the major press. Consequently, millions of Americans who followed the story came away with the conviction that Laetrile is just another hoax. That, too, is merely an extension of the kind of biased media reporting that has become a permanent part of the coverage of Laetrile. It continues today.

The most notable example of continuity has been the so-called scientific tests conducted by the nation's largest cancer-research centers to establish if Laetrile works or is a hoax. Both the Mayo Clinic and the Memorial Sloan-Kettering Cancer Center played conspicuous roles in this particular act. The evidence of foul play that rose from the smolders of the data debris left behind is so shocking and conclusive that I have created an entire new chapter in this edition to showcase it. If you read nothing else in this book, read that section for sure. It will change your view of the integrity of American medical research, to say the least. But even that was a continuation of pseudo science enlisted in defense of economic vested interest that was well established in the early 70s.

So, although many events have happened since this book was first published, the basic story remains the same. Unfortunately, to bring it up to date has required an amazingly small amount of revision. It is still bad news for freedom-of-choice in cancer therapy.

It was during the summer of 1971 that I first remember hearing the word Laetrile. The late Dr. John Richardson and I were sharing a short vacation in Oregon attempting to enjoy the natural beauties of that state. I say *attempting* because the good doctor, who was an extremely intense person, had brought his briefcase with him. It was not loaded with fishing gear. In fact, it yielded an almost endless supply of correspondence, research papers, and books all on the unlikely subject of "L-mandelonitrile-beta-glucuroniside in the Treatment of Human Cancer."

At first, I had about as much interest in this topic as in learning about internal stresses in the construction of girder bridges. Undoubtedly, these are fascinating subjects to the physician and the engineer whose professions are wrapped around the minutiae of related theory and formula. But to me, the lush green forest and the babbling stream were objects infinitely more worthy of my attention, and I'm sure that my impatience had begun to show. But my determined companion continued with all the persistence of a bulldog with a fresh hold on a seat of pants. And he insisted that I read the first draft of a manuscript he

had prepared with the possibility of submission for magazine publication.

In the course of reading that manuscript, I became aware for the first time that, although there was overwhelming evidence that vitamin therapy is effective in the treatment of cancer, apparently there were powerful forces at work to prevent this fact from being known. Reacting as most people do when they first hear this assertion, I remember asking skeptically, "Who are *they*, John? Who on earth would want to hold back a cure for cancer?"

With the asking of that question, my interest finally had been aroused and, even though I wouldn't have believed it at the time, I was already embarked upon a course of inquiry that was to lead to the uncovering of one of the most amazing stories of the twentieth century. The ambitious purpose of this book is to present at least the highlights of that story and to answer the question "Who are *they*, John?"

G. Edward Griffin

Part One

THE SCIENCE OF CANCER THERAPY

Chapter One

THE WATERGATE SYNDROME

Examples of dishonesty and corruption in the field of drug research; a close look at the first major study which declared Laetrile (vitamin B₁₇) "of no value;" proof that the study was fraudulent; the FDA's ruling against the use of Laetrile because it had not been tested; and the refusal then to allow anyone (except its opponents) to test it.

This year 550,000 Americans will die from cancer. One out of three of us will develop cancer in our lifetime. That is eighty-eight million people in the United States alone.

The purpose of this study is to show that this great human tragedy can be stopped *now* entirely on the basis of existing scientific knowledge.

We will explore the theory that cancer, like scurvy or pellagra, is a deficiency disease aggravated by the lack of an essential food compound in modern man's diet, and that its ultimate control is to be found simply in restoring this substance to our daily intake.

What you are about to read does not carry the approval of organized medicine. The Food and Drug Administration, the American Cancer Society, and the American Medical Association have labelled it fraud and quackery. In fact, the FDA and other agencies of government have used every means at their disposal to prevent this story from being told. They have arrested citizens for holding public meetings to tell others of their convictions on this subject. They have confiscated films and books. They even have prosecuted doctors who apply these theories in an effort to save the lives of their own patients.

The attitude of Big Brother, expressed bluntly in 1971 by Grant Leake, Chief of the fraud section of California's food and

drug bureau, is this: "We're going to protect them even if some of them don't want to be protected."¹

Early in 1974, the California medical board brought formal charges against Stewart M. Jones, M.D., for using Laetrile in the treatment of cancer patients. It was learned later, however, that Dr. Julius Levine, one of the members of that board, *himself* had been using Laetrile in the treatment of his own cancer. When Dr. Jones' case came up for review, the political pressures were so great that Dr. Levine felt compelled to resign from his post rather than come out openly in support of Dr. Jones and his patients.²

This is happening in a land which boasts of freedom and whose symbol is the Statue of Liberty. For the first time in our history, people are being forced to flee *from* our shores as medical emigrants seeking freedom-of-choice and sovereignty over their own bodies. Laetrile has been available in Australia, Brazil, Belgium, Costa Rica, England, Germany, Greece, India, Israel, Italy, Japan, Lebanon, Mexico, Peru, the Philippines, Spain, Switzerland, the U.S.S.R., Venezuela, and Vietnam—but it is not allowed in the "land of the free."

In spite of this, however, many doctors have defied the bureaucracy and have proved in their own clinics that the vitamin-deficiency concept of cancer is valid.

With billions of dollars spent each year in research, with additional billions taken in from the cancer-related sale of drugs, and with vote-hungry politicians promising ever-increasing government programs, we find that, today, there are more people making a living from cancer than dying from it. If the riddle were to be solved by a simple vitamin, this gigantic commercial and political industry could be wiped out overnight. The result is that the *science* of cancer therapy is not nearly as complicated as the *politics* of cancer therapy.

If there was any good that that came from the Watergate scandals of the Seventies, it was the public awakening to the reality that government officials sometimes do not tell the truth. And when caught in such "mendacities," they invariably claim that they lied only to protect national security, public health, or some other equally noble objective.

This Watergate syndrome is not new. Several years ago, an FDA agent who had testified in court against a Kansas City

1. "Debate Over Laetrile," *Time*, April 12, 1971, p. 20.

2. "Laetrile Tiff, State Medic Out," *San Jose Mercury (Calif.)*, April 10, 1974.

businessman admitted under cross-examination that he had lied under oath twenty-eight times. When asked if he regretted what he had done, he replied: "No. I don't have any regrets. I wouldn't hesitate to tell a lie if it would help the American consumer."¹

The FDA is not squeamish over its tactics to "help the American consumer." When a businessman falls into disfavor with the bureaucracy, there are no holds barred, and the law is used, not as a *reason* for attack, but as a *weapon* of attack. In other words, the FDA does not take action because the law says it should. It does so because it wants to, and then searches through the law for an excuse. In the celebrated case of *U.S. vs Dextra Fortified Sugar*, for example, the FDA had ruled that it was "misbranding" to fortify sugar with vitamins and minerals and still call it sugar. But the court ruled otherwise, pointing out:

The basic flaw in the government's case is that it is seeking, under the guise of misbranding charges, to prohibit the sale of a food in the market place simply because it is not in sympathy with its use.

Usually there is much more going on in these cases than over-zealousness on the part of a few bureaucrats. Pretending to protect the public is the favorite cover for hidden agendas. Legislation claiming to protect the consumer usually is written by representatives of the very industries from which the consumer supposedly is to be protected. Politicians who are grateful for the financial support of those industries are eager to put their names on the legislation and push for its enactment. Once it becomes law, it serves merely to protect the sponsoring industries against competition. The consumer is the victim, not the beneficiary.

This is just as true in the field of medicine as in any other. In medicine, however, there is the added necessity to pretend that everything is being done scientifically. Therefore, in addition to recruiting the aid of politicians, scientists also must be enlisted—a feat that is easily accomplished by the judicious allocation of funding for research.

This reality was revealed by former FDA Commissioner, James L. Goddard in a 1966 speech before the Pharmaceutical Manufacturers Association. Expressing concern over dishonesty in the testing for new drugs, he said:

1. Omar Garrison, *The Dictocrats* (Chicago-London-Melbourne: Books for Today, Ltd., 1970), p. 130.

I have been shocked at the materials that come in. In addition to the problem of quality, there is the problem of dishonesty in the investigational new drug usage. I will admit there are gray areas in the IND [Investigation of New Drug] situation, but the conscious withholding of unfavorable animal clinical data is not a gray matter. The deliberate choice of clinical investigators known to be more concerned about industry friendships than in developing good data is not a gray matter.¹

Goddard's successor at the FDA was Dr. Herbert Ley. In 1969, he testified before a Senate committee and described several cases of blatant dishonesty in drug testing. One case involved an assistant professor of medicine who had tested 24 drugs for 9 different companies. Dr. Ley said:

Patients who died while on clinical trials were not reported to the sponsor.... Dead people were listed as subjects of testing. People reported as subjects of testing were not in the hospital at the time of tests. Patient consent forms bore dates indicating they were signed after the subjects died.²

Another case involved a commercial drug-testing firm that had worked on 82 drugs from 28 companies. Dr. Ley continued:

Patients who died, left the hospital, or dropped out of the study were replaced by other patients in the tests without notification in the records. Forty-one patients reported as participating in studies were dead or not in the hospital during the studies.... Record-keeping, supervision and observation of patients in general were grossly inadequate.³

Between 1977 and 1980, it was discovered that 62 doctors had submitted clinical data to the FDA which was manipulated or completely falsified.⁴ In one study conducted by the FDA itself, it was discovered that one in every five doctors investigated—doctors researching the effects of new drugs—had invented the data they reported and pocketed the fees.⁵

1. See Subcommittee on Health of the Committee on Labor and Public Welfare, *Preclinical and Clinical Testing by the Pharmaceutical Industry*, 1976, U.S. Senate, Washington, D.C., 1976, pt. II, p. 157.

2. U.S. Senate, *Competitive Problems in the Pharmaceutical Industry*, 1969, pts. 6, 7 & 10; cited by John Braithwaite, *Corporate Crime in the Pharmaceutical Industry* (London: Routledge & Kegan Paul, 1984), p. 52.

3. *Ibid.*

4. Braithwaite, *op. cit.* p. 53.

5. *Science*, 1973, vol. 180, p. 1038.

These are not unusual or isolated cases. John Braithwaite, a criminologist at the Australian Institute of Criminology (and also former Commissioner of Trade Practices in Australia), states: "The problem is that most fraud in clinical trials is unlikely to even be detected. Most cases which do come to public attention only do so because of extraordinary carelessness by the criminal physician."¹

According to Dr. Judith Jones, former Director of the Division of Drug Experience at the FDA, if a research facility obtains results that do not demonstrate the safety or effectiveness of a drug, it is not uncommon for the drug company to bury the report and continue testing elsewhere until they find a facility that gives them the results they want. Unfavorable reports are rarely published, and clinicians are pressured into keeping quiet about them.²

The incentive for clinical investigators to fabricate data is enormous. American drug companies pay as much as \$1,000 per patient, which enables some doctors to collect over \$1 million per year from drug research—all the easier if the treatments are imaginary. Even if the tests are not fabricated, there is still the effect of subconscious bias. These doctors know that, if they don't produce the results the drug companies are seeking, the likelihood of their receiving future work is greatly diminished.

That commercially operated testing facilities should become corrupted by money is not hard to imagine. But it is often assumed that university laboratories are different, that they are immune to the profits that flow from criminal science. The truth, however, is that money speaks just as loudly on campus as it does elsewhere. Referring to a survey conducted by the FDA, Dr. Braithwaite explains:

As one would predict from the foregoing discussion of how contract labs can be used by sponsors to abrogate responsibility for quality research, contract labs were found to have a worse record of GLP [Good Laboratory Practices] violations than sponsor labs. The worst record of all, however, was with university laboratories. One must be extremely cautious about this finding since there were only five university laboratories in the study. Nevertheless, it must undermine any automatic assumption that university researchers,

1. Braithwaite, *op. cit.*, p. 54.

2. Arabella Melville and Colin Johnson, *Cured to Death; The Effects of Prescription Drugs* (New York: Stein & Day, 1982), p. 119.

with their supposed detachment from the profit motive, are unlikely to cut corners on research standards.¹

Let's bring this into focus on the issue of cancer. Science can be used, not only to push drugs into the market that do *not* work, but also to hold back remedies that *do*—because these remedies represent potential competition to the pharmaceutical industry which controls the drug-approving process. The controversy that once surrounded Dr. Andrew Ivy's anti-cancer drug known as Krebiozen is an example of this phenomenon.

Prior to crossing swords with the FDA in the early 1960s, Dr. Ivy had been widely acknowledged as one of the nation's foremost medical specialists. As head of the University of Illinois Clinical Sciences Department, he had prepared 350 candidates for the graduate degrees of Doctor of Philosophy (Ph.D.) and Master of Science (M.S.). He was an American representative at the Nuremberg trials after World War II in Germany. The American Medical Association had awarded him bronze, silver, and gold medals in recognition of his outstanding work in the field of medicine. He had written over a thousand articles published in scientific and medical journals. In fact, the FDA itself often had called upon him as an expert to offer medical testimony in court. But when he began to use an unorthodox approach to cancer therapy, overnight he was branded as a "quack."

During the course of Dr. Ivy's trial, a letter was read into the court record written by a doctor from Indianapolis. The doctor stated in his letter that he was treating a patient who had multiple tumors, and that a biopsy of the tissue had shown these tumors to be cancerous. The doctor said that he had obtained Krebiozen from Dr. Ivy's laboratories and had administered it, but that it had done absolutely no good. When called to the witness stand, however, the doctor's answers were vague and evasive. Under the pressure of cross-examination, he finally broke down and admitted that he never had treated such a patient, never had ordered the biopsy in question, and never had used Krebiozen even once. The whole story had been a lie. Why did he give false testimony? His reply was that one of the FDA agents had written the letter and asked him to sign it. He did so because he wanted to help the agency put an end to quackery.²

1. Braithwaite, *op. cit.*, p. 82.

2. Garrison, *op. cit.*, pp. 134-5.

In September of 1963, the FDA released a report to the effect that Krebiozen was, for all practical purposes, the same as creatine, a common substance that was found in every hamburger. To prove this point, they produced a photographic overlay supposedly showing the spectrograms of Krebiozen and creatine superimposed over each other. These were published in *Life* magazine and other segments of the mass communications media as "unimpeachable proof" that Krebiozen was useless.

When Senator Paul Douglas saw the spectrograms, he was suspicious. So he asked Dr. Scott Anderson, one of the nation's foremost authorities on spectrograms, to make his own study. Using standard techniques of analysis, Dr. Anderson identified twenty-nine differences between the two substances. There were sixteen chemical and color differences. The version released to the press by the FDA had been carefully moved off center until there was a maximum *appearance* of similarity, but when restored to the true axis, the two were as different as night and day.¹

The tactics used against Laetrile are even more dishonest than those against Krebiozen. Perhaps the most damaging of them has been a pseudo-scientific report released in 1953 by the Cancer Commission of the California Medical Association. Published in the April issue of *California Medicine*, the report presented an impressive collection of charts and technical data indicating that exhaustive research had been carried out into every aspect of Laetrile. Its molecular composition had been analyzed, its chemical action studied, its effect on tumor-bearing rats observed, and its effectiveness on human cancer patients determined. The stern conclusion of all this supposedly objective research was stated: "No satisfactory evidence has been produced to indicate any significant cytotoxic effect of Laetrile on the cancer cell."

The conclusions of this California Report are sufficient for most physicians and researchers. Not one in ten thousand has ever even seen Laetrile, much less used it. Yet, they all know that Laetrile does not work because the California AMA Cancer Commission said so, and they have had no reason to question the reliability of those who did the work.

Reporter Tom Valentine interviewed many leading cancer specialists to determine what they thought about Laetrile. Here he describes a typical reaction:

1. *Ibid.*, pp. 278-280.

Dr. Edwin Mirand of Roswell Memorial Hospital in Buffalo, N.Y., said: "We've looked into it and found it has no value." When asked if the renowned little hospital, which deals only with cancer, actually tested Laetrile, Dr. Mirand said, "No, we didn't feel it was necessary after others of good reputation had tested it and found it had no effectiveness in the treatment of cancer." He referred, as all authorities do, to the California Report.¹

Others have run up against the same stone wall. Professional researcher, David Martin, reported this experience:

The cancer expert in question, as I had anticipated, told me that Laetrile was "sugar pills." Had he told me that he had used Laetrile experimentally on X number of patients and found it completely ineffective, I might have been impressed. But when I asked him whether he had ever used it himself, he said that he had not. When I asked him whether he had ever travelled abroad to study the experience with Laetrile therapy in Germany, Italy, Mexico, the Philippines, or other countries, he replied that he had not. And when I asked him if he had ever made a first-hand study of the pros and cons of the subject, again he conceded that he had not. He was simply repeating what he had heard from others who, in turn, were probably repeating what they had heard from others, going all the way back to the antiquated 1953 report of the California Cancer Commission.²

It is important, therefore, to know something of the nature of the California Report and of the scientific integrity of those who drafted it.

Although the report as published in *California Medicine* was unsigned, it was written by Dr. Ian MacDonald, Chairman of the Commission, and Dr. Henry Garland, Secretary. Dr. MacDonald was a prominent cancer surgeon, and Dr. Garland was an internationally famous radiologist. Both were listed in *Who's Who*.

There were seven other prominent physicians on the commission—including four more surgeons, another radiologist, and a pathologist—but they played no major part in the preparation of the report. Not one of these men—not even MacDonald or Garland—had ever used Laetrile in first-hand experiments of their own. All they had done was to make *evaluations* and *summaries* of the written records of others.

1. "Government Is Suppressing Cancer Control," *The National Tattler*, March 11, 1973, p. 2.

2. *Cancer News Journal*, January/April, 1971, p. 22.

Before examining those evaluations and summaries, let us first recall that MacDonald and Garland were the two physicians who had made national headlines claiming that there was no connection between cigarette smoking and lung cancer. In an address before the Public Health Section of the Commonwealth Club of San Francisco on July 9, 1964, Dr. Garland had said:

A current widely held hypothesis is that cigarette smoking is causally related to a vast number of different diseases, ranging from cancer to coronary arteriosclerosis. After studying the question for several years, notably in its reported relationship to primary bronchial cancer, it is my considered opinion that the hypothesis is not proven....

Cigarettes in moderation are regarded by many as one of the better tranquilizers.... It is likely that obesity is a greater hazard to American health than cigarettes.

Dr. MacDonald was even more emphatic. In an article in *U.S. News & World Report*, he was shown with a cigarette in his hand, and is quoted as saying that smoking is "a harmless pastime up to twenty-four cigarettes per day." And then he added: "One could modify an old slogan: A pack a day keeps lung cancer away."¹

It is a curious fact that it was precisely at this time that cigarette manufacturers were beginning to experience a slump in sales because of public concern over lung cancer. In fact, the tobacco industry had already pledged the first ten-million dollars out of a total of eighteen million to the AMA for "research" into the question of smoking and health.

The effect of this veritable flood of money from a source with, shall we say, "a vested interest" in the outcome of the research, was incredible and did *not* speak well for the AMA. The result was the conversion of a relatively simple, straight-forward project into a monstrous boondoggle of confusion and waste.

In the report of the AMA's Committee for Research on Tobacco and Health, it says:

To date, approximately \$14 million has been awarded [from the tobacco industry] to 203 individual research projects at 90 universities and institutions. As a direct result of these grants, 450 reports have been published in scientific journals and periodicals.²

1. "Here's Another View: Tobacco May be Harmless," *U.S. News & World Report*, Aug. 2, 1957, pp. 85, 86.

2. *Third Research Conference*, Committee for Research on Tobacco and Health, AMA Education and Research Foundation, May 7-9, 1972, p. 4.

The report then listed the research projects and described their purposes. Here are just a few:

Nicotine Receptors in Identified Cells of the Snail Brain.

The Effects of Nicotine on Behavior of Mice.

Angina Pectoris and Bronchitis in Relation to Smoking—A Study in American and Swedish Twin Roosters.

Post-Maturity Syndrome in the Pregnant Rat After Nicotine Absorption During Pregnancy.

Interactions of Nicotine, Caffeine and Alcohol in Squirrel Monkeys.

The Effect of Smoking in Placental Oxygen Transfer in Gravid Ewes.

Urinary Excretion, Tissue Distribution and Destruction of Nicotine in Monkey and Dog.

Body Build and Mortality in 105,000 World War II Army Veterans.

Upon going through the back reports of the AMA's Committee for Research on Tobacco and Health, one is able to count but five research projects that are primarily concerned with cancer. One of those dealt with laboratory-testing procedures only, and another was an experiment to see if tobacco smoke could be used to *cure* cancer of the skin! So only *three* of these projects really dealt with the area of major public concern. Three out of two hundred and three is only about one-and-a-half percent—which tells us something about the AMA's scientific integrity on the subject of smoking and cancer.

With the expenditure of a mere eighteen-million dollars—which is small, indeed, compared to the tobacco industry's advertising budget over the same period—it was possible to direct the AMA's medical research away from the important question of cancer and into a hundred giddy questions that served only to confuse and delay the ultimate truth.

Dazzled by the meteor shower of thousand-dollar bills, the AMA, in its December 1959 issue of the *American Medical Association Journal*, published an editorial stating flatly that there was insufficient evidence "to warrant the assumption" that cigarette smoking was the principal factor in the increase of lung cancer. Furthermore, through its gargantuan research program, the AMA was making it increasingly difficult to obtain that evidence.

Was there any connection between the eighteen-million dollars given to the AMA from the tobacco industry and the public pronouncements of MacDonald and Garland, two of its most prominent members in California? Perhaps not, although it has

been rumored that these gentlemen of science actually did receive \$50,000 for their "testimonials."¹

Whether or not this is true is not important now. What is important is the fact that their medical opinion, if it had been widely followed, clearly would have resulted in the suffering and death of untold additional millions. Also important is the fact that these are the same "experts" whose medical opinion *has been* widely quoted and followed in the question of Laetrile.

An interesting footnote to this subject is the fact that Dr. MacDonald was burned to death in bed a few years later in a fire started by his cigarette. Dr. Garland, who had boasted of chain-smoking since early childhood and who claimed to be living proof that cigarettes are harmless, a few years later died of lung cancer.

In 1963, ten years after publication of the original California Report, the California State Department of Health officially decreed that the findings of the antiquated study were "true" and adopted them as its own. When it did so, however, it performed an unexpected favor for the public because it published for the first time all the original experiments and studies upon which the report had been based and, in doing so, it made available the documentary evidence proving that MacDonald and Garland had *falsified* their summary of those experiments.

In the 1953 report, the authors published the conclusions of John W. Mehl, M.D., to the effect that cyanide could not be released from Laetrile. As will be explained in a later chapter, the release of cyanide at the cancer cell is part of the reason that Laetrile works. Therefore, implying that cyanide *cannot* be produced was a severe blow to the credibility of Laetrile theory. Dr. Mehl was quoted as saying: "These results are inconclusive, and will be extended, but they do not support the claims made for Laetrile."

With the publication of the original experiments ten years later, however, quite a different story emerged. Buried in a maze of statistics, tables, and charts can be found an item labeled "Laetrile Report Appendix 4." It is a laboratory report signed by G. Schroetenboer and W. Wolman. It states:

1. See *The Immoral Banning of Vitamin B₁₇*, by Stewart M. Jones, M.S., M.D., Palo Alto, Calif., Jan., 1974, p. 1. Also *Cancer News Journal*, Jan./April, 1971, p. 3.

After refluxing for three hours, the odor of hydrogen cyanide could be detected.... The hydrogen cyanide was distilled into sodium hydroxide and determined by the Prussian Blue technique.¹

This report was dated January 14, 1953—two months *before* Dr. Mehl claimed that cyanide could not be released from Laetrile. It is significant, therefore, that MacDonald and Garland completely ignored the positive report while giving prominence to the negative one.

Since that time, the release of cyanide from Laetrile has been confirmed by the AMA's chemical lab, by the cytochemistry section of the National Cancer Institute, and even by the California Department of Public Health. This is the same California Department of Public Health that then officially pronounced the original report to be "true" and adopted it as its own.

Another claim made by Drs. MacDonald and Garland was that microscopic examinations of tumors from patients who had been treated with Laetrile showed absolutely no indication of favorable chemical effect. Ten years later, however, this assertion was shown to be a bald-faced lie. Appendix Three contains the findings of two pathologists who stated in plain English that they *did* observe anti-tumor effects which, indeed, could have been caused by the Laetrile. In a statement dated December 15, 1952, for example, John W. Budd, M.D., reported: "Case 1M.... Hemorrhagic necrosis of tumor is extensive.... An interpretation of chemotherapeutic effect might be entertained."

Also an autopsy report by J.L. Zundell, dated September 10, 1952, discusses two clear cases of observed anti-tumor effect. It states:

M-1.... This might represent a chemical effect since the cells affected show coagulation necrosis and pyknosis....

M-3.... There appears to be more degeneration in the tumor cells in the lymph node. I would consider this as a possible result of chemical agent....

Two cases ... showed moderate changes ... which might be considered as chemotherapeutic toxic cellular changes.²

Nothing could be more plain than that. Nevertheless, MacDonald and Garland stated flatly in the California Report: "No

1. *Report by Cancer Advisory Council on Treatment of Cancer with Beta-Cyanogenic Glucosides ("Laetriles")*, California Department of Public Health, 1963, Appendix 4, pp. 1, 2.

2. *Ibid.*, Appendix 3, pp. 1, 2.

*evidence of cytotoxic changes was observed by any of the consultants."*¹ That statement, of course, was a lie of gigantic proportions.

Even if the findings of these researchers had not been falsely summarized by MacDonald and Garland, the 1953 California Report still would have been totally useless as a scientific verdict against Laetrile because the strength of the doses used on cancer patients was too weak to prove anything. In fact, it was about one-fiftieth of what generally is used to obtain optimum results.

In the earlier days of Laetrile research, clinicians cautiously administered only fifty to one-hundred milligrams at a time. Gaining confidence with experience, these levels gradually were raised until, by 1974, Laetrile was being used intravenously at levels of six to nine thousand milligrams daily. Generally, it takes an accumulation of fifty to seventy thousand milligrams over a period of about a week or ten days before the patient can report tangible indications of improvement. But in the experiments used for the California Report, the typical dose given was only about fifty milligrams per injection. The maximum single dose was less than two hundred milligrams, and the maximum accumulative dose was only two thousand milligrams spread over twelve injections. Five patients received only two injections, and five received only one.

It is not surprising, therefore, that the California experiments failed to produce conclusive evidence that Laetrile was effective against cancer. As Dr. Krebs observed at the time, "There is nothing quite so easy to accomplish as failure."

In spite of all the incredible distortions of fact and the perversions of scientific truth, Drs. MacDonald and Garland were forced to admit on page three of their California Report:

All of the physicians whose patients were reviewed spoke of increase in the sense of well-being and appetite, gain in weight, and decrease in pain....

Then, attempting to belittle these important results, they added:

... as though these observations constituted evidence of definite therapeutic effect.

That statement, alone, should have disqualified the California Report, for these observations *are, indeed*, among the very things which indicate to a physician whether or not his drug therapy is

1. *Report by Cancer Advisory Council, op. cit.*, p. 324.

effective.¹ Most doctors would be ecstatically happy if they could cause their cancer patients to experience an increase in a sense of well-being and appetite, a gain in weight, and especially a decrease in pain.

In the 1970s, there was little chance that Laetrile would be given a chance to be tested except by its opponents. Every time proponents attempted to obtain permission to do so, they were turned down cold. On April 6, 1970, for example, the McNaughton Foundation, under the sponsorship of Andrew McNaughton, submitted an application to the FDA for permission to engage in what is called IND (Investigation of New Drug) Phase One studies. Permission was granted on April 27. Then, in the words of one reporter, "All hell broke loose."² The FDA apparently received a phone call from an irate and politically influential figure who passed the word: "Stop the tests!"

The next day, April 28, the FDA sent another letter to the McNaughton Foundation advising that, upon reviewing the records, certain "deficiencies" had been found in the IND application, and demanding extensive additional data *within ten days*. Curiously, the letter was not delivered to the McNaughton Foundation until May 6, nine days after it supposedly had been written, and it is suspected that the letter may actually have been written much later but back-dated so as to make it impossible to comply with the already ridiculous ten-day deadline. On May 12, six days after receipt of the "deficiency letter," McNaughton received a telegram from the FDA advising him that the approval for Investigation of New Drug had been revoked.

Nevertheless, hoping that the FDA would reinstate its IND approval upon receipt of the additional data, McNaughton proceeded with the paperwork and, on May 15, just nine days after receipt of the FDA's initial order, sent off to Washington everything that had been requested. By now, however, the FDA was firm. Laetrile would *not* be tested.

A former high official of the FDA told Dr. Dean Burk of the National Cancer Institute that he could not recall in over thirty years of service any instance in which just ten short days were demanded for a fifty page reply to alleged deficiencies. And, on October 1, 1970, there was nothing in the FDA procedural manual

1. *Current Diagnosis & Treatment*, (Palo Alto: Lange Med. Publications, 1972), p. 902.

2. Don C. Matchan, "Why Won't They Test Laetrile?" *Prevention*, Jan., 1971, pp. 149-150.

requiring termination notices after allowing only ten days for compliance.¹ Clearly, the entire action was contrived in response to political pressures as an excuse to stop the testing of Laetrile.

One of the reasons given for revoking approval for IND was that Laetrile might be toxic. The FDA said solemnly:

Although it is often stated in the IND that amygdalin is non-toxic, data to demonstrate this lack of toxicity are absent.... It is considered to be dangerous to base the starting dose for a chronic (6 + weeks) study in man on a single dose study in mice. It is also dangerous to initiate human studies while the nature of the toxicity has not been elucidated in large animal species.²

This is an incredible statement. First of all, as will be illustrated in a later chapter, the non-toxicity of amygdalin (Laetrile) has been a well-known, fully accepted, and non-controversial fact for a hundred years. Second, the case histories submitted as part of the IND application were further proof of Laetrile's safety. And third, the very question of toxicity is absurd inasmuch as *all* of the drugs approved by the FDA and currently used in orthodox cancer therapy are *extremely* toxic. To deny the testing of Laetrile on the grounds that it *might* be toxic is the height of sophistry.

Another reason given by the FDA for refusing to permit the testing of Laetrile was that the doctors who had used it did not keep sufficiently detailed clinical records. This, too, was a lame excuse, because Phase One studies do not require clinical records.

In righteous indignation, the courageous Dr. Burk of the National Cancer Institute wrote to Elliot Richardson, then Secretary of HEW (which administered the FDA), and said:

The granting of FDA permission for Phase One studies of IND has no absolute or invariable requirements for any clinical studies at all, although the sponsor is requested to supply any type of indication that he may possess, which the McNaughton Foundation has complied with to the limit of current feasibility. Dr. Contreras [of Mexico] and Dr. Nieper [of Germany] have been primarily preoccupied, quite justifiably, with treating cancer patients with Laetrile and related adjunctive therapies, and not with carrying out a clinical evaluation of Laetrile in the precise and complete schedule of FDA protocols. For you to indicate that their records are inadequate for

1. Letter from Dr. Dean Burk to Elliot Richardson, Secretary of HEW, dated Oct. 19, 1971; G. Edward Griffin, ed., *Private Papers Relating to Laetrile*, (Westlake Village, CA: American Media, 1997)

2. *The Ad Hoc Committee of Oncology Consultants For Review and Evaluation of Amygdalin (Laetrile)*, FDA, Aug. 12, 1961, pp. 3, 4.

such a purpose is clearly a red herring, since there is no such IND Phase One requirement involved, nor corresponding claim made.¹

But the "fix" was on. Laetrile would *not* be approved for testing, regardless of the facts. On September 1, 1971, the FDA announced that the Ad Hoc Committee of Consultants for Review and Evaluation of Laetrile had found "no acceptable evidence of therapeutic effect to justify clinical trials." And then it announced that, because of their findings, Laetrile could no longer be promoted, sold, or *even tested* in the United States.²

The California Report has remained as one of the primary authorities cited by cancer "experts" *ad nauseum* and as the basis of legal restraints against Laetrile. The cancer industry has also refused the advocates of Laetrile a chance to conduct their own clinical trials on the basis of such flimsy excuses that they would be laughable if the consequences were not so serious. All of this is the product of bias, not objectivity. The reports and pronouncements are calculated to deceive, not to clarify. It is fiat, not science.

Why is this happening? We shall deal with that part of the story next.

1. Letter from Dr. Dean Burk to Elliot Richardson, Oct. 19, 1971, op. cit.
2. Press release, HFW/FDA, Sept. 1, 1971.

Chapter Two

GENOCIDE IN MANHATTAN

Continued attempts by the cancer industry to prove that Laetrile is worthless; the suppressed lab reports from the Sloan-Kettering Institute which proved that Laetrile works; the Rockefeller connection to the pharmaceutical industry; the story of how a group of employees at Sloan-Kettering leaked the truth to the outside world.

In addition to the California Report, there have been numerous other Laetrile studies by supposedly qualified and reputable organizations. These include a 1953 project at Stanford University, a 1961 study at the University of California-Berkeley, one in 1962 at the Diablo Labs in Berkeley, and a 1965 study on behalf of the Canadian Medical Association at McGill University in Montreal. Every one of these has been tarnished by the same kind of scientific ineptitude, bias, and outright deception as found in the 1953 California Report. Some of these studies openly admitted evidence of anti-cancer effect but hastened to attribute this effect to other causes. Some were toxicity studies only, which means they weren't trying to see if Laetrile was effective, but merely to determine how much of it was required to kill the patient.

In most of these experiments, the only criterion used to measure the success of Laetrile was reduction in tumor size. That may sound reasonable at first, but one must realize that most tumors are a mixture of malignant and benign cells and that the transplanted tumors used on laboratory mice contain only about three or four percent outright cancer tissue. The more malignant tissues are rejected by the healthy mouse and cannot be successfully transplanted. Even if Laetrile eliminated one-hundred percent of the cancer, these tumors would be reduced only three

or four percent *at the most*. Life extension, not tumor size, is the only meaningful test of therapeutic success.

In 1973, after months of extensive Laetrile studies on mice, the Southern Research Institute in Birmingham, Alabama, released a report of its findings to the National Cancer Institute. The NCI then announced that these studies once again proved Laetrile had no effect in the treatment of cancer. Upon further investigation, however, all was not as it appeared. Digging into the raw data contained in the report's tables and charts, Dr. Burk discovered that there were three groups of mice in the experiment: (1) a large group that received too little Laetrile, (2) another large group that received too much, and (3) a small group that received an optimum dose. Those that received too little died just as quickly as those in the control group which received none at all. Those that received too much died sooner than those in the control group. But those that received the proper dosage survived significantly longer than those that received none at all!

In view of these results, one may wonder how the National Cancer Institute could have said that Laetrile was of no value. Here is how it was done. All *three* groups were lumped into the same statistics—including those which received too little and those that received too much. When these large groups were added to the small group that survived significantly longer, they brought down the *average* to the point where they honestly could say that these mice, *as a total group*, did not survive significantly longer than those which had received no Laetrile at all. The statistics didn't lie. But liars had used statistics.¹

Meanwhile, the number of recovered cancer patients singing the praise of Laetrile continued to grow. These patients and their families established a national, grass-roots organization called The Committee for Freedom-of-Choice in Cancer Therapy. Several hundred chapters across the country held public meetings and press conferences, and provided testimony before state legislative committees calling for the legalization of Laetrile. Somehow, these "laetrilists" had to be answered.

So, in 1978, the National Cancer Institute launched yet another study to debunk the movement. Ninety-three cancer

1. Dr. Dean Burk presented a devastating exposé of this manipulation of statistics in a fourteen-page open letter to Dr. Seymour Perry of the NCI, March 22, 1974. See *Private Papers Relating to Laetrile*, edited by G. Edward Griffin (Westlake Village, Calif.: American Media, 1997)

cases were selected in which the medical records indicated that Laetrile had been effective. The details were submitted to a panel of twelve cancer specialists for evaluation. Cases involving traditional therapy were also mixed in, and the panel was not informed which cases received which treatment. Judgment would be based only on results. NCI sifted through the Laetrile cases and rejected most of them, so the panel was allowed to review only twenty-two.

How does one evaluate the success of a cancer treatment? Is it the length of life? The quality of life? The feeling of well-being and absence of pain? The ability to function normally on a daily basis? All of these are the criteria used by doctors who apply nutritional therapy. They are not concerned with the size of a tumor because, as stated previously, they know most tumors are a mixture of malignant and benign cells, and that most tumors have only a small percentage of cancer cells. If Laetrile succeeds in removing 100% of a patient's cancer, his tumor may only decrease by 5% or 10%. But who cares? The patient is back among the living again. The tumor is not the disease; it is merely the symptom of the disease.

Orthodox medicine, on the other hand, is totally focused on the tumor. To most oncologists, the tumor is the cancer. If they remove it surgically or burn it away, they happily announce to the patient: "Good news. We got it all!" They may have all of the tumor, but did they get what caused the tumor? And, in the process, did they dislodge some of those malignant cells, causing them to migrate through the circulatory system only to find new homes elsewhere in the body? Is that the reason so many cancer patients die of metastasized cancer to multiple locations only a few months after hearing those ludicrous words: "We got it all"?

In any event, Laetrile practitioners have always warned that reduction in tumor size is the least meaningful of all the measures of success. So what was the primary criterion chosen by NCI? Tumor size, of course. Not only was that consistent with the orthodox view of cancer, but it also would skew the results in favor of treatments, such as radiation and chemotherapy, which have a more pronounced effect on tumor shrinkage than Laetrile. A living and healthy patient with a tumor reduced by only 15% would be classified as a failure. A sick and dying patient with a tumor reduced 60% would be a success.

In spite of this stacked deck, here is what the panel found: Among the Laetrile cases reviewed, 2 patients showed complete

response (total tumor disappearance), 4 had partial regression (greater than 50%), 9 were "stabilized" (tumors had stopped growing), and 3 had "increased disease-free intervals." In other words, 18 out of 22, or 82%, had some kind of beneficial response—even when using tumor size as the criterion. There are very few "approved" anti-cancer drugs that can show a report card as good as that.

None of these encouraging numbers made any difference. The official report of the NCI stated: "These results allow no definite conclusions supporting the anti-cancer activity of Laetrile."¹ The wording was brilliantly deceptive. No one was expecting "definite conclusions" from a single study. But an honest and full report of the results would have been quite nice, thank you. Nevertheless, the carefully structured statement conveyed the impression that Laetrile once again had failed a scientific test. Words had been used, not to communicate, but to obfuscate.

The next act in this drama of pseudo science was a clinical trial involving 178 patients at the Mayo Clinic. Amygdalin was to be tested again, but this time it was to be combined with "metabolic therapy" consisting of diet, enzymes, and nutritional supplements—exactly what the nutritional doctors had been advocating. The leading Laetrile practitioners, however, bitterly objected that the protocol used was not comparable to theirs. Furthermore, there was serious doubt about the purity of the amygdalin being used. It was suspected that the entire experiment was carefully crafted to fail. And fail, it did. The Mayo doctors reported: "No substantive benefit was observed."

It is hard to beat this unbroken record of deception in the cloak of science, but the granddaddy of them all occurred a few years later at the Memorial Sloan-Kettering Cancer Center in Manhattan. For five years, between 1972 and 1977, Laetrile was meticulously tested at Sloan-Kettering under the direction of Dr. Kanematsu Sugiura. As the senior laboratory researcher there, with over 60 years of experience, Dr. Sugiura had earned the highest respect for his knowledge and integrity. In a science laboratory, where truth is sought to the exclusion of all else, he would have been the perfect man for this test. For the purposes of Sloan-Kettering, however, he was the worst possible choice.

1. N.M. Ellison, "Special Report on Laetrile: The NCI Laetrile Review. Results of the National Cancer Institute's Retrospective Laetrile Analysis." *New England Journal of Medicine* 299:549-52, Sept. 7, 1978.

Sugiura broke his experiments down into a series of tests using different types of laboratory animals and different tumors: some transplanted and some naturally occurring. At the conclusion of his experiment, he reported five results: (1) Laetrile stopped metastasis (the spreading of cancer) in mice, (2) it improved their general health, (3) it inhibited the growth of small tumors, (4) it provided relief from pain, and (5) it acted as a cancer prevention. The official report stated:

The results clearly show that Amygdalin significantly inhibits the appearance of lung metastasis in mice bearing spontaneous mammary tumors and increases significantly the inhibition of the growth of the primary tumors.... Laetrile also seemed to prevent slightly the appearance of new tumors.... The improvement of health and appearance of the treated animals in comparison to controls is always a common observation.... Dr. Sugiura has never observed complete regression of these tumors in all his cosmic experience with other chemotherapeutic agents.¹

The reader is advised to go back and read that last section again for, as we shall see, just a few months later, spokesmen for Sloan-Kettering were flatly denying that there was any evidence that Laetrile had any value.

To fully appreciate what happened next, a little background is in order. The board of directors at Sloan-Kettering is virtually controlled by corporate executives representing the financial interests of pharmaceutical companies. Most of that control is held by the Rockefeller dynasty and their cartel partners. At the time of the Sugiura tests, there were three Rockefellers sitting on the board (James, Laurance, and William) plus more than a dozen men whose companies were within the Rockefeller financial orbit.

The history of how the Rockefellers became involved in the pharmaceutical industry is contained in Part Two of this book. But, to appreciate how that effects this part of the story, we must know that John D. Rockefeller, Sr., and his son, J.D., II, began donating to Memorial Hospital in 1927. They also gave a full block of land on which the new hospital was built in the 1930s. Nothing was given without something to be received. In this case, it was control over one of the great medical centers of the world. How that happened was described by Ralph Moss, former

1. "A Summary of the Effect of Amygdalin Upon Spontaneous Mammary Tumors in Mice," Sloan-Kettering report, June 13, 1973.

Assistant Director of Public Affairs at Sloan-Kettering. Speaking of the expansion of Sloan-Kettering after World War II, Moss wrote:

The composition of the board of trustees at that time reveals a kind of balance of power, with the Rockefellers and their allies in overall control, but with those representing the Morgan interests assuming many positions of power... From this period forward the world's largest private cancer center was ruled by what looks like a consortium of Wall Street's top banks and corporations.

By the mid 1960s, the MSKCC board had begun to take on a rather uniform appearance. What stood out was that many of its leading members were individuals whose corporations stood to lose or gain a great deal of money, depending on the outcome of the "cancer war."¹

With this background in mind, it should come as no surprise to learn that Sugiura's findings did not please his employer. What goes on inside the laboratories is generally of little interest to board members. It is assumed that, whatever it is, it will result in a new patented drug that will keep the cash flow moving in their direction. They were slow to pick up on the implications of Sugiura's work but, when they did, all hell broke loose in the board room. If a cure for cancer were to be found in an extract from the lowly apricot seed, it would be a terrible economic blow to the cancer-drug industry.

Never before had Sugiura's work been questioned. In 1962, more than 200 of his scientific papers were published in a four-volume set. The introduction was written by Dr. C. Chester Stock, the man in charge of Sloan-Kettering's laboratory-testing division. Dr. Stock wrote:

Few, if any, names in cancer research are as widely known as Kanematsu Sugiura's.... Possibly the high regard in which his work is held is best characterized by a comment made to me by a visiting investigator in cancer research from Russia. He said, "When Dr. Sugiura publishes, we know we don't have to repeat the study, for we would obtain the same results he has reported."

All that was forgotten now that Sugiura's findings were threatening the cash flow. The same Dr. Stock who wrote those words was now a Sloan-Kettering vice-president and part of the pack howling for a whole new series of tests. Sugiura *had* to be proven wrong!

1. Ralph Moss, *The Cancer Syndrome* (New York: Grove Press, 1980), p. 258.

As it turned out, several others had already duplicated Sugiura's experiments and had obtained essentially the same positive results. One was Dr. Elizabeth Stockert and another was Dr. Lloyd Schloen. Both were biochemists at Sloan-Kettering when they did the work. Schloen had gone so far as to add proteolytic enzymes to the injections—as is commonly done by Laetrile doctors—and reported a 100% cure rate among his Swiss albino mice!¹ That was not the result they wanted. In fact, it was down-right embarrassing. It would have been nice if they could simply dump these reports into the memory hole and then claim that they never existed. But it was too late for that. They were already in the public record, and too many people knew the facts. It was now time to bury all of these findings under a mountain of contrary reports and statistics. Even the sweetest smelling rose will be ignored in a heap of garbage.

The easiest thing in the world to accomplish is failure. It is not difficult to fail to make Laetrile work. All that is necessary is to make a few changes in protocol, lower the dose, switch the source of material, change the criteria for evaluation, bungle the procedure, and, if necessary, lie. All of these stratagems were used to discredit Sugiura's findings.

For those who cannot believe that scientists would lie about such important matters, it should be remembered that, in 1974, Sloan-Kettering was the scene of one of the greatest scientific scandals of the century. Dr. William Summerlin, one of the top-ranking researchers there, claimed to have found a way to prevent transplanted tissue from being rejected by the recipient. To prove his case, he displayed white mice with square black patches of fur, claiming that the skin grafts from black mice were now accepted by the white mice.

Not so. He had created the black patches with a marker pen.²

If success can be falsified, so can failure. Dr. Daniel S. Martin at the Catholic Medical Center in Queens, New York, had previously failed to obtain positive results with Laetrile, but had not used the same protocol as Sugiura. To overcome this problem, Sugiura was asked to participate in a second series of tests by Martin, which he did. This time, however, *the results were in favor of Laetrile.*

1. *Ibid.*, p. 139.

2. See Joseph Hixon, *The Patchwork Mouse; Politics and Intrigue in the Campaign to Conquer Cancer* (New York: Anchor Press/Doubleday, 1976)

By visual examination, there were twice as many new tumors in mice that did not receive Laetrile than in those that did. The next step in the Sugiura protocol would have been to use a microscope to examine the lung tissue (which is where the cancer had been located) to measure the extent of tumor growth at the end of the experiment. Martin, however, refused to accept either visual or microscope examination and insisted instead that a process be used called bioassay. In bioassay, the mouse's lung tissue was shredded and then injected into two other mice. If cancer developed in either of them, it was assumed that the injected tissue was cancerous.

This cleared away all the variances between great improvement, small improvement, or no improvement at all. No matter how much the cancer might have been weakened, no matter that it might be in the process of being destroyed altogether by Laetrile, so long as there were any cancer cells left for transfer to the living mice, it was called a failure. Since the original mice were sacrificed before the Laetrile had a long-term chance to do its work, it was assured that virtually all of them, no matter how improved they may be, would still have at least some cancer cells. Therefore, they all would be classified as failures for Laetrile. By this method, Dr. Martin was able to announce with a straight face that there was no difference between the treated and the control animals.¹ One again, science had been used to conceal the truth.

By this time, a group of employees at Sloan-Kettering became angered over the way their top management was attempting to cover up Sugiura's findings. They began to circulate a series of open letters to the public under the name *Second Opinion*. The identities of the authors were not known, but it was obvious from the data they released that they were well connected within the organization. Photocopies of important internal memos—even copies of Sugiura's laboratory notes—were sent to Laetrile advocates and to selected members of the press.

These broadsides became a source of embarrassment to the administrators who were anxious to close the book on the subject and let it fade from public attention. One of the most outspoken proponents of this view was Benno Schmidt, Sloan-Kettering's Vice Chairman. Schmidt was an investment banker with powerful connections in all the right places. He was a close friend of Laurance Rockefeller, a member of SK's board of managers, and

1. Moss, *Cancer Syndrome*, op. cit., p. 140.

Chairman of President Carter's National Panel of Consultants on the Conquest of Cancer. That is the group that dreamed up the so-called "war on cancer" which turned out to be primarily a means for channeling billions of tax dollars into research centers such as Sloan-Kettering.

To Schmidt, the only purpose of testing Laetrile was to convince the public that it doesn't work. Whether it might work or not was unimportant. This reality was brought to light—quite accidentally, no doubt—in an interview with Dr. Martin that appeared in the December 23, 1977, issue of *Science*. When the reporter asked Martin if the Sloan-Kettering tests were aimed primarily at scientists, he replied: "Nonsense. Of course this was done to help people like [Benno] Schmidt and congressmen answer the laetrilists."

Not to advance science, not to test a possible cancer cure, not to find the truth, but to "answer the laetrilists"!

In a statement carried in the August 11, 1975, issue of *Medical World News*, Schmidt said: "Clinical trials? No way! There's no way, I believe, that they can convince the people at Sloan-Kettering there's any basis for going further."

Normally, if the Vice Chairman says there's no way, there's no way. But the furor caused by publication of *Second Opinion* forced the strategists to keep the book open a little longer and to assume the stance of fairness and open-mindedness. And what could be more fair than another test?

So here we go again. On October 6, less than four weeks after the "no basis for going further" statement, *Medical World News* carried another story explaining that a new round of trials had been scheduled. It said: "He [Sugiura] will have another chance to check [his] belief, in a collaborative experiment with Dr. Schmid."

Franze A. Schmid, was a veterinarian with many years of service with Sloan-Kettering. He also was Sugiura's son-in-law who shared his living quarters in Westchester. Needless to say, that relationship was placed under considerable strain in the following months.

Schmid was apparently chosen to co-conduct these tests because of two previous Laetrile tests he performed which produced negative results, or at least that's what the press was told. In truth, in the first test, Schmid had not used microscope examination to evaluate the results, so there was no way to know what the results really were. In the second test, he had been

instructed to use a dose of Laetrile that was one-fiftieth the amount used by Sugiura. Naturally, there was no positive effect on tumor shrinkage or metastasis. But, in both cases, the Laetrile-treated mice lived longer than the control mice—a fact that was never reported to the public. No one outside the Institute knew of this until a reporter extracted the information from Dr. Stock a year later.

The new test, conducted jointly by Sugiura and Schmid, solidly confirmed Sugiura's original results. There was less than half as much cancer in the mice receiving Laetrile than in those in the control group.

The results were promptly leaked to the press by *Second Opinion*, and the fallout was not good news for SK's damage-control department. In a feature article in the *San Francisco Examiner*, reporter Mort Young wrote: "The mice in Doctor Schmid's test divided this way: 100 per cent of the control mice had lung metastases, while of the group given Laetrile, 31 per cent had lung metastases.... It is a dramatic reversal of Dr. Schmid's previous tests."¹

The casual observer might have concluded that the issue was finally settled. Sugiura was vindicated at last. But the casual observer would have been wrong. There was too much at stake here to simply jump over the net and congratulate the victorious opponent. It was a case of "Damn it all. Let's play another round, and another, and another until the proper side wins."

Sloan-Kettering handled its defeat in the only way it could—with total silence. Dr. Schmid was told to say nothing to anyone about his results, and he dutifully complied. Management, on the other hand, responded by scheduling still another test to "clarify" the results of the previous one; the implication being that, somehow, it had been flawed. No one would discuss it.

The next test was to be performed at the Catholic Medical Center and supervised, as before, by Dr. Martin. This time, however, Dr. Sugiura was to be what they call "blinded." Blind testing means that the patients and the people administering the program are not informed who is receiving the real medication and who gets the placebo. That serves a valuable function with humans because, otherwise, the patient might be influenced by a subconscious anticipation of what the results are supposed to be.

1. "Sloan-Kettering Tests Continue," *San Francisco Examiner*, Nov. 12, 1975, p. 8.

But, in this case, the patients were mice. Apparently, it was feared that Sugiura would handle the Laetrile mice more gently, imparting to their little psyches the anticipation of becoming well. Or perhaps his prior knowledge might translate into telepathic power which would corrupt the judgment of the evaluation team. In any event, only Dr. Martin was to know which mice were being treated—or, for that matter, whether *any* of them were. Ah, isn't science wonderful?

Apparently half of the mice were being given Laetrile in this test because, after four weeks, Sugiura was able to see which cages contained specimens with fewer and smaller tumors. And they were friskier, too. His guess was eventually confirmed by none other than SK's vice president. Sugiura was jubilant when he told the news to Ralph Moss. "Last Friday," he said, "Dr. Stock told me that I picked the controls and the experimental correctly.... That means I don't have to rewrite my progress report."¹ The tally at the end of the test showed that the Laetrile-treated mice had less than half the number of tumors as the controls. Once again, Sugiura had been proven correct.

The reaction of Sloan-Kettering management was predictable. They had no choice—considering the nature of the economic forces that control them—but to scrap this test, also, and move on to another one. Dr. Stock told reporters that the experiment had to be terminated because Dr. Sugiura had figured out which mice were being treated. "We lost the blindness aspect of it," he said. In an interview with *Science* magazine, he added that the experiment "went bad because of clumsy injection procedures."

According to the official Sloan-Kettering report on Laetrile, released at a much later date, Dr. Martin claims that he did not keep all of the Laetrile mice in the same cages but mixed them together with the control mice. Therefore, Sugiura could not have picked the right cages.² Interesting. That means either (1) Dr. Stock lied when he said the blind had been removed, or (2) Dr. Martin lied when he said the mice were mixed, or (3) the report was in error.

Most likely, the report was in error. The authors possibly confused the circumstances with the next series of tests (yes, one more) which, indeed, did mix the mice all together. This was also under the supervision of Dr. Martin and it was also blinded to

1. Moss, *Cancer Syndrome*, op. cit., p. 147.

2. *Ibid.* p. 147.

Sugiura, but it was conducted at Sloan-Kettering where things could be watched more closely. Sugiura warned that mixing the mice was very dangerous, because there would be no dependable way to insure that the lab technicians would always make the correct identification. What would happen if the controls were accidentally given Laetrile instead of saline solution? His warnings were ignored, and the experiment proceeded. Martin was in total control.

It is apparent that treating the wrong mice is exactly what happened. The data showed that some of the mice supposedly receiving saline solution had their tumors stop growing 40% of the time! That is impossible. Salt water never before in history stopped tumor growth. Yet, in this test, all of a sudden it is a magic bullet. How did the Laetrile mice fare by comparison? Their tumors were arrested only 27% of the time. The untreated mice did better than the treated ones! At last, they had the results they had been waiting for.

Dr. Sugiura was incensed at the audacity of releasing blatantly impossible statistics. He said:

There's something funny here. The small tumors stopped growing 40% of the time in the saline control group and only 27% of the time in the treated group. We people in chemotherapy use saline solution because it does not affect tumor growth. Now this happens. They must not forget to mention that there was more stoppage in the controls than in the treated! I won't give in to this.¹

Dr. Stock was not concerned about the integrity of the data. It supported the desired conclusion and was good enough. His final statement was short and to the point: "Results from the experiment do not confirm the earlier positive findings of Sugiura." Of course, they didn't. The experiment was rigged.

Once again, truth was sacrificed on the altar of monetary avarice. The book was finally closed. There would be no more tests.

Five months later, on June 15, 1977, a news conference was called at Sloan-Kettering to announce the conclusion of the Laetrile trials. All of the key players were in the room: Dr. Robert Good, Director and President of the Institute; Dr. Lewis Thomas, President of the Center; Dr. C. Chester Stock, vice president; Dr. Daniel Martin, from the Catholic Medical Center; and seven

1. *Ibid.* p. 148.

others including Dr. Kanematsu Sugiura who had been invited to attend but not to participate.

Dr. Good began the conference by reading aloud the press release which said that, after exhaustive and carefully controlled testing, "Laetrile was found to possess neither preventive, nor tumor-regressant, nor anti-metastatic, nor curative anti-cancer activity. After he was finished with his statement, the floor was opened to questions.

"Dr. Sugiura," someone shouted out suddenly. "Do you stick by your belief that Laetrile stops the spread of cancer?"

The television cameras quickly turned to Sugiura for his reply. A hush fell across the room. Sugiura looked at the reporter and, in a loud, clear voice, said: "I stick!"

The following month, in July of 1977, hearings were held before the Subcommittee on Health and Scientific Research, which was under the chairmanship of Senator Edward Kennedy. The nature of the hearings was made obvious by the title under which they were published, which was "Banning of the Drug Laetrile from Interstate Commerce by FDA." One of the experts to testify was Dr. Lewis Thomas, President of Sloan-Kettering. This is what he said:

There is not a particle of scientific evidence to suggest that Laetrile possesses any anti-cancer properties at all. I am not aware of any scientific papers, published in any of the world's accredited journals of medical science, presenting data in support of the substance, although there are several papers, one of these recently made public by Sloan-Kettering Institute, reporting the complete absence of anti-cancer properties in a variety of experimental animals.

In the following months, the directors and officers at Sloan-Kettering continued to denigrate Sugiura's findings, claiming that no one else had ever been able to duplicate them. In other words, they lied. Not only did they lie, they did so on a subject that directly effects the lives of hundreds of thousands of cancer victims each year. It is not an exaggeration to say that over a million people have needlessly gone to their death as a result of that lie. There is a word for that.

It is genocide.

Ralph Moss was the Assistant Director of Public Affairs at Sloan-Kettering during most of these events. In fact, he was the one who was required to write the press release claiming that Laetrile was ineffective. But Moss was one of the leaders in the

Second Opinion underground and had helped to get the truth out to the rest of the world. Finally, in November of 1977, he decided to "surface" and go public. He called a press conference of his own and, before a battery of reporters and cameramen, charged that Sloan-Kettering officials had engineered a massive cover-up. He provided supporting documents and named names.

Not surprisingly, Moss was fired the next day. What was the official justification? As he explained it: "I had 'failed to carry out my most basic job responsibilities'—in other words, to collaborate in falsifying evidence."¹

Moss and the other whistle-blowers were soon forgotten by the mainstream media, and the public has been spared the trouble of hearing any more about it. In the end, the cancer industry had won. As in all wars, it is the victor who writes the accepted history. What follows is the way our medical historians now explain this episode. It was written by Dr. Arnold S. Relman, and appeared in the *New England Journal of Medicine* on January 28, 1982:

Over the past few years we have devoted a lot of attention to Laetrile. By 1978 it had achieved a certain folk status, celebrated as a kind of anti-establishment natural remedy being suppressed by a venal conspiracy between pharmaceutical manufacturers and physicians. According to the folklore, the conspirators were ignoring evidence of Laetrile's effectiveness and attempting to promote their more orthodox (and more toxic) forms of cancer chemotherapy. There have never been any facts to support this folklore....

Laetrile, I believe, has now had its day in court. The evidence, beyond reasonable doubt, is that it doesn't benefit patients.... No sensible person will want to advocate its further use, and no state legislature should sanction it any longer.²

This, then, is the background on the so-called scientific evidence that Laetrile is a fraud. Based upon this perversion of truth, laws have been passed making it illegal to prescribe, administer, sell, or distribute Laetrile or to "make any representation that said agents have any value in arresting, alleviating, or curing cancer."³

1. Ralph Moss, *The Cancer Industry; Unraveling the Politics* (New York: Paragon House, 1989), p. xi.

2. "Closing the Books on Laetrile," *New England Journal of Medicine*, January 28, 1982, p. 236.

3. See Section 10400.1, Title 17, of the Calif. Administrative Code.

Why would anyone, in or out of government, deliberately falsify the clinical results of past Laetrile experiments and then make it impossible for anyone else to do tests of his own? In spite of Dr. Relman's smug derision, the pharmaceutical connection is the key to understanding the answer. That is an amazing and fascinating story in itself and it is so rich in detail that the entire second half of this book is devoted to the telling of it. But we must understand at the outset that the economics of cancer therapy often weigh more heavily than the science of cancer therapy.

This fact was dramatically revealed at a high-level meeting which was held at Sloan-Kettering on July 2, 1974. The discussions were very private and candid. We would never have known about it except for the fact that the minutes of the meeting were obtained several years later under the Freedom-of-Information Act by Representative John Kelsey of the Michigan House of Representatives. The minutes showed that, even then, numerous Sloan-Kettering officials were convinced of the effectiveness of Laetrile, although there remained some question about the *extent* of that effectiveness. Then the minutes read: "Sloan-Kettering is not enthusiastic about studying amygdalin [Laetrile] but would like to study CN[cyanide]-releasing drugs."

That is precisely the prediction this author made in 1974 in the first edition of the book you are now reading. (It is still there in chapter 24.) The substance of that prediction is that amygdalin cannot be patented because it is found in nature. Big money can be made only with patented drugs. Therefore, the cancer industry will never be interested in amygdalin, no matter how effective it may be. Instead, they will seek to create a man-made chemical to imitate the mechanism by which it works. Since the mechanism by which amygdalin works is the selective release of cyanide at the cancer site (see chapter 6), it is logical that the moguls at Sloan-Kettering were "not enthusiastic about studying amygdalin but would like to study CN-releasing drugs instead."

Although the entire second half of this book is devoted to an analysis of the economics and politics of the cancer industry, that one sentence taken from the minutes of a policy meeting at Sloan-Kettering tells it all.

Returning one more time to the vexing question of why the cancer industry wages war on Laetrile, let us listen to the answer given by the unsinkable Dr. Burk in a letter to the Honorable Robert A. Roe, dated July 3, 1973. He said:

You may wonder, Congressman Roe, why anyone should go to such pains and mendacity to avoid conceding what happened in the NCI-directed experiment. Such an admission and concession is crucially central. Once any of the FDA-NCI-AMA-ACS hierarchy so much as concedes that Laetrile anti-tumor efficacy was even once observed in NCI experimentation, a permanent crack in bureaucratic armor has taken place that can widen indefinitely by further appropriate experimentation. For this reason, I rather doubt that experimentation ... will be continued or initiated. On the contrary, efforts probably will be made, as they already have, to "explain away" the already observed positive efficacy by vague and unscientific modalities intended to mislead, along early Watergate lines of corruption....

There are now several thousand persons in the United States taking Laetrile daily. M.D.'s by the hundreds are studying or even taking it themselves, and certain hospitals are now undertaking its study. FDA or no FDA, NCI or no NCI, obfuscations or no obfuscations. The day may not be far off when face-saving on the part of the NCI-FDA spokesmen of the type just indicated will have lagged beyond possibility, as is already now the case for some Watergate casualties of Courts and Hearings, as a result of persons placing personal integrity secondary to other considerations.¹

Now, that takes *guts*. For a man who is employed by the federal government, especially as head of the Cytochemistry section of the National Cancer Institute, to charge openly that his superiors are corrupt—well, such a man is, unfortunately, a rare specimen in Washington. Concluding his testimony on Laetrile before a Congressional committee in 1972, Dr. Burk explained:

I don't think of myself as a maverick. I am just telling you what I honestly think, and when I think something is true, I am quite willing to say so and let the chips fall where they may....

And now, I will get back to my laboratory where truth is distilled.²

Let us, figuratively speaking, follow Dr. Burk to his laboratory. Let us put aside, for the moment, the question of politics and corruption, and turn now to the distillation of scientific truth.

1. Letter reprinted in *Cancer Control Journal*, Sept./Oct., 1973, pp. 8, 9.

2. From Hearings, Subcommittee on Public Health and Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-Second Congress.

Chapter Three

AN APPLE A DAY

A review of entrenched scientific error in history; the vitamin-deficiency concept of cancer as advanced in 1952 by Dr. Ernst T. Krebs, Jr.; and a survey of the evidence both in nature and in history to support that concept.

The history of science is the history of struggle against entrenched error. Many of the world's greatest discoveries initially were rejected by the scientific community. And those who pioneered those discoveries often were ridiculed and condemned as quacks or charlatans.

Columbus was bitterly attacked for believing the Earth was round. Bruno was burned at the stake for claiming that Earth was not the center of the Universe. Galileo was imprisoned for teaching that the Earth moved around the Sun. Even the Wright Brothers were ridiculed for claiming that a machine could fly.

In the field of medicine, in the year 130 A.D., the physician Galen announced certain anatomic theories that later proved to be correct, but at the time he was bitterly opposed and actually forced to flee from Rome to escape the frenzy of the mob. In the Sixteenth Century, the physician Andreas Vesalius was denounced as an impostor and heretic because of his discoveries in the field of human anatomy. His theories were accepted after his death but, at the time, his career was ruined, and he was forced to flee from Italy. William Harvey was disgraced as a physician for believing that blood was pumped by the heart and moved around the body through arteries. William Roentgen, the discoverer of X-rays, at first was called a quack and then condemned out of fear that his "ray" would invade the privacy of the bedroom. William Jenner, when he first developed a vaccine against smallpox, also was called a quack and was strongly criticized as a physician for his supposedly cruel and inhuman experiments on children. And Ignaz Semmelweis was fired from

his Vienna hospital post for requiring his maternity staff to wash their hands.

Centuries ago it was not unusual for entire naval expeditions to be wiped out by scurvy. Between 1600 and 1800 the casualty list of the British Navy alone was over one million sailors. Medical experts of the time were baffled as they searched in vain for some kind of strange bacterium, virus, or toxin that supposedly lurked in the dark holds of ships. And yet, for hundreds of years, the cure was already known and written in the record.

In the winter of 1535, when the French explorer Jacques Cartier found his ships frozen in the ice off the St. Lawrence River, scurvy began to take its deadly toll. Out of a crew of one hundred and ten, twenty-five already had died, and most of the others were so ill they weren't expected to recover.

And then a friendly Indian showed them the simple remedy. Tree bark and needles from the white pine—both rich in ascorbic acid, or vitamin C—were stirred into a drink which produced immediate improvement and swift recovery.

Upon returning to Europe, Cartier reported this incident to the medical authorities. But they were amused by such "witch-doctor cures of ignorant savages" and did nothing to follow it up.¹

Yes, the cure for scurvy was known. But, because of scientific arrogance, it took over two hundred years and cost hundreds of thousands of lives before the medical experts began to accept and apply this knowledge.

Finally, in 1747, John Lind, a young surgeon's mate in the British Navy discovered that oranges and lemons produced relief from scurvy and recommended that the Royal Navy include citrus fruits in the stores of all its ships. And yet, it still took forty-eight *more* years before his recommendation was put into effect. When it was, of course, the British were able to surpass all other sea-faring nations, and the "Limeys" (so-called because they carried limes aboard ship) soon became the rulers of the Seven Seas. It is no exaggeration to say that the greatness of the British Empire in large measure was the direct result of overcoming scientific prejudice against vitamin therapy.

The twentieth century has proven to be no exception to this pattern. Only two generations ago large portions of the American

1. See Virgil J. Vogel's *American Indian Medicine* (Norman, Oklahoma: University of Oklahoma Press, 1970).

Southeast were decimated by the dread disease of pellagra. The well-known physician Sir William Osler, in his *Principles and Practice of Medicine*, explained that in one institution for the insane in Leonard, North Carolina, one-third of the inmates died of this disease during the winter months. This proved, he said, that pellagra was contagious and caused probably by an as yet undiscovered virus. As far back as 1914, however, Dr. Joseph Goldberger had proven that this condition was related to diet, and later showed that it could be prevented simply by eating liver or yeast. But it wasn't until the 1940's—almost thirty years later—that the "modern" medical world fully accepted pellagra as a vitamin B deficiency.¹

The story behind pernicious anemia is almost exactly the same. The reason that these diseases were so reluctantly accepted as vitamin deficiencies is because men tend to look for positive cause-and-effect relationships in which something *causes* something else. They find it more difficult to comprehend the negative relationship in which *nothing* or the *lack* of something can cause an effect. But perhaps of even more importance is the reality of intellectual pride. A man who has spent his life acquiring scientific knowledge far beyond the grasp of his fellow human beings is not usually inclined to listen with patience to someone who lacks that knowledge—especially if that person suggests that the solution to the scientist's most puzzling medical problem is to be found in a simple back-woods or near-primitive concoction of herbs and foods. The scientist is trained to search for *complex* answers and tends to look with smug amusement upon solutions that are not dependent upon his hard-earned skills.

To bring this a little closer to home, the average M.D. today has spent over ten years of intensive training to learn about health and disease. This educational process continues for as long as he practices his art. The greatest challenge to the medical profession today is cancer. If the solution to the cancer puzzle were to be found in the simple foods we eat (or *don't* eat), then what other diseases might also be traced to this cause? The implications are explosive. As one doctor put it so aptly, "Most of my medical training has been wasted. I've learned the wrong things!" And no one wants to discover that he has learned—or taught—the wrong things. Hence, there is an unconscious, but

1. See Edwin H. Ackerknecht, *History and Geography of the Most Important Diseases* (New York: Hafner Publishing Co., Inc., 1972) pp. 148-149.

natural, tendency among many scientists and physicians to reject the vitamin-deficiency concept of disease until it is proven, and proven, and proven again.

By 1952, Dr. Ernst T. Krebs, Jr., a biochemist in San Francisco, had advanced the theory that cancer, like scurvy and pellagra, is not caused by some kind of mysterious bacterium, virus, or toxin, but is merely a deficiency disease aggravated by the lack of an essential food compound in modern-man's diet. He identified this compound as part of the nitriloside family which occurs abundantly in nature in over twelve-hundred edible plants and found virtually in every part of the world. It is particularly prevalent in the seeds of those fruits in the *Prunus Rosacea* family (bitter almond, apricot, blackthorn, cherry, nectarine, peach, and plum), but also contained in grasses, maize, sorghum, millet, cassava, linseed, apple seeds, and many other foods that, generally, have been deleted from the menus of modern civilization.

It is difficult to establish a clear-cut classification for a nitriloside. Since it does not occur entirely by itself but rather is found in foods, it probably should not be classified as a *food*. Like sugar, it is a food component or a food factor. Nor can it be classified as a drug inasmuch as it is a natural, non-toxic, water-soluble substance entirely normal to and compatible with human metabolism. The proper name for a food factor that contains these properties is *vitamin*. Since this vitamin normally is found with the B-complex, and since it was the seventeenth such substance to be isolated within this complex, Dr. Krebs identified it as *vitamin B₁₇*. He said:

Can the water-soluble non-toxic nitrilosides properly be described as food? Probably not in the strict sense of the word. They are certainly not drugs *per se*.... Since the nitrilosides are neither food nor drug, they may be considered as accessory food factors. Another term for water-soluble, non-toxic accessory food factors is vitamin.¹

A chronic disease is one which usually does not pass away of its own accord. A metabolic disease is one which occurs within the body and is not transmittable to another person. Cancer, therefore, being all of these, is a chronic, metabolic disease.

There are many of these diseases that plague modern man, such as muscular dystrophy, heart disease, multiple sclerosis, and

1. Krebs, *The Laetriles/Nitrilosides in the Prevention and Control of Cancer* (Montreal: The McNaughton Foundation, n.d.), p. 16.

sickle-cell anemia. Scientists have spent billions of dollars searching for a prevention of these cripplers and killers, but they are no closer to the answers today than they were when they started. Perhaps the reason is that they are still looking for that *something* which causes these diseases instead of the *lack* of something.

Dr. Krebs has pointed out that, in the entire history of medical science, there has not been one chronic, metabolic disease that was ever cured or prevented by drugs, surgery, or mechanical manipulation of the body. In every case—whether it be scurvy, pellagra, rickets, beri-beri, night blindness, pernicious anemia, or any of the others—the ultimate solution was found only in factors relating to adequate nutrition. And he thinks that this is an important clue as to where to concentrate our scientific curiosity in the search for a better understanding of today's diseases, particularly cancer.

But there are other clues as well. As everyone who owns a dog or cat has observed, these domesticated pets often seek out certain grasses to eat even though they are adequately filled by other foods. This is particularly likely to happen if the animals are not well. It is interesting to note that the grasses selected by instinct are Johnson grass, Tunis grass, Sudan grass, and others that are especially rich in nitrilosides or vitamin B₁₇.

Monkeys and other primates at the zoo when given a fresh peach or apricot will carefully pull away the sweet fleshy part, crack open the hard pit, and devour the seed that remains. Instinct compels them to do this even though they have never seen that kind of fruit before. These seeds are one of the most concentrated sources of nitrilosides to be found anywhere in nature.

Wild bears are great consumers of nitrilosides in their natural diet. Not only do they seek berries that are rich in this substance, but when they kill small grazing animals for their own food, instinctively they pass over the muscle portions and consume first the viscera and rumen which are filled with nitrilosite grasses.¹

In captivity, animals seldom are allowed to eat all the foods of their instinctive choice. In the San Diego Zoo, for example, the routine diet for bears, although nutritious in many other respects, is almost totally devoid of nitrilosides. In one grotto alone, over a

1. See Peter Krott, Ph.D., *Bears in The Family* (New York: E.P. Dutton & Co., 1962).

six-year period, five bears died of cancer. It was generally speculated by the experts that a virus had been the cause.

It is significant that one seldom finds cancer in the carcasses of wild animals killed in the hunt. These creatures contract the disease only when they are domesticated by man and forced to eat the foods he provides or the scraps from his table.

It is amazing how cancer researchers can come face-to-face with this evidence and still fail to realize its significance. Dr. Dennis P. Burkitt, the man who first identified the form of cancer known as Burkitt Lymphoma, delivered a lecture at the College of Medicine at the University of Iowa. After two decades of experience and research in Uganda and similar parts of the world, Dr. Burkitt observed that non-infectious (chronic metabolic) diseases such as cancer of the colon, diverticular disease, ulcerative colitis, polyps, and appendicitis, all seem to be related in some way. "They all go together," he said, "and I'm going to go so far as to suggest that they all have a common cause." He went on to say that all of these diseases are unknown in primitive societies and "always have their maximum incidence in the more economically developed nations."

Then Dr. Burkitt turned his attention to cancer specifically and observed:

This is a disease caused by the way we live. This form of cancer is almost unknown in the animal kingdom. The only animals who get cancer or polyps of the large bowel are those that live closest to our way of life—our domestic dogs eating our leftovers.¹

These are all excellent observations. But apparently neither Dr. Burkitt nor anyone in his esteemed audience could find any meaning in these facts. The lecture closed with the conclusion that colon cancer probably is related to bacteria in the large bowel and that we should all eat more bran and other cereal fibers to increase the roughage content of our intestines and the size of our stools!

At least Dr. Burkitt was looking at the foods we eat, which was a huge step forward. He may have been heading in the wrong direction, but at least he was on the right track. If more cancer researchers would think in terms of foods and vitamins

1. "The Evidence Leavens: We Invite Colon Cancer," *Medical World News*, Aug. 11, 1972, pp. 33, 34.

rather than bacteria and viruses, it wouldn't take them long to see why the cancer rate in America is steadily climbing.

Measured in terms of taste, volume, and variety, Americans eat very well, indeed. But expensive or tasty food is not necessarily good food. Many people assume that it makes little difference what they put into their stomachs as long as they are full. Magically, everything that goes in somehow will be converted into perfect health. They scoff at the thought of proper diet. Yet, many of these same people are fastidious about what they feed their pedigreed dogs and cats or their registered cattle and horses.

Dr. George M. Briggs, professor of nutrition at the University of California, and member of the Research Advisory Committee of the National Livestock and Meat Board, has said: "The typical American diet is a national disaster.... If I fed it to pigs or cows, without adding vitamins and other supplements, I could wipe out the livestock industry."¹

A brief look at the American diet tells the story. Grocery shelves are now lined with high carbohydrate foods that have been processed refined, synthesized, artificially flavored, and loaded with chemical preservatives.² Some manufacturers, aiming their advertisements at the diet-conscious consumer, even boast of how little real food there is in their product.

Everyone knows that modern processing removes many of the original vitamins from our foods, but we are told not to worry about it, because they have been put back before sending to market. And so we see the word "enriched" printed cheerfully across our bread, milk, and other foods. But make no mistake about it, these are *not* the same as the original. As the June 1971 *Journal of the American Geriatric Society* reported:

Vitamins removed from food and returned as "enrichment" are not a safe substitute, as witnessed by the study in which Roger J. Williams, Ph.D., reported that rats fed enriched bread died or were

1. "University of California Nutrition Professor, A Health Advisor to the U.S. Government... Charges the Typical American Diet is a National Disaster," *National Enquirer*, Dec. 5, 1971, p. 2.

2. There are now approximately 3,000 additives used in U.S. food products for flavoring, coloring, preservation, and similar purposes. Most are safe in the quantities used, but many of these chemicals pose a serious health hazard with prolonged use. See *Toxics A to Z*, by Harte, Holdren, Schneider, and Shirley (Berkeley: University of California Press, 1991).

severely stunted due to malnutrition. Rats fed a more whole bread flourished, for the most part, by comparison.

Much illness, we are learning, may be due to vitamin-mineral deficiencies. Even senility has been proven to be caused by a deficiency of Vitamins B and C.

Indeed, here is a worthy experiment that can and should be carried out in every grade-school science class. Rodents fed only "enriched" bread very soon become anti-social. Some even become cannibalistic, apparently responding to an instinctive drive to obtain the vital food elements they are lacking. Most will die within a month or two. Once children have witnessed this, they seldom retain the same appetite for white bread that they may have had prior to the experiment.

"Enriched" bread is just one small part of the larger picture. Millet once was the world's staple grain. It is high in nitriloside content. But now it has been replaced by wheat which has practically none at all—even whole wheat. Sorghum cane has been replaced by sugar cane with the same result. Even our cattle are fed increasingly on quick-growing, low-nitriloside grasses so there is less vitamin B₁₇ residue in the meat we eat. In some places, livestock now are being fed a diet containing fifteen percent *paper* to fatten them quicker for market.¹

In retrospect, there were many customs of our grandparents that, although lacking in scientific rationale at the time, were based upon centuries of accumulated experience through trial and error, and have since been proven to be infinitely wise. "An apple a day keeps the doctor away" could well have been more than an idle slogan, especially in an era when it was customary for everyone to eat the seeds of those apples as well. It is a fact that the whole fruit—including the seeds—of an apple contains an amazingly high concentration of vitamins, minerals, fats, and proteins that are essential for health. Apple seeds are especially rich in nitrilosides or vitamin B₁₇. The distasteful "spring tonic" or sorghum molasses and sulphur also was a rich source of nitriloside. And grandma's apricot and peach preserves almost always contained the kernels of these canned fruits for winter eating. She probably didn't know what they contained or why they were good for you. But she knew that they *were* good for you simply because her mother had told her so.

1. "Paper Fattens Cattle," (UPI) *Oakland Tribune*, Nov. 22, 1971.

And so we see that the foods that once provided the American people with ample amounts of natural vitamin B₁₇ gradually have been pushed aside or replaced altogether by foods almost devoid of this factor. Significantly, it is during this same period that the cancer rate has moved steadily upward to the point where, today, one out of every three persons in the United States is destined to contract this disease.

It cannot be argued that the cancer rate is up merely because other causes of death are down and, thus, people are living longer. First of all, they are *not* living that much longer—only a few years, on the average, over the past four generations. In 1972, a year in which the average age of the American population was headed *downward*, a year in which the population growth rate had shrunk practically to *zero*, the death rate from cancer rose to the highest level it had yet reached: *three times* the 1950 rate.¹ Secondly, in those countries where people live *longer* than in the United States, the cancer rate for them is *lower* than for us.

There is no escape from the significance of these facts. While the medical world, the federal government, and the American Cancer Society are spending billions of dollars and millions of man-hours searching for an exotic cancer virus against which they plan to spend an equal amount to create an effective man-made immunization, the answer lies right under their noses. In fact, it has existed in the written and spoken record for thousands of years:

And God said: Behold I have given you every herb-bearing seed upon the earth, and all trees that have in themselves seed of their own kind, to be your meat. (*Genesis 1:29*)

1. "Cancer Cure Still Eludes Scientists," (NEA) *News Chronicle* (Calif.) Aug. 29, 1973, p. A-9.

Chapter Four

THE ULTIMATE TEST

A look at the many cultures around the world that are, or have been, free from cancer; and an analysis of their native foods.

The best way to prove or disprove the vitamin theory of cancer would be to take a large group of people numbering in the thousands and, over a period of many years, expose them to a consistent diet of rich nitriloside foods, and then check the results. This, surely, would be the ultimate test.

Fortunately, it already has been done.

In the remote recesses of the Himalaya Mountains, between West Pakistan, India, and China, there is a tiny kingdom called Hunza. These people are known world over for their amazing longevity and good health. It is not uncommon for Hunzakuts to live beyond a hundred years, and some even to a hundred and twenty or more. Visiting medical teams from the outside world have reported that they found no cancer in Hunza.

Although presently accepted science is unable to explain *why* these people should have been free of cancer, it is interesting to note that the traditional Hunza diet contains over two-hundred times more nitriloside than the average American diet. In fact, in that land where there was no such thing as money, a man's wealth was measured by the number of apricot trees he owned. And the most prized of all foods was considered to be the apricot seed.

One of the first medical teams to gain access to the remote kingdom of Hunza was headed by the world-renowned British surgeon and physician Dr. Robert McCarrison. Writing in the January 7, 1922, issue of the *Journal of The American Medical Association*, Dr. McCarrison reported:

The Hunza has no known incidence of cancer. They have ... an abundant crop of apricots. These they dry in the sun and use very largely in their food.

Visitors to Hunza, when offered a fresh apricot or peach to eat, usually drop the hard pit to the ground when they are through. This brings looks of dismay and disbelief to the faces of their guides. To them, the seed inside is the delicacy of the fruit.

Dr. Allen E. Banik, an optometrist from Kearney, Nebraska, was one such visitor. In his book, *Hunza Land*, he describes what happened:

My first experience with Hunza apricots, fresh from the tree, came when my guide picked several, washed them in a mountain stream, and handed them to me. I ate the luscious fruit and casually tossed the seeds to the ground. After an incredulous glance at me, one of the older men stooped and picked up the seeds. He cracked them between two stones, and handed them to me. The guide said with a smile: "Eat them. It is the best part of the fruit."

My curiosity aroused, I asked, "What do you do with the seeds you do not eat?"

The guide informed me that many are stored, but most of them are ground very fine and then squeezed under pressure to produce a very rich oil. "This oil," my guide claimed, "looks much like olive oil. Sometimes we swallow a spoonful of it when we need it. On special days, we deep-fry our *chappatis* [bread] in it. On festival nights, our women use the oil to shine their hair. It makes a good rubbing compound for body bruises."¹

In 1973, Prince Mohammed Ameen Khan, son of the Mir of Hunza, told Charles Hillinger of the *Los Angeles Times* that the average life expectancy of his people is about eighty-five years. He added: "Many members of the Council of Elders who help my father govern the state have been over one hundred."²

With a scientific distrust for both hearsay and the printed word, Dr. Ernst T. Krebs, Jr., met with Prince Khan for dinner where he queried him on the accuracy of the *L.A. Times* report. The prince happily confirmed it and then described how it was not uncommon to eat thirty to fifty apricot seeds as an after-lunch snack.³ These often account for about 30 mg. of vitamin B₁₇ per day in addition to as much as 75,000 International Units of vitamin A. Despite all of this, or possibly because of it, the life expectancy in Hunza, the Prince affirmed, is about

1. Allen E. Banik and Renee Taylor, *Hunza Land* (Long Beach, Calif.: Whitehorn, 1960), pp. 123-24.

2. *Los Angeles Times*, May 7, 1973, Part I-A.

3. Seeds in Hunza contain only about 6% of the amygdalin in typical California apricots. Eating that many U.S.-grown seeds would not be wise because of the possibility of a toxic effect. See Chapter Seven for information on toxicity.

eighty-five years. This is in puzzling contrast to the United States where, at that time, life expectancy was about seventy-one years. Even now, more than two decades later, life expectancy at birth in the U.S. is only about seventy-six.

That number may sound pretty good, but remember that it includes millions of old people who are alive but not really *living*. The *length* of their lives may have been extended by surgery or medication, but the *quality* of their lives has been devastated in the process. They are the ones who stare blankly into space with impaired mental capacity, or who are dependent on life-support mechanisms, or who are confined to bed requiring round-the-clock care. There are no such cases buried in the statistics from Hunza. Most of those people are healthy, vigorous, and vital right up to within a few days of the end. The quality of life is more important than the quantity. The Hunzakuts have both.

It will be noted that the Hunzakut intake of vitamin A may run seven-and-a-half times the maximum amount the FDA allows to be used in a tablet or capsule, while that agency has tried to outlaw entirely the eating of apricot seeds.

The women of Hunza are renowned for their strikingly smooth skin even into advanced age. Generally, their faces appear fifteen to twenty years younger than their counterparts in other areas of the world. They claim that their secret is merely the apricot oil which they apply to their skins almost daily.

In 1974 Senator Charles Percy, a member of the Senate Special Committee on Aging, visited Hunza. When he returned to the United States he wrote:

We began curiously to observe the life style of the Hunzakuts. Could their eating habits be a source of longevity? ...

Some Hunzakuts believe their long lives are due in part to the apricot. Eaten fresh in the summer, dried in the sun for the long winter, the apricot is a staple in Hunza, much as rice is in other parts of the world. Apricot seeds are ground fine and squeezed for their rich oil, used for both frying and lighting.¹

And so, the Hunzakuts use the apricot, its seed, and the oil from its seed for practically everything. They share with most western scientists an ignorance of the chemistry and physiology of the nitriloside content of this fruit, but they have learned empirically that their life is enhanced by its generous use.

1. "You Live To Be 100 in Hunza," *Parade*, Feb. 17, 1974, p. 11.

Five or six excellent volumes similar to Dr. Banik's have been written by those who have risked their lives over the treacherous Himalaya Mountain passes to gain entrance to Hunza. Also, there have been scores of magazine and newspaper articles published over the years. They all present the identical picture of the average Hunza diet. In addition to the ever-present apricot, the Hunzakuts eat mainly grain and fresh vegetables. These include buckwheat, millet, alfalfa, peas, broad beans, turnips, lettuce, sprouting pulse or gram, and berries of various sorts. All of these, with the exception of lettuce and turnips, contain nitriloside or vitamin B₁₇.

It is sad to note that, in recent years, a narrow road was finally carved through the mountains, and food supplies from the "modern world" have at last arrived in Hunza. So have the first few cases of cancer.

In 1927 Dr. McCarrison was appointed Director of Nutrition Research in India. Part of his work consisted of experiments on albino rats to see what effect the Hunza diet had on them compared to the diets of other countries. Over a thousand rats were involved in the experiment and carefully observed from birth to twenty-seven months, which corresponds to about fifty years of age in man. At this point the Hunza-fed rats were killed and autopsied. Here is what McCarrison reported:

During the past two and a quarter years there has been no case of illness in the "universe" of albino rats, no death from natural causes in the adult stock, and, but for a few accidental deaths, no infantile mortality. Both clinically and at post-mortem, examination of this stock has been shown to be remarkably free from disease. It may be that some of them have cryptic disease of one kind or another, but if so, I have failed to find either clinical or microscopic evidence of it.¹

By comparison, over two thousand rats fed on typical Indian and Pakistani diets soon developed eye ailments, ulcers, boils, bad teeth, crooked spines, loss of hair, anemia, skin disorders, heart, kidney and glandular weaknesses, and a wide variety of gastrointestinal disorders.

In follow-up experiments, McCarrison gave a group of rats the diet of the lower classes of England. It consisted of white bread, margarine, sweetened tea, boiled vegetables, canned meat,

1. Quoted by Renee Taylor, *Hunza Health Secrets* (New York: Award Books, 1964), pp. 96-7.

and inexpensive jams and jellies—a diet not too far removed from that of many Americans. Not only did the rats develop all kinds of chronic metabolic diseases, but they also became nervous wrecks. McCarrison wrote:

They were nervous and apt to bite their attendants; they lived unhappily together, and by the sixteenth day of the experiment they began to kill and eat the weaker ones amongst them.¹

It is not surprising, therefore, to learn that westernized man is victimized by the chronic metabolic disease of cancer while his counterpart in Hunza is not. And lest anyone suspect that this difference is due to hereditary factors, it is important to know that when the Hunzakuts leave their secluded land and adopt the menus of other countries, they soon succumb to the same diseases and infirmities—including cancer—as the rest of mankind.

The Eskimos are another people that have been observed by medical teams for many decades and found to be totally free of cancer. In VilhJalmur Stefanson's book, *Cancer: Disease of Civilization? An Anthropological and Historical Study*,² it is revealed that the traditional Eskimo diet is amazingly rich in nitrilosides that come from the residue of the meat of caribou and other grazing animals, and also from the salmon berry which grows abundantly in the Arctic areas. Another Eskimo delicacy is a green salad made out of the stomach contents of caribou and reindeer which are full of fresh tundra grasses. Among these grasses, Arrow grass (*Triglochin Maritima*) is very common. Studies made by the U.S. Department of Agriculture have shown that Arrow grass is probably richer in nitriloside content than any other grass.

What happens when the Eskimo abandons his traditional way of life and begins to rely on westernized foods? He becomes even more cancer-prone than the average American.

Dr. Otto Schaefer, M.D., who has studied the diets and health patterns of the Eskimos, reports that these people have undergone a drastic change in their eating habits, caused indirectly by the construction of military and civilian airports across the Canadian Arctic in the mid-50's. These attracted the Eskimos to new jobs, new homes, new schools—and new menus. Just a little over one generation previously, their diet consisted almost entirely of game and fish, along with seasonal berries, roots, leafy

1. *Ibid.* p. 97.

2. New York: Hill and Wang, 1960.

greens and seaweed. Carbohydrates were almost completely lacking.

Suddenly, all of that changed. Dr. Schaefer reports:

When the Eskimo gives up his nomadic life and moves into the settlement, he and his family undergo remarkable changes. His children grow faster and taller, and reach puberty sooner. Their teeth rot, his wife comes down with gallbladder disease and, likely as not, a member of his family will suffer one of the degenerative diseases for which the white man is well known.¹

There are many other peoples in the world that could be cited with the same characteristics. The Abkhazians deep in the Caucasus Mountains on the Northeast side of the Black Sea are a people with almost exactly the same record of health and longevity as the Hunzakuts. The parallels between the two are striking. First, Abkhazia is a *hard* land which does not yield up a harvest easily. The inhabitants are accustomed to daily hard work throughout their lives. Consequently, their bodies and minds are strong right up until death, which comes swiftly with little or no preliminary illness. Like the Hunzakuts, the Abkhazians expect to live well beyond eighty years of age. Many are over a hundred. One of the oldest persons in the world was Mrs. Shirali Mislimov of Abkhazia who, in 1972, was estimated to be 165 years old.²

The other common factor, of course, is the food, which, typically, is low in carbohydrates, high in vegetable proteins, and rich in minerals and vitamins, especially vitamin B₁₇.

The Indians of North America, while they remained true to their native customs and foods, also were remarkably free from cancer. At one time, the American Medical Association urged the federal government to conduct a study in an effort to discover why there was so little cancer among the Hopi and Navajo Indians. The February 5, 1949, issue of the *Journal* of the AMA declared:

The Indian's diet seems to be low in quality and quantity and wanting in variety, and the doctors wondered if this had anything to do with the fact that only 36 cases of malignant cancer were found out of 30,000 admissions to the Ganado Arizona Mission Hospital.

1. *Nutrition Today*, Nov./Dec., 1971, as quoted in "Modern Refined Foods Finally Reach The Eskimos," *Kaysers Health Research*, May, 1972, pp. 11, 46, 48.

2. "The Secret of Long Life" by Sula Benet, (N.Y. Times News Service), *L.A. Herald Examiner*, Jan. 2, 1972, p. A-12. Also "Soviet Study Finds Recipe for Long Life," *National Enquirer*, Aug. 27, 1972, p. 13.

In the same population of white persons, the doctors said there would have been about 1,800.

Thirty-six cases compared to eighteen hundred represents only two percent of the expected number. Obviously, *something* is responsible.

Dr. Krebs, who has done exhaustive research on this subject, has written:

I have analyzed from historical and anthropological records the nitrilosidic content of the diets of these various North American tribes. The evidence should put to rest forever the notion of toxicity in nitrilosidic foods. Some of these tribes would ingest over 8,000 milligrams of vitamin B₁₇ (nitriloside) a day. My data on the Modoc Indians are particularly complete.¹

A quick glance at the cancer-free native populations in tropical areas, such as South America and Africa, reveals a great abundance and variety of nitriloside-rich foods. In fact, over one-third of all plants native to these areas contain vitamin B₁₇. One of the most common is cassava, sometimes described as "the bread of the tropic." But this is not the same as the sweet cassava preferred in the cities of western civilization. The native fruit is more bitter, but it is rich in nitriloside. The sweet cassava has much less of this vital substance, and even that is so processed as to eliminate practically all nitrile ions.²

As far back as 1913, Dr. Albert Schweitzer, the world-famous medical missionary to Africa, had put his finger on the basic cause of cancer. He had not isolated the specific substance, but he was convinced from his observations that a difference in food was the key. In his preface to Alexander Berglas' *Cancer: Cause and Cure* (Paris: Pasteur Institute, 1957), he wrote:

On my arrival in Gabon in 1913, I was astonished to encounter no cases of cancer. I saw none among the natives two hundred miles from the coast.... I can not, of course, say positively that there was no cancer at all, but, like other frontier doctors, I can only say that, if any cases existed, they must have been quite rare. This absence of cancer seemed to be due to the difference in nutrition of the natives compared to the Europeans....

The missionary and medical journals have recorded many such cancer-free populations all over the world. Some are in

1. Letter from Dr. E.T. Krebs, Jr. to Dr. Dean Burk of the National Cancer Institute, dated March 14, 1972, Griffin; *Private Papers*, op. cit.

2. *The Laetriles/Nitrilosides*, op. cit., pp. 9, 10.

tropic regions, some in the Arctic. Some are hunters who eat great quantities of meat, some are vegetarians who eat almost no meat at all. From all continents and all races, the *one* thing they have in common is that the degree to which they are free from cancer is in direct proportion to the amount of nitriloside or vitamin B₁₇ found in their natural diet.

In answer to this, the skeptic may argue that these primitive groups are not exposed to the same cancer-producing elements that modern man is, and perhaps *that* is the reason they are immune. Let them breathe the same smog-filled air, smoke the same cigarettes, swallow the same chemicals added to their food or water, use the same soaps or deodorants, and *then* see how they fare.

This is a valid argument. But, fortunately, even that question now has been resolved by experience. In the highly populated and often air-polluted State of California there are over 100,000 people comprising a population that shows a cancer incidence of less than fifty per cent of that for the remaining population. This unique group has the same sex, age, socioeconomic, educational, occupational, ethnic and cultural profile as the remainder of the State's population that suffers twice as high an incidence of cancer. This is the Seventh Day Adventist population of the State.

There is only one material difference that sets this population apart from that of the rest of the State. This population is predominantly vegetarian. By increasing greatly the quantity of vegetables in their diet to compensate for the absence of meat they increase proportionately their dietary intake of vitamin B₁₇ (nitriloside).¹ Probably the reason that this population is not totally free from cancer—as are the Hunzakuts, the aboriginal Eskimos, and other such populations—is that (1) many members of this sect have joined it after almost a lifetime on a general or standard dietary pattern; (2) the fruits and vegetables ingested are not consciously chosen for vitamin B₁₇ content nor are fruit seeds generally eaten by them; and (3) not *all* Seventh Day Adventists adhere to the vegetarian diet.

1. There are other substances found in vegetables that also have shown an anti-cancer effect—such as beta-carotene and a group of chemicals known as saponins which are found in a wide variety of vegetables and legumes. Nitrilosides, however, appear to be the most potent. See "Vegemania, Scientists Tout the Health Benefits of Saponins," by Richard Lipkin, *Science News*, December 9, 1995, pp. 392–3.

Another group that, because of religious doctrine, eats very little meat and, thus, a greater quantity of grains, vegetables, and fruits which contain B₁₇, is the Mormon population. In Utah, which is seventy-three percent Mormon, the cancer rate is twenty-five percent below the national average. In Utah county, which includes the city of Provo and is ninety percent Mormon, the cancer rate is below the national average by twenty-eight percent for women and thirty-five percent for men.¹

In the summer of 1940, the Netherlands became occupied by the military forces of Nazi Germany. Under a dictatorial regime the entire nation of about nine-million people was compelled to change its eating habits drastically. Dr. C. Moerman, a physician in Vlaardingen, the Netherlands, described what happened during that period:

White bread was replaced by whole-meal bread and rye bread. The supply of sugar was drastically cut down and soon entirely stopped. Honey was used, if available. The oil supply from abroad was stopped and, as a result, no margarine was produced any more, causing the people to try and get butter. Add to this that the consumer received as much fruit and as many vegetables as possible, hoarding and buying from the farmers what they could. In short: people satisfied their hunger with large quantities of natural elements rich in vitamins.

Now think of what happened later: in 1945 this forced nutrition suddenly came to an end. What was the result? People started eating again white bread, margarine, skimmed milk, much sugar, much meat, and only few vegetables and little fruit.... In short: people ate too much unnatural and too little natural food, and therefore got too few vitamins.²

Dr. Moerman showed that the cancer rate in the Netherlands dropped straight down from a peak in 1942 to its lowest point in 1945. But after 1945, with the return of processed foods, the cancer rate began to climb again and has shown a steady rise ever since.

Of course the experience in the Netherlands or among the Seventh Day Adventists or Mormons is not conclusive for it still leaves open the question of the *specific* food factor or factors that were responsible. So let us narrow the field.

Since the 1960s, there has been a steadily-growing group of people who have accepted the vitamin theory of cancer and who

1. "Cancer Rate for Mormons Among Lowest," *Los Angeles Times*, Aug. 22, 1974, Part II, p. 1.

2. "The Solution of the Cancer Problem" (m.s., 1962) p. 31.

have altered their diets accordingly. They represent all walks of life, all ages, both sexes, and reside in almost every advanced nation in the world. There are many thousands in the United States alone.¹ It is significant, therefore, that, after maintaining a diet rich in vitamin B₁₇, *none* of these people has ever been known to contract cancer.²

In the summer of 1973, it was learned that Adelle Davis, one of the nation's best-known nutritionists—a woman who was considered to be an expert on the relationship between diet and cancer—herself was stricken with one of its most virulent forms. In May of the following year she passed away. It seemed that this was to be the end of the nutritional theory of cancer. But, upon closer investigation, in none of her many books or lectures did she ever treat nitrilosides as a vitamin or even as an essential food substance. She did mention that Laetrile was, in her opinion, an effective treatment for cancer *after* it was contracted, but she apparently failed to consider it, in its less concentrated and more natural form, as vital to one's daily nutrition. Even after her cancer had been diagnosed, she apparently still did not see the full connection. The author had corresponded with her on this very question, and her reply was, in part, as follows:

Since carcinogens surround us by the hundreds in food preservatives, additives, poison sprays, chemical fertilizers, pollutants and contaminants of air and water, the statement that cancer is a deficiency disease is certainly inaccurate and over-simplified.³

It should be stated for the record that this lady was an excellent nutritionist. She had helped thousands of people regain their health through better diet and more healthful cooking. But it

1. Dr. Dean Burk, in a letter to Congressman Lou Frey, Jr., on May 30, 1972, stated that he had been contacted by at least 750 persons, "including many M.D. physicians," most of whom were "using it merely with prevention of development of cancer in view." See *Cancer Control Journal*, May/June, 1973, p. 1. Likewise, the author has been in contact with literally thousands of Laetrile users over the past two decades.

2. Since writing those words in the 1974 edition of this book, the author has met two people who claimed they contracted cancer after routinely ingesting apricot kernels. *Two!* It is unknown how many kernels they ate or what else was in their diet (in one case the diet was known to be atrocious), or how faithful they were to the program, or what their prior health was, or to what kind of carcinogens they may have been exposed, including medical X-rays and smoking. Nevertheless, these cases prove that the vitamin concept of cancer control is not 100% perfect. Would you accept 99%?

3. Note from Adelle Davis to G. Edward Griffin dated August 1, 1973; Griffin, *Private Papers*, *op. cit.*

is plain that she did not agree with those mentioned previously who have altered their menus to include rich nitriloxide foods; and so the unfortunate fact that she contracted cancer is *not* a disproof of the effectiveness of Laetrile.

So let us repeat the reality. While their fellow citizens are suffering from cancer at the rate of one out of every three, not one in a *thousand* who regularly ingests nitrilosides has been known to contract this dread disease.

For many persons, the logic of all these facts put together is so great that it would be easy to close the case right here. But, in view of the powerful opposition against this concept, let us not content ourselves with the *logic* of the theory. Let us reinforce our convictions with the *science* of the theory also, that we may understand *why* it works the way our logic tells us that it must.

Chapter Five

CANCER: THE ONRUSH OF LIFE

An explanation of the trophoblast thesis of cancer; a description of a simple urine test for cancer; an appraisal of BCG vaccine as an anti-cancer agent; and a review of the vital role played by the pancreas in the control of cancer.

In 1902, John Beard, a professor of embryology at the University of Edinburgh in Scotland, authored a paper published in the British medical journal *Lancet* in which he stated there were no differences between cancer cells and certain pre-embryonic cells that were normal to the early stages of pregnancy. In technical terms, these normal cells are called *trophoblasts*. Extensive research had led Professor Beard to the conclusion that cancer and trophoblast are, in fact, one and the same. His theory, therefore, is known as the trophoblast thesis of cancer.¹

The trophoblast in pregnancy does exhibit all the classical characteristics of cancer. It spreads and multiplies rapidly as it invades into the uterus wall preparing a place where the embryo can attach itself for maternal protection and nourishment.

The trophoblast is formed as a result of a chain reaction starting with another cell identified as the *diploid totipotent*.² For our purposes, let us call this simply the "total-life" cell because it contains within it all the separate characteristics of the complete

1. Sometimes referred to as the unitarian thesis of cancer on the basis that all cancers are, fundamentally, the same.

2. There is no need to go into all the details surrounding the formation of these cells, for they only tend to burden us with facts that are not essential to an understanding of the basic theory. Anyone interested in this background can readily obtain it at the public library from any standard reference book on embryology. Of particular value are John Beard's *The Enzyme Treatment of Cancer and Its Scientific Basis* (London: Chatto & Windus, 1911) and Charles Gurchot's *The Biology of Cancer* (San Francisco: Friedman, 1948).

organism and has the total capacity to evolve into any organ or tissue or, for that matter, into the complete embryo itself.

About eighty percent of these total-life cells are located in the ovaries or testes serving as a genetic reservoir for future offspring. The rest of them are distributed elsewhere in the body for a purpose not yet fully understood but which may involve the regenerative or healing process of damaged or aging tissue.

The hormone estrogen is well known for its ability to effect changes in living tissue. Although it is generally thought of as a female hormone, it is found in both sexes and performs many vital functions. Wherever the body is damaged, either by physical trauma, chemical action, or illness, estrogen and other steroid hormones always appear in great concentration, possibly serving as stimulators or catalysts for cellular growth and body repair.

It is now known that the total-life cell is triggered into producing trophoblast when it comes into contact with these steroid hormones acting as "organizer stimuli." When this happens to those total-life cells that have evolved from the fertilized egg, the result is a placenta and umbilical cord, a means of nourishing the embryo. But when it occurs non-sexually as a part of the general healing process, the result is cancer. To be more accurate, we should say that it is cancer *if* the healing process is not terminated upon completion of its task.

Hardin B. Jones, Ph.D., in his highly revealing "A Report on Cancer,"¹ touched upon this phenomenon as follows:

A second important consideration about cancer is that all forms of overt cancer are associated with a random chance of survival which does not lessen with the duration of cancer. This strongly implies that there is some natural physiological restraint against progress of the disease and that the cause of the commonly observed rapid development of cancer in the terminal stages is the failure of the natural restraining influence.

We shall see shortly why this natural restraining influence on the healing process should fail but, for now, at the risk of greatly over-simplifying the process, we may say that cancer is the result of *over-healing*. That is why it has been said that smoking, or excessive exposure to the sun, or any number of harmful chemicals seem to cause cancer. *Anything* that causes damage to the

1. Paper delivered before the American Cancer Society's Eleventh Annual Science Writer's Conference, New Orleans, March 7, 1969.

body can lead to cancer *if* the body's healing processes are not functioning properly—as we shall see.

Dr. Stewart M. Jones of Palo Alto, California, described the process this way:

Whenever a trophoblast cell appears in the body outside of pregnancy, the natural forces that control it in a normal pregnancy may be absent and, in this case, it begins uncontrolled proliferation, invasion, extension, and metastasis. When this happens, it is initiated by an organizer substance, usually estrogen, the presence of which further promotes the trophoblast activity. This is the beginning of cancer.¹

If it is true that the trophoblast cell is brought into being by a chain reaction which involves estrogen or other steroid hormones, then it would follow logically that an unnaturally high exposure to these substances would be a factor that favored the onset of cancer. And, indeed, this has been proven to be true. The use of diethylstilbestrol as a fattening agent for cattle was halted in 1972 because it was proven that this synthetic estrogen compound, which was present in trace amounts in the beef at our grocery stores, had caused stomach cancer in experimental rats.

It also has been found that women taking contraceptive pills—especially those containing estrogen—not only undergo irreversible breast changes, but become almost three times more cancer-prone than women who do not. This fact was stressed by Dr. Otto Sartorius, Director of the Cancer Control Clinic at Santa Barbara General Hospital in California, who then added: "Estrogen is the fodder on which carcinoma [cancer] grows. To produce cancer in lower animals, you first introduce an estrogen base."²

There is a confusion factor in all this because, occasionally, *some* cancers appear to respond to hormone therapy—the administration of estrogen or testosterone. But the only cases in which this kind of therapy is rewarded with favorable results are those involving cancer of the sexual glands, such as the breasts or prostate, or those organs that are heavily affected by sexual hormones. Female patients are given male hormones and males

1. "Nutrition Rudiments in Cancer," by S.M. Jones, M.S., B.A., Ph.D., M.D., (Palo Alto, California., 1972) p. 6.

2. As quoted in "Birth Control Pills Endanger Your Breasts," by Ida Honorof, *Prevention*, July, 1972, p. 89. Also see "Pill Linked to Cancer Risk," *L.A. Times*, Nov. 21, 1972, p. A-21.

are given female hormones. The apparent favorable action is the result of the hormones' attempt to oppose or neuter those glands. If the cancer is retarded, it is because the *organ* is retarded.

The side-effects of this kind of therapy are the altering of the sexual physiology of the patient. Also, the beneficial results it produces, if any, are usually described by physicians as palliative, which means that the cancer is not cured, only retarded temporarily. But the worst part is that—especially in the case of men using estrogen—the presence of unnaturally high levels of steroids throughout the system could well be a factor favorable to the production of new cancer tissue other than at the primary site.

When cancer begins to form, the body reacts by attempting to seal it off and surrounding it with cells that are similar to those in the location where it occurs. A bump or lump is the initial result. Dr. Jones continues:

In order to counteract the estrogenic action on the trophoblast, the body floods the areas of the trophoblast in a sea of beta-glucuronidase (BG) which inactivates all estrogen on contact. At the same time the cells of the tissues being invaded by the trophoblasts defensively multiply in an effort at local containment.

Usually the efforts of the body to control the nidus of trophoblast are successful, the trophoblast dies, and a benign polyp or other benign tumor remains as a monument to the victory of the body over cancer.¹

Under microscopic examination, many of these tumors are found to resemble a mixture or hybrid of both trophoblast and surrounding cells; a fact which has led some researchers to the premature conclusion that there are many different types of cancer. But the degree to which tumors appear to be different is the same degree to which they are benign; which means that it is the degree to which there are *non-cancerous* cells within it.

The greater the malignancy, the more these tumors begin to resemble each other, and the more clearly they begin to take on the classic characteristics of pregnancy trophoblast. And the most malignant of all cancers—the chorionepitheliomas—are almost indistinguishable from trophoblast cells. For, as Dr. Beard pointed out almost a century ago, they are one and the same.

An interesting sidelight to these facts is that trophoblast cells produce a distinct hormone that readily can be detected in the urine. This is known as the chorionic gonadotrophic hormone

1. *Ibid.*, p. 7.

(CGH).¹ If cancer is trophoblast, then one would expect that cancer cells also would secrete this hormone. And, indeed, they do. It is also true that no other cell is known to produce CGH.² This means that, if CGH is detected in the urine, it indicates that there is present either normal pregnancy trophoblast or abnormal malignant cancer. If the patient is a woman, she either is pregnant or has cancer. If he is a man, cancer can be the only cause.

The significance of this fact is far-reaching. A simple urine test similar to the well-known rabbit test for pregnancy can detect the presence of cancer long before it manifests itself as illness or a lump, and it throws serious doubt upon the rationale behind surgical biopsies. Many physicians are convinced that any cutting into a malignant tumor, even for a biopsy, increases the likelihood that the tumor will spread. (More on that in a later chapter.) In any event, there is questionable need for such procedures in view of the fact that the CGH urine test is available.³ In the 1960s and '70s, Dr. Manuel Navarro, Professor of Medicine and Surgery at the University of Santo Tomas in Manila, offered this test to American physicians and reported 95% accuracy with both cancer and non-cancer patients. Almost all of the so-called errors were in showing cancer activity with patients who presumably did not have cancer. But in a large percentage of these, those same patients later developed clinical manifestations of cancer, suggesting that the CGH test was accurate after all. Doctors who have had experience with this test have learned never to assume it is in error when it indicates the presence of trophoblast.

Let us turn now to the question of defense mechanisms. Before we can hope to conquer cancer, first we must understand how *nature* conquers cancer—how *nature* protects the body and controls the growth of trophoblast cells. One would suppose that this would be the primary question that determines the direction of cancer research today. Unfortunately, it is not. Most research projects are preoccupied with exotic and toxic drugs or machines that deliver death rays to selected parts of the body. There is no

1. In human biology, it is sometimes referred to as the HCG (human chorionic gonadotrophic) hormone.

2. A similar substance is produced in the anterior pituitary gland, but it is not the same.

3. This is a modified, more sensitive micro-Aschheim Zondek test and is not to be confused with the Anthrone test which is based upon a similar principle but, due to technical problems connected with the test itself, so far has not been as reliable as the CGH test.

counterpart for any of this in nature, and it is small wonder that progress has been disappointing. But, recently, a small group of researchers has begun to look back to nature, and, if they persist in this course, they cannot help but succeed eventually. The most promising of all this work lies in the study of the body's natural mechanism for immunity.

All animals contain billions of white blood cells. There are different types such as lymphocytes, leukocytes, and monocytes, but they all serve the same function which is to attack and destroy anything that is foreign and harmful to our bodies. Persons who develop a low white-cell blood count become susceptible to infections of all kinds and, in fact, if the condition is sufficiently severe, they can die from a simple infected cut or a common cold.

Since the destruction of foreign bodies is the function of the white cells, it would seem logical, therefore, that they would attack cancer cells also. As one medical journal stated the problem:

One crucial property our bodies have is the ability to distinguish between self and non-self. In other words, we can recognize (biologically) foreign material that finds its way into our bodies. This ability enables us to fight infections and to build up resistance to future infection. It also means that organ transplantation is not just a simple matter of intricate surgery. As far as the body's defense systems—the immunological apparatus—are concerned, bacteria, viruses, and transplanted organs are all foreign invaders and have to be repelled. What has puzzled immunologists for a very long time is that, although cancer cells are undoubtedly foreign, they seem to escape the lethal attentions of immunological systems. The crucial question is, how?¹

In this otherwise excellent article, we find one of the great false assumptions that plagues almost all orthodox cancer research today: the assumption that cancer cells are foreign to the body. Quite to the contrary, they are a vital part of the life cycle (pregnancy and healing). Consequently, nature has provided them with an effective means of avoiding the white blood cells.

One of the characteristics of the trophoblast is that it is surrounded by a thin protein coating that carries a negative electrostatic charge. In technical terms this is called the *pericellular sialomucin* coat. The white blood cells also carry a negative

1. "New Assaults on Cancer," by Roger Lewin, *World of Research*, Jan. 13, 1973, p. 32.

charge. And, since like polarities repel each other, the trophoblast is well protected. The blocking factor is nothing more than a cellular electrostatic field. Commenting on the significance of these facts, Dr. Krebs wrote:

For three-quarters of a century classical immunology has, in effect, been pounding its head against a stone wall in the vain quest for "cancer antigens," the production of cancer antibodies, etc., etc. The cancer or trophoblast cell is non-antigenic because of the pericellular sialomucin coat....¹

Part of nature's solution to this problem, as pointed out by Professor Beard in 1905, is found in the ten or more pancreatic enzymes, of which trypsin and chymotrypsin are especially important in trophoblast destruction. These enzymes exist in their *inactive* form (as zymogens) in the pancreas gland. Only after they reach the small intestine are they converted to their active form. When these are absorbed into the blood stream and reach the trophoblast, they digest the negatively-charged protein coat. The cancer then is exposed to the attack of the white cells and it dies.²

In most discussions of this subject, it is assumed that the lymphocytes are the most active counterpart of all the various white blood cells. But opinions on this currently are in a state of flux. In one study, for example, it was reported that the real aggressor was the monocyte. Although monocytes compose only two or three percent of the total, they were found to be far more destructive of cancer tissue than the lymphocytes which were more numerous. Either way, the end result is the same.³

Soon after Beard advanced his startling theory, physicians began experimenting with pancreatic enzymes in the treatment of cancer, and favorable reports began to appear in the medical

1. Letter from Dr. Krebs to Andrew McNaughton, the McNaughton Foundation, San Francisco, Calif., dated Aug. 2, 1971, Griffin, *Private Papers*, *op. cit.*

2. The operation of this mechanism is considerably more complex than this simplified description would indicate, and there is much that is not yet fully understood. For instance, investigators have not yet solved the puzzle of how the pregnancy trophoblast cells are protected from chymotrypsin during the initial phase of pregnancy. Obviously they have *some* kind of extra blocking factor that non-pregnancy trophoblast cells do not enjoy. It is possible that it is an increased local level of cobalamin that converts the hydro-cyanic acid into thiocyanate (vitamin B₁₂), plus a temporarily high level of rhodanese (protecting enzyme). But this is not at all certain, and it represents an interesting area for future research.

3. See "Cancer Killing Cells Found to Eat Tumors," by Harry Nelson, *Times* Medical writer, *L.A. Times*, April 4, 1973, p. 32.

journals of the day. In 1906, Frederick Wiggins, M.D., described his success in a case of cancer of the tongue and concluded with a hope "that further discussion of and clinical experience with Trypsin and Amylopsin within a reasonable time will demonstrate beyond question that we have at our disposal a sure and efficient remedy for the treatment of malignant disease."¹

Between November, 1906 and January, 1907, the medical journals carried this and three additional reports of cancer successfully treated by pancreatic enzymes.

Starting in 1972, there was a flurry of publicity given to the "promising" experimental work done with BCG (the anti-tuberculosis vaccine known as *Bacillus Calmette Guerin*). The theory behind it is that BCG—which is a TB virus that has been weakened so as to pose no threat to the patient—stimulates the body's production of white-blood cells as part of its natural defense mechanism. When the vaccine enters the blood stream, the body does not know that the TB virus is weak and it begins to produce white cells to repel the invader. And they remain as a barrier to any real TB virus that may come along later. These cells not only act as a future barrier against TB but, theoretically at least, they also are presumed to be effective against cancer cells. And there have been cautious reports of some progress in this direction. As we have seen, however, the presence of white cells *by themselves* is but one part of the solution to the cancer problem. Without consideration of the pancreatic and nutrition factors, real progress along these lines will be highly limited.

Many of the reports of success with BCG may have been due as much to nutritional factors as anything else. One such report described the treatment for cancer administered by Dr. Virginia Livingston. The patient, who was also a physician, had decided from his own experience that, since conventional cancer therapy was so unproductive of results, he would try BCG instead. So he approached Dr. Livingston who, at the time, was one of the few physicians who knew about this approach. The article then explained the treatment:

Dr. Wheeler [the patient] was injected with BCG and put on a strict low-cholesterol diet and given antibiotics. The diet, he said,

1. Wiggin, F.H., "Case of Multiple Fibrosarcoma of the Tongue, with Remarks on the Use of Trypsin and Amylopsin in the Treatment of Malignant Disease," *J. Am. Med. Assoc.*, December 15, 1906; 47:2003-8.

banned refined sugar, poultry and eggs, and called for raw vegetables, plenty of fish and multiple vitamin supplements.

Within two months, the swelling was down, Dr. Wheeler said.

Recent laboratory tests showed a remission of cancerous cells—that is, a return to a normal healthy state—and the presence of new, healthy tissue, he said.¹

Let us analyze. The diet given to Dr. Wheeler consists of foods that do *not* consume pancreatic enzymes for their digestion. This is similar to the kind of diet prescribed by doctors using vitamin B₁₇ therapy because it releases almost all of the pancreatic enzymes for absorption into the blood stream where they can do their work on the cancer cell. In addition to this, Dr. Wheeler was given “multiple vitamin supplements.” It is quite possible, therefore, that these two factors were just as important, if not more so, than the administration of BCG.

Returning to the subject of pancreatic enzymes, we find that the trophoblast cells in the normal embryo continue to grow and spread right up to the eighth week. Then suddenly, with no apparent reason, they stop growing and are destroyed. Dr. Beard had the general answer to why this happens as long ago as 1905. But recent research has provided the specific explanation. *It is in the eighth week that the baby's pancreas begins to function.*

It is significant that the small intestine, near the point where the pancreas empties into it, is one of the few places in the human body where cancer is almost never found. The pancreas itself often is involved with primary malignancy, but this is because the all-important enzymes do not become activated until they leave the pancreas and enter the intestines or the blood stream. Thus, the small intestine is bathed in these substances, whereas the pancreas itself may receive very little. As one clinician has observed:

One of the most striking features about the pathology of malignant disease is the almost complete absence of carcinoma [cancer] in the duodenum [first segment of the small intestine] and its increasing frequency throughout the gastrointestinal tract in direct proportion to the distance from this exempt segment.²

1. “Vaccine BCG Used With Amazing Success—Brings Complete Reversal of Cancer in Patient With Malignant Neck Tumor,” *National Enquirer*, Nov. 26, 1972.

2. Raab, W.: *Klin. Wchnschr.* 14:1633, quoted in *Laetriles/Nitrosides*, op. cit., p. 35.

We note, also, that diabetics—those who suffer from a pancreas malfunction—are three times more likely to contract cancer than non-diabetics.¹

These facts, which have puzzled medical investigators for years, at last can be explained in light of the trophoblast thesis of cancer. This thesis, as Dr. Krebs has asserted, “is not a dogma inflexibly held by its proponents; it is merely the only explanation that finds total congruence with all established facts on cancer.”

To which Dr. Stewart M. Jones adds:

This theory is the oldest, strongest, and most plausible theory of cancer now extant. It has stood the test of seventy years of confrontation with new information about cancer without ever being disproved by any new fact.... The voluminous, heterogeneous science of cancer developed since then is coherent only in the light of this theory.²

It is the height of restraint to call this a *theory*. There comes a time when we must admit that truth is truth and that the search is over. That finally happened on October 15, 1995, in the pages of an orthodox medical journal—93 years after Professor Beard published the theory and 43 years after Dr. Krebs shouted it from the housetops. It was the report of a study at the Allegheny Medical College in Pittsburgh by Doctors Acevedo, Tong, and Hartsock. The study, involving the genetic characteristics of human chorioic gonadotrophin hormone, confirmed that cancer and trophoblast were the same. The report concluded: “After 93 years, Beard has been proven to be conceptually correct.”³

The debate, however, will continue. For many, the search is more exciting (and more profitable) than the discovery. So they will continue to clutter their minds and laboratories with dead-end theories and projects for as long as the money holds out.

But the truth is both startling and simple. While most researchers are operating on the assumption that cancer is foreign to the body and part of a process of death and decay, it is, instead, a vital part of the life cycle and an expression of the onrush of both life and healing.

1. Jones, *Nutrition Rudiments in Cancer*, *op. cit.*, p. 8.

2. *Ibid.*, pp. 1, 6.

3. “Human Chorionic Gonadotropin-Beta Subunit Gene Expression in Cultured Human Fetal and Cancer Cells of Different Types and Origins,” by Herman F. Acevedo, Ph.D., Jennifer Y. Tong, Ph.D., and Robert J. Hartsock, M.D., *Cancer*, October 15, 1995, Volume 76, No. 8, pp. 1467-1473.

Chapter Six

THE TOTAL MECHANISM

The nutritional factor as a back-up mechanism to the enzyme factor; a biographical sketch of Dr. Ernst T. Krebs, Jr., and his development of Laetrile; the beneficial effects of vitamin B₁₇ on a wide range of human disorders; and an appraisal of the complexity of nature's total anti-cancer mechanism.

As demonstrated in the previous chapter, cancer can be thought of as a kind of over-healing process in which the body produces trophoblast cells as a part of its attempt to overcome specific damage to or aging of normal tissue. These trophoblast cells are protected by an electrostatically charged protein coat. But in the presence of sufficient quantities of the pancreatic enzymes, this protective coating is digested away, exposing the trophoblast to the destructive force of the body's white blood cells. Thus, nature has assigned to the pancreas the vital job of preventing cancer by keeping trophoblast cells under control.

But what happens if, due to age or hereditary factors, the pancreas is weak, or if the kinds of foods we eat consume almost all of the pancreatic enzymes for their digestion leaving very little for the blood stream? What if, due to surgery or radiation, there is scar tissue around the cancer which inhibits circulation and prevents the enzymes from reaching it? And what if the rate of cancer growth is so high that the pancreatic enzymes can't keep up with it? Then what?

The answer is that nature has provided a back-up mechanism, a second line of defense, that has an excellent chance of doing the job even if the first line should fail. It involves a unique chemical compound that literally poisons the malignant cancer cell while

nourishing all the rest. And this is where the vitamin concept of cancer finally comes back into the picture.

The chemical compound in question is vitamin B₁₇, which is found in those natural foods containing nitriloside. It is known also as amygdalin and, as such, has been used and studied extensively for well over a hundred years. But, in its concentrated and purified form developed by Dr. Krebs specifically for cancer therapy, it is known as Laetrile. For the sake of clarity in this volume, however, we shall favor the more simple name: vitamin B₁₇.

Professor John Beard, the man who first advanced the trophoblast thesis of cancer, had suspected that there was a nutritional factor in addition to the enzyme factor but was never able to identify it. It wasn't until 1952 that this "extrinsic" factor was discovered by Dr. Ernst T. Krebs, Jr., and his famous father of the same name.

During the great flu epidemic of 1918 which took the lives of over ten-million Americans, Dr. Krebs, Sr., was able to save almost 100% of the hundreds of patients who came under his care. As both a graduate pharmacist and an accredited physician practicing in Nevada, he had taken a keen interest in the fact that the Washoe Indians of that area enjoyed almost complete freedom from the respiratory diseases of the white man. He discovered that their native remedy for such ailments was called "Dortza Water," a decoction of the root of a wild parsley-like plant known botanically as *Leptotaenia Dissecta*. He experimented with this herb, devised more efficient methods to extract the active ingredients, and discovered that it possessed amazing antiseptic and healing properties. It was this extract that was used to save the lives of his patients during the epidemic of 1918.

Thus Dr. Krebs, Sr., in 1918 was the first to introduce and use an antibiotic in scientific medicine. At that time, however, even the claim for the possibility of an antibiotic or "internal germicide" that would kill bacteria without harming the body was considered preposterous. The *Journal of the American Medical Association* on June 5, 1920, dismissed these claims out of hand. Thirty years passed before Carlson and Douglas of the Western Reserve University in Cleveland, Ohio, rediscovered leptoin—the antibiotic in the roots of *Leptotaenia*—and published their findings in the *Journal of Bacteriology* in May of 1948. Their summary reads:

The antibiotic activity of oil fractions from the root of *Leptotaenia dissecta* was determined on 62 strains and species of bacteria, molds and fungi. The ... agent was bactericidal for gram-positive bacteria ... and gram-negative bacteria.

In 1953, scientists at the University of Utah School of Medicine published a number of papers called "Studies on Antibiotic Extract of *Leptotaenia*."¹ They confirmed the effect Dr. Krebs, Sr., had claimed for leptonin against flu viruses. The reality of leptonin as a broad-spectrum antibiotic had become so well established that the Department of Bacteriology at the University of Southern California School of Medicine granted a student a master's degree in microbiology for its study. The same student, Daniel Everett Johnson, later obtained his doctorate in microbiology at the University of California at Los Angeles in 1953 on the basis of his thesis showing the antibiotic action of leptonin against hundreds of different microorganisms.

Dr. Krebs, Sr., also had taken an early interest in cancer. He noticed that this appeared to be primarily a white man's disease. Remembering the lesson of "Dortza Water," he suspected that the key probably was hidden either in an herb or in the food supply. The final discovery, however, was made, not by him, but by his son who, by that time, had become totally wrapped up in the search for an answer to the cancer riddle.

Dr. Ernst T. Krebs, Jr., initially wanted to follow his father in the practice of medicine. Soon after he enrolled in medical school, he realized that his interest lay, not in the treatment of patients, but in the world of medical chemistry. After three years of anatomy and medicine at Hahnemann Medical College, he changed his direction and became a doctor of biochemistry.

He pursued his undergraduate work at the University of Illinois between 1938 and 1941. Specializing in bacteriology, he received his Bachelor's Degree at the University of Illinois in 1942. He did graduate work at the University of Mississippi and also at the University of California.

During his lifetime, Dr. Krebs authored many scientific papers including "The Unitarian or Trophoblastic Thesis of Cancer" and "The Nitrilosides in Plants and Animals." He was the recipient of numerous honors and doctorates both at home and abroad. He was the science director of the John Beard Memorial Foundation

1. *Antibiotics and Chemotherapy* (3 (4) 393), 1953.

prior to his death in 1996. He was also the discoverer of vitamin B₁₅ (pangamic acid), which has proven to be an important adjunctive therapy in the treatment of many illnesses related to impaired circulation.

Early in his student work, Dr. Krebs became familiar with the trophoblast thesis of cancer advanced by Professor John Beard. Working within the context of this theory, and encouraged by Dr. Charles Gurchot, a professor of pharmacology at the University of California Medical School, he began a search for the nutritional factor hinted at by Beard.

By 1950 he had identified the specific composition of this substance, had isolated it into crystalline form, had given it the name Laetrile,¹ and had tested it on animals to make sure it was not toxic. The next step was to prove that it was not harmful to humans. There was only one way to do that. So he rolled up his sleeve and injected it into his own bloodstream.

Just as he had predicted, there were absolutely no harmful or distressing side effects. He was now ready for the final state of experiments—cancer patients themselves.

The B₁₇ molecule contains two units of glucose (sugar), one of benzaldehyde, and one of cyanide, all tightly locked together within it. As everyone knows, cyanide can be highly toxic and even fatal if taken in sufficient quantity. However, locked as it is in this natural state, it is chemically inert and has absolutely no effect on living tissue. By way of analogy, chlorine gas also is known to be deadly. But when the chlorine is chemically bound together with sodium forming sodium chloride, it is a relatively harmless compound known as common table salt.

There is only one substance that can unlock the B₁₇ molecule and release the cyanide. That substance is an enzyme called *beta-glucosidase*, which we shall call the “unlocking enzyme.”² When B₁₇ comes in contact with this enzyme in the presence of water, not only is the cyanide released, but also the benzaldehyde, which is highly toxic by itself. In fact, these two substances working together are at least a hundred times more poisonous

1. The material was derived from apricot kernels. Because it was *laevorotatory* (left-handed) to polarized light, and because chemically it was a “Mandelonitrile,” the first and last syllables were united to produce the word *Laetrile*.

2. This is a generic term applied to a category of enzymes. The specific one that appears to unlock the synthesized B₁₇ known as Laetrile is *beta-glucuronidase*.

than either of them separately; a phenomenon known in biochemistry as synergism.¹

Fortunately, the unlocking enzyme is not found to any dangerous degree anywhere in the body *except at the cancer cell*, where it always is present in great quantity, sometimes at levels in excess of one-hundred times that of the surrounding normal cells. The result is that vitamin B₁₇ is unlocked at the cancer cell, releases its poisons to the cancer cell, and *only to the cancer cell*.

There is another important enzyme called *rhodanese*, which we shall identify as the "protecting enzyme."² The reason is that it has the ability to neutralize cyanide by converting it instantly into by-products that actually are beneficial and essential to health. This enzyme is found in great quantities in every part of the body *except the cancer cell* which, consequently, is not protected.

Let us examine what, at first, may appear to be exceptions to these rules. We have said that the unlocking enzyme is not found to any dangerous degree anywhere in the body except at the cancer cell. That is true, but note the phrase "to any dangerous degree." The unlocking enzyme actually is found in various concentrations *everywhere* in the human body. It is particularly prevalent in the healthy spleen, liver, and endocrine organs. In all of these instances, however, there *also* is present an even greater quantity of the protecting enzyme (*rhodanese*). The healthy tissue is protected, therefore, because the excess of this protecting enzyme completely neutralizes the effect of the unlocking enzyme.

The malignant cell, by comparison, not only has a greater concentration of the unlocking enzyme than found in most normal cells but it is totally lacking in the protecting enzyme. Thus, it is singularly vulnerable to the release of cyanide and benzaldehyde.

The non-cancerous organs, therefore, are endowed by nature with the unique capacity of protecting themselves and even

1. In passing, it is interesting to note that nature has used this same synergism as a defense mechanism for the poisonous millipede found in Louisiana and Mississippi. The creature is equipped with paired glands located on eleven of its segments. When threatened, it ejects cyanide and benzaldehyde from these glands with a deadly effectiveness that is well known. See "Secretion of Benzaldehyde and Hydrogen Cyanide by the Millipede *Pachydesmus Crassicutis*," *Science*, 138:513, 1962.

2. Since about 1965, *rhodanese* has been identified in technical literature as *thiosulfate transulfurase*.

nourishing themselves from the digestion of the B₁₇ molecule, whereas cancerous tissue converts the same vitamin substance into powerful toxins against which it has no defense.

With this in mind, it is amusing to watch the scientific "experts" who oppose Laetrile reveal their abysmal ignorance and arrogance on this subject. In the 1963 report of the California Cancer Advisory Commission, for example, we read:

The opinion of Dr. Jesse P. Greenstein, chief of the laboratory of biochemistry at the National Cancer Institute, was obtained in respect to the distribution of beta-glucuronidase in neoplastic [cancer] and non-neoplastic [healthy] tissues, and as to the implication that there was a "tumor" beta-glucuronidase [unlocking] enzyme. The fact is, reported Doctor Greenstein, that beta-glucuronidase is found in all tissues of the animal body.... In other words, there is much more "normal" beta-glucuronidase than "tumor" beta-glucuronidase in any animal body. In a letter dated November 10, 1952, Dr. Greenstein wrote "Such statement as ... 'the malignant cell ... is virtually an island surrounded by a sea of beta-glucuronidase' is sheer nonsense."¹

Dr. Greenstein is perfectly correct in observing that the unlocking enzyme is found in all tissue of the animal body, but he is one-hundred percent in error when he tries to scoff at its abundance within and around the malignant cell. His lack of expertise, however, is made abundantly clear by the fact that apparently he is totally unaware of the corresponding presence and counteraction of the protecting enzyme in these tissues. He is castigating as "sheer nonsense" a biochemical mechanism of which he apparently is totally ignorant.

Dr. Otto Warburg received the Nobel Prize for proving that cancer cells obtain nourishment, not through oxidation as do other cells, but through fermentation of sugar. Warburg explained:

From the standpoint of physics and chemistry of life, this difference between normal and cancer cells is so great that one can scarcely picture a greater difference. Oxygen gas, the donor of energy in plants and animals, is dethroned in the cancer cells and replaced by an energy-yielding reaction of the lowest living forms; namely, a fermentation of glucose.²

1. Report by Cancer Advisory Council, *op. cit.*, pp. 14, 15.

2. As quoted in *Prevention*, May 1968.

From this it is easy to see why anything that improves normal respiratory metabolism is an inhibitor to cancer growth. The point, however, is that any benzaldehyde that might diffuse away from the cancer cell and come into contact with normal cells, will be oxidized and converted into harmless benzoic acid. Benzoic acid is known to have certain anti-rheumatic, antiseptic, and analgesic properties. This could partially account for the fact that B₁₇ produces the unexpected effect of relieving the intense pain associated with terminal cancer, and does so without the aid of narcotics. Although not a pain reliever *per se*, when it comes in contact with cancer cells, it releases benzoic acid right at the inflicted location and, thus, bathes that area with a natural analgesic.¹ Meanwhile, the benzaldehyde that remains at the cancer cell will find itself in an almost total lack of oxygen causing it to linger and perform its deadly synergistic action for a prolonged period of time.

On the other hand, if a small amount of cyanide should diffuse into adjacent normal cells, it is converted by the enzyme rhodanese, in the presence of sulphur, into thiocyanate which, as stated previously, is perfectly harmless. But, more than that, thiocyanate is known as a natural regulator of blood pressure. It also serves as a metabolic pool for the body's self-production of vitamin B₁₂ or cyanocobalamin, a substance essential for health. It comes as a great surprise for many to learn that cyanide is an essential and integral part of vitamin B₁₂ as well as B₁₇.²

Another unexpected, but welcome, consequence of vitamin B₁₇ is that it stimulates the hemoglobin or red blood cell count. As long ago as 1933 it was shown that exposure to small amounts of cyanide gas produced this effect in mice,³ but only since the work begun by Dr. Krebs has this also been demonstrated in humans as a result of the internal chemical action of Laetrile.

Other experiments have indicated that trace amounts of cyanide and benzaldehyde released in the mouth and intestine, far from being cause for panic, actually are a part of the delicate

1. It is the opinion of Laetrile clinicians, however, that the *primary* cause of pain reduction probably is the halting of the tumor's invasion and destruction of healthy tissue.

2. Vitamin B₁₂ is not produced in plant tissue. It is the product of animal metabolism in which the cyanide radical is combined with hydrocobalamin (B_{12a}) to form cyanocobalamin (B₁₂).

3. Maxwell and Bischoff, *Journal of Pharmacology and Experimental Therapy*, 49:270.

balance of nature and serve entirely beneficial purposes. In the mouth and stomach, these chemicals attack the bacteria that cause tooth decay and bad breath. In the intestines they interact with the bacterial microflora to suppress or eliminate the flatulence long associated with westernized foods.

The most interesting sidelight of all, however, is the probable connection between vitamin B₁₇ and the disease, *sickle-cell anemia*. In Africa, the black race has developed sickle cells in the blood apparently as a natural immunity factor to malaria. The development of this trait was dependent, in part, on the rich nitrilosidic content of the native African diet. Once the black man began to migrate into the modern cities of America and Europe, his eating habits were changed drastically. The result is the painful hemolytic crisis caused by the clumping of the red cells. It already has been learned that this disease can be ameliorated by cyanate tablets. But cyanate also can be produced by vitamin B₁₇ acting within the body, and it seems logical to assume that this is the way nature intended it to be taken.

Let us pause, then, and reflect on the significance of these indicators. Is it possible that the rheumatic diseases, certain aspects of hypertension (high-blood pressure), tooth decay, many of our gastrointestinal disorders, sickle-cell anemia—and cancer—all are related directly or indirectly to a simple vitamin B₁₇ deficiency? And if this is possible, what then of the other non-infectious diseases that plague mankind and puzzle medical research? Could their solutions also be found in the field of nutrition rather than drugs?

The answers to these questions may not be fully answered for decades, but let us return to the main topic—cancer—and to the realm of those questions for which we *do* have answers. It is no longer a speculation but a fact supported by a mountain of evidence that vitamin B₁₇ is a vital part of an amazing biochemical process that destroys cancer cells while, at the same time, nourishing and sustaining non-cancer cells.

Every person possesses trophoblast cells as a result of the continuing and normal regeneration process. These, however, are held in check by a metabolic barrier consisting of the pancreatic enzyme chymotrypsin and the nitriloxide food factor vitamin B₁₇. This barrier is an intricate and perfect mechanism of nature that simply could not have been accidental.

As mentioned in the previous chapter, there is much speculation today about carcinogens—the things that supposedly cause cancer. We are told that smoking, or extensive exposure to the sun, or chemical additives to our food, or even certain viruses all can cause cancer. But, as we have seen, the real cause is an enzyme and vitamin deficiency. These other things merely are the specific triggers that start the process.

Anything that produces prolonged stress or damage to the body can trigger the healing process. If this goes unchecked because the body lacks the necessary chemical ingredients to restore the equilibrium, then the result is cancer.

Specific carcinogens, therefore, like cigarette smoke or viruses, do not *cause* cancer; they merely determine where it is going to occur.

Nature's defenses against cancer include more than just the pancreatic enzymes and vitamin B₁₇. For example, doctors in Europe have reported that *hyperthermy*—the deliberate raising of the patient's body temperature—has increased the effectiveness of vitamin therapy so greatly as to suggest another synergism, as between cyanide and benzaldehyde. They tell us that when the body temperature is raised from its normal 37 degrees to 41 degrees Celsius (98.6 to 105.8 degrees Fahrenheit), there is a gain in effect of from three to ten-fold. In other words, at the higher level of 41 degrees, it takes only one-third to one-tenth as much Laetrile to achieve a given anti-cancer effect. It is possible that the fermentive function of the cancer cell is impaired by the increased oxygenation and circulation associated with fever.

Along this line, it is interesting to note that Dr. Wilfrid Shute (the world-famous champion of vitamin E therapy for heart patients) reported that, for some reason unknown to him, patients who were on massive doses of E did not appear to contract cancer as often as other patients. Nobel Prize winner Dr. Linus Pauling has suggested that vitamin C might also have value as an anti-cancer agent. Dr. Umberto Saffiotti of the National Cancer Institute has blocked lung cancer in mice with vitamin A.¹ And, as reported in the October, 1971, issue of *Biomedical News*, massive oral doses of the vitamin-B complex reduced the growth of cancer in experimental mice by as much as seventy percent.

1. "Is There An Anti-Cancer Food?" by Gena Larsen, *Prevention*, April, 1972.

It is plain to see that there is much yet to be learned, and no one claims that vitamin B₁₇ is the whole answer. In addition to hyperthermy and vitamins A, B, C, and E, it is probable that an important role is played by other enzymes, other vitamins, and even pH levels. Vitamin B₁₇ seems to be the most vital and direct-acting of all these factors, but none of them can be ignored, for they are an interlocking part of the total natural mechanism.

Fortunately, it is not necessary for man to fully understand every aspect of this mechanism in order to make it work for him. The necessity of eating foods rich in *all* the vitamins and minerals—particularly vitamin B₁₇—and of minimizing prolonged damage or stress to the body is all that he really needs to know.¹

1. An excellent guide to the preparation of foods rich in vitamin B₁₇ is June de Spain's *The Little Cyanide Cookbook* (Westlake Village, CA: American Media, 1975).

Chapter Seven

THE CYANIDE SCARE

A newspaper account of a couple who reportedly were poisoned by eating apricot kernels; a close look at the facts in this case; an evaluation of the toxic potential of seeds containing B₁₇; and proof that Laetrile is less toxic than sugar.

On September 1, 1972, the California State Health Department released its Monthly Morbidity Report to the medical profession and to the press. It contained an entry about a Los Angeles couple who were treated for "cyanide poisoning" after eating thirty apricot kernels. On September 4, the *Los Angeles Examiner* ran a UPI dispatch under the heading: FRUIT PITS CAN CAUSE CYANIDE. And six days later, the *New York Times* ran a similar story: APRICOT KERNELS LINKED TO POISONINGS ON COAST.

All Americans had been warned—and scared—to stay away from those seeds! For those who were only vaguely familiar with the story of Laetrile, it was a near knock-out blow to the use of vitamin B₁₇. And, as shall be demonstrated in a following chapter, it is likely that it was intended to be just that.

In response to this news story, Mr. Jay Huchinson, a former cancer patient who attributes his recovery to Laetrile, dashed off the following whimsical letter, sent airmail special delivery, to Mohammed Jamel Khan, Mir of Hunza:

Dear Mir and Rhani of Hunza:

I am rushing this extremely urgent warning to you so that you can take immediate steps to notify your government and your people of the health hazard reported by the California State Department of Public Health during the week of September 3, 1972. I enclose articles from San Francisco newspapers....

Mir, you must get your people to stop eating those pits! Stop making flour out of them! Stop feeding your new-born infants the oil, and, for Mohammed's sake, stop anointing them with it!...

Please write soon, and when you do, would you mind telling us why your people are among the healthiest in the world, and why

your men and women live vigorous lives well into their 90's, and why you and your beautiful people never get cancer?¹

For most people, however, the sarcasm was completely lost. They took the story of the poisoned couple with *deadly* seriousness. Many who had heard that these seeds might be helpful against cancer, but who did not understand the chemistry involved, now were afraid to use them and were filled with doubts. An over-zealous health department in Hawaii confiscated all apricot seeds from the shelves of health food stores, and most of the stores on the mainland were intimidated into dropping them from their line. The "news" story had served its purpose well.

Suspecting that there might be more to the story than met the eye, this writer attempted to get more details from the Department of Health—particularly the names of the couple in question. But it seemed that the department did not want them questioned. Dr. Ralph W. Weilerstein, the California public health medical officer, Bureau of Food and Drug, replied: "We regret that the confidentiality of morbidity reporting precludes interviewing the patients who were poisoned in Los Angeles."²

Dr. Dean Burk of the National Cancer Institute apparently was able to get more information. In a letter dated December 13, 1972, he explained:

This couple from Los Angeles ... really got sick and were treated in an emergency hospital, following ingestion by mouth of an overnight brew made from apricot nuts, apricot fruit, and distilled water—a concoction that probably fermented somewhat overnight, and was undoubtedly very bitter, and which brought on the illness (nausea, vomiting, etc.) after "about an hour," which is rather long for cyanide, which usually acts within minutes of being swallowed. Mr. Murray [of the Los Angeles County Health Department] was not willing to commit himself that cyanide was the chief cause of the illness, from which it would appear they promptly recovered. He said "that under the circumstances ... you don't want to leap to conclusions and say that their illness was definitely due to the ingestion of amygdalin.... I don't think I could personally say that I proved that their illness was due to apricot kernels."

It is interesting, of course, that, somehow, out of the, I presume, thousands of items in the California Monthly Morbidity Reports, the

1. Quoted in "Of Apricot Pits and Hunzaland," by Mike Culbert, *Berkeley Daily Gazette*, August 13, 1972.

2. Letter to author, dated Sept. 20, 1972; Griffin, *Private Papers*, *op. cit.*

Murray-Chinn material on amygdalin [the story of the Los Angeles couple] made the press throughout the country—presumably with the help and guidance of the state health authorities.

Mr. Gray has written, in an incipient article, "The health department's approach has been to discredit Laetrile without ever mentioning it directly. They have gotten the cooperation of the press when reporters have not gone beyond the offices of the health department in writing their stories."¹

In another letter, dated December 20, 1972, Dr. Burk expanded his views further:

The facts are that a very considerable number of people eat 10-20 apricot kernels throughout a day, and after awhile, even 50-100 kernels safely, though hardly all at once as the ... Angeleno gastronomes actually did. The same general situation holds with respect to a large number of ordinary foods that can be poisonous or allergic, etc., such as strawberries, onions, shrimps, and so on, that are never removed *en masse* or *in toto*, from food store shelves by health agencies imbued with the spirit of 1984....

It is one thing for a health agency to warn people against foolish and rare actions with respect to any aspect of health, and quite another to totally deprive people of excellent food quite safe if ingested in a normal common sense way observed by 99.999% of the population.²

We have said that vitamin B₁₇ is harmless to non-cancer cells. This is true, but perhaps it would be more accurate to say it is as harmless as any substance *can* be. After all, even life-essential water or oxygen can be fatal if taken in unnaturally large doses. And this is true also of vitamin B₁₇. For instance, there normally is a very small amount of beta-glucosidase (the "unlocking" enzyme) found within the seeds of most nitriloxide fruits. This enzyme, when activated by the secretions of the mouth and stomach, causes a minute amount of cyanide and benzaldehyde to be released in these locations. As mentioned previously, the presence of limited amounts of these chemicals in the mouth, stomach, and intestines, is not dangerous and, in fact, appears to be part of an intended delicate chemical balance of nature, the absence of which can contribute to tooth decay, bad breath, and

1. Letter from Dr. Dean Burk to Mr. M. Standard, December 13, 1972; Griffin, *Private Papers*, *op. cit.*

2. Letter from Dr. Dean Burk to Mr. B. Stenjen, President of the Waikiki Chapter of the National Health Federation, December 20, 1972, Griffin, *Private Papers*, *op. cit.*

all kinds of gastrointestinal disorders. But what happens if these seeds are eaten in gigantic quantities?

There is one case of a man who, reportedly, died from devouring almost a cup of apple seeds. Incidentally, the case never has been authenticated and could well be entirely fictitious; but assuming it's true, if the man had eaten the apples also, he would have obtained enough extra rhodanese (the "protecting enzyme") from the fleshy part of the fruit to offset the effect of even that many seeds in his stomach. But that would have required that he eat several *cases* of apples which, of course, would have been impossible in the first place.

It should be noted that, in a few places in the world, there are certain strains of apricot trees that produce seeds containing ten times the concentration of nitriloside found in those trees grown in the United States. Even these seeds are not dangerous, of course, when eaten in reasonable quantity and with the whole fruit, but when eaten as seeds only, and in large quantity, they can present a danger. In Hunza, seeds from the first fruit of all new apricot trees are tested by the elders for extreme bitterness. If they are found to be so—which is very rare—the tree is destroyed.

Occasionally, these unusual trees are found also in Turkey. But here, they are not destroyed because the seed is considered to be "good for health." As a result, there have been one or two cases in Turkey where little children have mistaken the seeds from the "wild apricot" to be those from the domestic variety, and they have become ill or died. But even in Turkey this is extremely rare. In the United States, of course, there is no record of such trees even having been in existence.

During a public lecture on the subject of Laetrile, Dr. E.T. Krebs, Jr., was asked by a woman in the audience if there was any danger from eating too many seeds containing the B₁₇ factor. Here was his reply:

This is an excellent question. In fact, it sometimes illustrates the indwelling cussedness of the human spirit. If we eat the seed with the whole fruit, it is impossible for us to get an excess of nitrilosides from the seeds. On the other hand, if we take apples, throw away all of the fruit, and collect half a cup of apple seeds, and decide to eat that half cup of apple seeds, there is a possibility we can suffer seriously from an overdose of cyanide....

You can't eat enough peaches or apricots or prunes or cherries or apples to get a sufficient amount of seeds to provide a toxic

quantity of nitrilosides, but you can take a part of the plant and do so.¹

Dr. Krebs further pointed out that roasting these seeds does not impair the vitamin B₁₇ factor, but it does destroy the unlocking enzyme. So, those who are concerned about toxicity can take the added precaution of roasting their seeds before eating.² It should be remembered, however, that this is not the way nature intended them to be consumed and, by so doing, we lose whatever benefit there may be from chemical activity in the mouth, stomach, and intestines.

The amount of nitriloside needed by the body is an unknown quantity. Perhaps it never can be determined for, surely, it will vary depending on the person—his age, sex, condition of pancreas, diet, weight, and hereditary factors. That is why it is absurd for anyone to try to publish or decree by law the so-called Minimum Daily Requirements (MDR's) or Recommended Daily Allowances (RDA's), as they now are called.

Also, there is a tendency to think of deficiency diseases as either existing or not existing, with nothing in between. We either have scurvy or we don't. This can be misleading. Scurvy is the *extreme form* of a vitamin-C deficiency. A lesser form may not reveal the classic symptoms of scurvy but could manifest itself as fatigue, susceptibility to infection, and other non-fatal maladies.

World-famous biologist, Albert Szant-Gyorgyi, phrased it this way:

Scurvy is not the first symptom of deficiency. It is a sign of the final collapse of the organism, a pre-mortal syndrome, and there is a very wide gap between scurvy and a completely healthy condition....

If, owing to inadequate food, you contract a cold and die of pneumonia, your diagnosis will be pneumonia, not malnutrition, and chances are that your doctor will have treated you only for pneumonia.³

Likewise, it is impossible to know what health problems, short of cancer, may be caused by a *partial* vitamin B₁₇ deficiency. So, when in doubt, most observers agree that it is best to err in the direction of surplus.

1. *Cancer News Journal*, Sept./Dec., 1970, pp. 7, 8.

2. For those who want to do this, Dr. Krebs suggests roasting for 30 to 50 minutes at 100° centigrade or 212° fahrenheit to deactivate the beta-glucosidase.

3. *The Living State; With Observations on Cancer* (New York and London: Academic Press, 1972), p. 77.

Dr. Krebs has suggested a minimum level of fifty milligrams of B₁₇ per day for a normal, healthy adult. Naturally, one who is pre-disposed to cancer would require more, and one who already was afflicted with the disease would need *much* more.

The average apricot seed grown in the United States contains approximately four or five milligrams of B₁₇. But this is an average figure only and can vary by as much as a factor of six, depending on the size of the kernel, the type of tree, the climate, and soil conditions. But, using the average figure, we can see that it would take ten to twelve apricot kernels per day to obtain fifty milligrams of B₁₇.

Is this a dangerous quantity? Hardly. There are cases reported in which people eat eighty-five to one-hundred apricot kernels every day with no ill effects. Let us hasten to point out, however, that this is not a recommended dosage. Since it is possible for these kernels to vary in nitriloside content by as much as six to one, it is conceivable that eighty-five kernels from one tree could be the same as over *five-hundred* kernels from another tree.

Nature can only do so much. It cannot anticipate excess of this kind. Therefore, it is wise to follow the simple rule that one should not eat at one time more seeds than he likely could consume if he also were eating a reasonable quantity of the whole fruit. This is a common-sense rule with a large safety margin that can be followed with complete confidence.

There is no chemical substance in nature that has been more misunderstood than cyanide. There has developed over the years an ignorance bordering on superstition dating back to the early days of science when it was first discovered that cyanide had a toxic potential. This ancient misapprehension has been perpetuated right up to the present time so that, to the average person, the word *cyanide* is synonymous with *poison*. As a result, we have developed a cultural antipathy toward this substance whenever it is discovered in our food. Every effort has been made to eliminate it. Local health agencies swarm over our grocery shelves to make sure that it does not reach us, and the federal Food and Drug Administration even has promulgated laws that make it illegal to sell any substance containing more of it than one four-hundredths of one percent!¹ With that kind of "protection," it is

1. See "Requirements of the United States Food, Drug, and Cosmetic Act," FDA Publication No. 2, Revised June, 1970, p. 26.

small wonder that the American people are victims of the fulminating deficiency disease known as cancer.

So much for the cyanide in natural foods. What about the laboratory forms of vitamin B₁₇ known as amygdalin or Laetrile? The answer is that here there is even *less* cause for concern. For over a hundred years standard pharmacology reference books have described this substance as non-toxic. After almost two centuries of use in all parts of the world, there never has been even one reported case of related death or serious illness.

Amygdalin generally is said to have been first discovered in 1830 by the German chemist Leibig. According to the *American Illustrated Medical Dictionary* (1944 Edition) amygdalin means "like an almond," suggesting that the material from which the first sample was isolated was the bitter almond seed.¹ In one form or another, it has been used and studied almost constantly since that time and, according to Dr. Burk, "More is known chemically and pharmacologically about amygdalin than most drugs in general use." It was listed in pharmacopoeias by 1834. Toxicity studies were conducted with it on dogs as early as 1848. By 1907 it was listed in the Merck Index. And in 1961 it appeared in the Chinese-Korean Herbal Pharmacopoeias by Sun Chu Lee and Yung Chu Lee describing its reported use specifically for "cancer dissolution."²

Like many chemical compounds, amygdalin may exist in several different crystalline forms. Which form it takes depends on the number of molecules of water that are incorporated into it. Regardless of the form, however, once the crystals are dissolved, they all yield one and the same amygdalin.

The type of amygdalin crystal, known as Laetrile, developed by Dr. Krebs is unique because it is considerably more soluble than any of the other forms and, thus, can be administered to the patient in a much greater concentration in the same volume of injected material.

1. In the United States, commercial or "sweet" almonds contain no vitamin B₁₇. The "bitter" almonds, however, are very rich in this substance—even more rich than apricot kernels. But partly due to the American preference for the flavor of the sweet almond, and partly because the FDA has limited the sale of bitter almonds (see previous footnote), almost all bitter almond trees now have been destroyed.

2. Letter from Dr. Dean Burk to Mr. M. Standard, December 13, 1972; Griffin, *Private Papers*, *op. cit.*

Commenting on the question of possible toxicity of Laetrile, Dr. Burk has summed it up with this emphatic statement:

With forty-five years of study and research on the cancer problem, the last thirty-three years in the U.S. National Cancer Institute, and with files of virtually all published literature on the use of amygdalin ("Laetrile") with reference to cancer, and with innumerable files of unpublished documents and letters, I have found no statements of demonstrated pharmacological harmfulness of amygdalin to human beings at any dosages recommended or employed by medical doctors in the United States and abroad.¹

Dr. D.M. Greenberg, Professor Emeritus of Bio-Chemistry at the University of California at Berkeley, and consultant to the Cancer Advisory Council of the California Department of Public Health added this note of concurrence:

There is no question that pure amygdalin (Laetrile) is a non-toxic compound. This is not questioned by anyone who has studied the reports submitted to the Cancer Advisory Council of the State of California.²

In the early days of experimentation with Laetrile, it was feared that the substance might be toxic if taken orally. This concern was based on the fact that, in the beginning, ways had not yet been perfected to remove the beta-glucosidase (unlocking enzyme) from the apricot extract and, since Laetrile is a highly-concentrated form of B₁₇, on the basis of theory, it was feared that it might pose a problem when activated by the secretions of the stomach. Consequently, some of the early written works on Laetrile recommended injections only and cautioned against taking the substance orally. That caution, however, has long outlived its usefulness, and there is now no medical reason whatsoever to avoid the oral form.

Aspirin tablets are twenty times more toxic than the equivalent amount of Laetrile. The toxicity of aspirin is cumulative and can build up for days or even months. The chemical action of B₁₇, however, is completed usually within a few hours leaving behind absolutely no build-up. Each year in the United States, over ninety people die from aspirin poisoning. No one ever has died from B₁₇.

1. Letter from Dr. Dean Burk to Stephen Wise and Gregory Stout, Attorneys, dated Dec. 17, 1972; Griffin, *Private Papers*, op. cit.

2. Statement made on Oct. 13, 1969, as quoted in report attached to letter from Dr. Dean Burk, *Ibid*.

Aspirin is an analog of a substance found in nature but it is, nevertheless, a man-made drug. It is not the same as the model from which it was fashioned. By contrast, B₁₇ is a substance found abundantly in plants that are appropriate for human consumption. It is not a man-made chemical and is not alien to the body. Its purified form called Laetrile is even less toxic than sugar.

In a series of tests on adult mice, Dr. Dean Burk reported that they could live in perfect health to extreme old age when their normal diet consisted of fifty percent defatted apricot kernels. He said that this provided each mouse with a whopping one-hundred and twenty-five milligrams of vitamin B₁₇ per day. And he added that the kernels provided "in addition, excellent food material, rich in protein and minerals."¹

In another series of tests, white rats were fed *seventy times* the normal human dose of Laetrile, and the only side-effects produced were greater appetite, weight gain, and superior health; just what one would expect from taking a vitamin.

1. Letter from Dr. Dean Burk to Congressman Lou Frey, Jr., dated May 30, 1972, reprinted in *Cancer Control Journal*, May/June, 1973, p. 6.

Chapter Eight

THE LAETRILE "QUACKS"

The names, professional standings, medical achievements, and clinical findings of some of the more prominent doctors who endorse Laetrile; the beneficial side-effects produced by its use; a suggested anti-cancer diet; and a brief description of vitamin B₁₅.

"Laetrile is goddamned quackery!"

Such was the pronouncement of Helene Brown, president of the American Cancer Society of California.¹

As early as 1974, there were at least twenty-six published papers written by well-known physicians who had used Laetrile in the treatment of their own patients and who have concluded that Laetrile is both safe and effective in the treatment of cancer.² In addition, there are the voluminous private records of physicians who have used it clinically but have never published their findings except in letters to their colleagues or in public lectures or interviews. The American Cancer Society and other spokesmen for orthodox medicine would have us believe that only quacks and crackpots have endorsed this conclusion. But the doctors who conducted these experiments and those who share their conclusions are *not* quacks. Here are just a few of the names:

In West Germany there is Hans Nieper, M.D., former Director of the Department of Medicine at the Silbersee Hospital in Hanover. He is a pioneer in the medical use of cobalt and is credited with developing the anti-cancer drug, *cyclophosphamide*. He is the originator of the concept of "electrolyte carriers" in the

1. "The Pain Exploiters; The Victimized of Desperate Cancer Patients," *Today's Health*, Nov., 1973, p. 28.

2. A complete list of these papers is contained in *The Laetriles/Nitrilosides*, *op. cit.*, pp. 84, 85.

prevention of cardiac necrosis. He was formerly the head of the Aschaffenburg Hospital Laboratory for chemical circulatory research. He is listed in *Who's Who in World Science* and has been the Director of the German Society for Medical Tumor Treatment. He is one of the world's most famous and respected cancer specialists.

During a visit to the United States in 1972, Dr. Nieper told news reporters:

After more than twenty years of such specialized work, I have found the nontoxic Nitrilosides—that is, Laetrile—far superior to any other known cancer treatment or preventative. In my opinion it is the only existing possibility for the ultimate control of cancer.

In Canada there is N.R. Bouziane, M.D., former Director of Research Laboratories at St. Jeanne d'Arc Hospital in Montreal and a member of the hospital's tumor board in charge of chemotherapy. He graduated *magna cum laude* in medicine from the University of Montreal. He also received a doctorate in science from the University of Montreal and St. Joseph's University, an affiliate of Oxford University in New Brunswick. He was a Fellow in chemistry and a Fellow in hematology, and certified in clinical bacteriology, hematology and biochemistry from the college. He also was Dean of the American Association of Bio-Analysts.

After the first series of tests with Laetrile shortly after it was introduced, Dr. Bouziane reported:

We always have a diagnosis based on histology [microscopic analysis of the tissue]. We have never undertaken a case without histological proof of cancer....

In our investigation, some terminal cases were so hopeless that they did not even receive what we consider the basic dose of thirty grams. Most cases, however, became ambulatory and some have in this short time resumed their normal activities on a maintenance dose.¹

In the Philippines there is Manuel Navarro, M.D., former Professor of Medicine and Surgery at the University of Santo Tomas in Manila; an Associate Member of the National Research Council of the Philippines; a Fellow of the Philippine College of Physicians, the Philippine Society of Endocrinology and Metabolism; and a member of the Philippine Medical Association, the

1. "The Laetrile Story," *op. cit.* p. 3. Also *Cancer News Journal*, Jan./Apr., 1971, p. 20.

Philippine Cancer Society, and many other medical groups. He has been recognized internationally as a cancer researcher and has over one-hundred major scientific papers to his credit, some of which have been read before the International Cancer Congress. In 1971 Dr. Navarro wrote:

I ... have specialized in oncology [the study of tumors] for the past eighteen years. For the same number of years I have been using Laetrile-amygdalin in the treatment of my cancer patients. During this eighteen year period I have treated a total of over five hundred patients with Laetrile-amygdalin by various routes of administration, including the oral and the I.V. The majority of my patients receiving Laetrile-amygdalin have been in a terminal state when treatment with this material commenced.

It is my carefully considered clinical judgment, as a practicing oncologist and researcher in this field, that I have obtained most significant and encouraging results with the use of Laetrile-amygdalin in the treatment of terminal cancer patients, and that these results are comparable or superior to the results I have obtained with the use of the more toxic standard cytotoxic agents.¹

In Mexico there is Ernesto Contreras, M.D., who, for over three decades, has operated the Good Samaritan Cancer Clinic (now called the Oasis Hospital) in Tijuana. He is one of Mexico's most distinguished medical figures. He received postgraduate training at Harvard's Children's Hospital in Boston. He has served as Professor of Histology and Pathology at the Mexican Army Medical School and as the chief pathologist at the Army Hospital in Mexico City.

Dr. Contreras was introduced to Laetrile in 1963 by a terminal cancer patient from the United States who brought it to his attention and urged him to treat her with it. The woman recovered, and Dr. Contreras began extensive investigation of its properties and use. Since that time he has treated many thousands of cancer patients, most of whom are American citizens who have been denied the freedom to use Laetrile in their own country.

Dr. Contreras has summarized his experiences with vitamin therapy as follows:

The palliative action [improving the comfort and well-being of the patient] is in about 60% of the cases. Frequently, enough to be

1. Letter from Dr. Navarro to Mr. Andrew McNaughton, The McNaughton Foundation, dated January 8, 1971, published in the *Cancer News Journal*, Jan./April, 1971, pp. 19, 20.

significant, I see arrest of the disease or even regression in some 15% of the very advanced cases.¹

In Japan there is Shigeaki Sakai, a prominent physician in Tokyo. In a paper published in the October 1963 *Asian Medical Journal*, Dr. Sakai reported:

Administered to cancer patients, Laetrile has proven to be quite free from any harmful side-effects, and I would say that no anti-cancer drug could make a cancerous patient improve faster than Laetrile. It goes without saying that Laetrile controls cancer and is quite effective wherever it is located.

In Italy there is Professor Ettore Guidetti, M.D., of the University of Turin Medical School. Dr. Guidetti spoke before the Conference of the International Union Against Cancer held in Brazil in 1954 and revealed how his use of Laetrile in terminal cancer patients had caused the destruction of a wide variety of tumors including those of the uterus, cervix, rectum, and breast. "In some cases," he said, "one has been able to observe a group of fulminating and cauliflower-like neoplastic masses resolved very rapidly." He reported that, after giving Laetrile to patients with lung cancer, he had been "able to observe, with the aid of radiography, a regression of the neoplasm or the metastases."

After Guidetti's presentation, an American doctor rose in the audience and announced that Laetrile had been investigated in the United States and found to be worthless. Dr. Guidetti replied, "I do not care what was determined in the United States. I am merely reporting what I saw in my own clinic."²

In Belgium there is Professor Joseph H. Maisin, Sr., M.D., of the University of Louvain where he was Director of the Institute of Cancer. He also was President Emeritus of the International League Against Cancer which conducts the International Cancer Congress every four years.

And in the United States there are such respected names as Dr. Dean Burk of the National Cancer Institute; Dr. John A. Morrone of the Jersey City Medical Center; Dr. Ernst T. Krebs, Jr., who developed Laetrile; Dr. John A. Richardson, the courageous San Francisco physician who challenged the government's right

1. *Cancer News Journal*, Jan./April, 1971, p. 20. We must bear in mind that these are *terminal* patients—people who have been given up as hopeless by orthodox medicine. Fifteen percent recovery in *that* group is a most impressive accomplishment.

2. *Cancer News Journal*, Jan./April, 1971, p. 19.

to prevent Laetrile from being used in the United States;¹ Dr. Philip E. Binzel, Jr., a physician in Washington Court House, Ohio, who has used Laetrile for over twenty years with outstanding success; and many others from over twenty countries with equally impeccable credentials.

Most of these practitioners have reported independently that patients usually experience several important side effects. These include a normalizing of blood pressure in hypertensive patients, improved appetite, an increase in the hemoglobin and red blood cell count, the elimination of the fetor (which is the unpleasant odor often associated with terminal cancer patients), and above all, a release from pain without narcotics. Even if the patient has started Laetrile therapy too late to be saved, this last effect is a merciful blessing in itself.

One must not conclude that the only value in Laetrile is to improve the quality of life as the patient is dying. Extension of the *length* of life is the grand prize for many patients. Dr. Binzel, in his book, *Alive and Well*, compared the long-term survival statistics of his own cancer patients with the survival rates of those who undergo orthodox therapies. His study involved 108 patients representing 23 different types of cancer. This is what he reported:

This means that out of 108 patients with *metastatic* cancer, over a period of 18 years, 76 of those patients (70.4%) did not die of their disease. Again, even if I concede that the 9 patients who died of "cause unknown" did, indeed, die from their cancer, I am looking at ... 62.1% [long-term survival]....


If you consider only those patients who have survived five years or more, this means that my results were 287% better than those reported by the American Cancer Society for the treatment of *metastatic* cancer by "orthodox" methods alone.²

The following graph, taken from Dr. Binzel's book, *Alive and Well*, shows his comparison between nutritional and conventional therapies. *Primary Cancer* represents patients with only one cancer location. *Metastatic Cancer* represents patients whose cancer has spread to multiple locations.

1. See John A. Richardson, M.D., and Patricia Griffin, R.N., *Laetrile Case Histories; The Richardson Cancer Clinic Experience* (Westlake Village, CA: American Media, 1977).

2. Philip E. Binzel, M.D., *Alive and Well: One Doctor's Experience with Nutrition in the Treatment of Cancer Patients* (Westlake Village, CA: American Media, 1994), p. 113.

PATIENT SURVIVAL (5-yrs or more)



In addition to the clinical results obtained by these physicians in the treatment of humans, there have been at least five carefully controlled experiments on mice that have shown definite Laetrile anti-cancer action. These include: (1) the experiments done by Scind Laboratories of San Francisco in 1968, (2) the studies completed at the Pasteur Institute (Paris) in 1971, (3) those at the Institute von Ardenne (Dresden, Germany) in 1973, (4) the experiments at the Southern Research Institute in 1973, and (5) numerous trials at Sloan-Kettering from 1972 to 1977. In spite of all this, spokesmen for orthodox medicine still proclaim there is no evidence that Laetrile works. The evidence is everywhere.¹

While the use of Laetrile alone has proven to be effective in many instances, even better results usually are obtained with

1. "See How They Lie, See How They Lie," by Dr. Dean Burk, *Cancer News Journal*, Vol. 9, No. 3 (June, 1974), p. 5.

supplemental therapy as well. The late John Richardson, M.D., of San Francisco achieved one of the highest recovery rates among Laetrile practitioners in the entire world. Here, in his own words, is the advice he gave to his patients:

Vegetable Kingdom: In the vegetable kingdom eat anything and everything that is edible and for which you have no idiosyncrasy. Eat everything whole. Eat all of the edible parts of the food—especially the roughage. This food is preferably eaten raw; but when you cannot tolerate it raw, cook the food just sufficiently to make it tolerable.

Animal Kingdom: Eat any or all fish as fresh as possible and lightly cooked in the absence of animal fats (vegetable oils may be used). Eat the skin-free meat of poultry. Whatever does not fall within this formula, forget it. Don't eat it. The formula is all-inclusive, so it's not necessary to mention: no dairy products, beef, mutton, pork, bacon, ham, etc.

The liver is to neoplastic diseases what the heart is to circulatory diseases. The liver is central.

Adequate liquid intake with fresh juices plain or carbonated.

Vitamin Supplements: Vit. C, 1500 mg to 5000 mg; 800 – 1200 International Units of d-alpha tocopherol (vitamin E) plus a good brand of therapeutic multi-vitamins, preferably of organic or natural derivatives.

Toxins of all kinds to be avoided including tobacco, alcohol. Discourage coffee, tranquilizers, sedatives, analgesics. Antibiotics OK. Rest is important while exercise should spare the affected area....

You should include Vitamin B15 (pangamic acid) which detoxifies the liver as a transmethyating agent, and increases the oxygen uptake potential of the tissues, and since trophoblast lives by the fermentative process, the rationale for the B15 is obvious.

Pancreatic Enzyme Supplementation: We find dessicated pancreas substances to be an effective supplement.¹

The dietary restrictions prescribed by Dr. Richardson are for those who have cancer. It is not recommended for healthy persons because it is unnecessarily restrictive. For those who do not have cancer, a general diet containing foods rich in nitriloxide content should be adequate.² Here is what Dr. Krebs suggests:

1. Open letter to interested doctors dated Nov. 1972, revised 1974; Griffin, *Private Papers*, op. cit.

2. Again, we highly recommend June de Spain's *The Little Cyanide Cookbook*, op. cit.

For breakfast, gruel of buckwheat, millet, and flaxseed, with elderberry jelly on millet toast. All this accompanied by stewed prunes.

For lunch, lima beans or a succotash with chick peas; millet rolls with plum jam; elderberry wine.

For dinner, a salad with bean and millet sprouts; dinner rolls of buckwheat and millet sweetened with sorghum molasses extracted from sorghum cane; rabbit which, hopefully, fed on clover; and after dinner apricot, peach, cherry, or plum brandy originally prepared from crushing the entire or whole fruit.

Nibbling on any member of the raspberry family, macadamia nuts, and bamboo sprouts is also suggested.

Dr. Krebs has pointed out that in the Old Testament there is a formula for the preparation of grains for bread, and it speaks of six ingredients, five of which are rich in nitrilosides. They are barley, beans, lentils, millet and vetch (chickpea or garbanzo beans).¹

The intended balance of nature does not require a *vast* amount of vitamin B₁₇ in the daily diet any more than it is required of the other vitamins. It is possible that if one did no more than eat the seeds from an apple or two a day he could obtain an adequate supply. But that would probably be bordering on the low side, especially considering that, in westernized society, B₁₇ is not generally available in other foods to supplement it. So it probably would be advisable to obtain a higher level of intake than that.

Obviously, some of the foods mentioned by Dr. Krebs are not readily available to the average city dweller. As a substitute, many people simply have adopted the habit of eating six to twelve apricot or peach seeds each day, or have ground them in their blenders and used them as a light seasoning for cereals, salads, and the like. For those who dislike the slight bitter taste of these seeds, they can be ground up and loaded into empty capsules. Which means that no one need be deprived of this vitamin if he really wants it.

Vitamin B₁₅ has been mentioned several times as an important auxiliary therapy to vitamin B₁₇, and there often is confusion between the two. So let's take a moment to differentiate.

Vitamin B₁₅ sometimes is called *pangamic acid*. Pan implies *everywhere* and *gami* means *seed*. It was so named because it is found in small amounts almost everywhere on earth in seeds and

1. Ezekiel IV: 9.

usually in the company of other members of the vitamin-B complex.

Like B₁₇, it too was discovered by Dr. E.T. Krebs, Jr., while exploring the chemical properties of apricot kernels in 1952. It could be said that it was an unexpected bonus or by-product of the search for vitamin B₁₇.

The best way to understand the effect of vitamin B₁₅ is to think of it as instant oxygen. It increases the oxygen efficiency of the entire body and aids in the detoxification of waste products. Since cancer cells do not thrive in the presence of oxygen but depend rather on fermentation of glucose, it is probable that B₁₅, indirectly, is an enemy of cancer.

Vitamin B₁₅ is not widely known or used in the United States. The reason is almost an exact parallel to the Laetrile story. The government officially has refused to recognize that B₁₅ is of value. Meanwhile it is used extensively in many other countries. Russia in particular is far ahead of the United States in the use of this substance and has conducted extensive research into its uses. In fact, in 1965 the U.S.S.R. Academy of Sciences released a 205-page symposium of its findings up to that date. In 1968 the Scientific Advisory Committee of the Ministry of Health unanimously ratified all the original claims in the report and authorized the Soviet drug industry to begin mass-production of B₁₅ for general use.

It has been reported that the Russian athletes have been given heavy doses of B₁₅ during their participation at the Olympics. If this is true, there is good reason for it. Experiments have shown that this substance, although just a natural food factor, greatly increases physical strength and stamina. When rats were put into tubs of water and forced to swim, those that had been vitaminized with B₁₅ were all still swimming long after the others had fatigued and drowned. When other rats were put into glass chambers from which oxygen gradually was removed, the vitaminized rats lived much longer—thus on less oxygen—than the control group.

The Soviet scientists disclosed that vitamin B₁₅ is effective in such areas as circulatory problems, heart conditions, elevated blood cholesterol, skin disorders, hardening of the arteries, bronchial asthma, diabetes mellitus, and wound healing. They were especially emphatic in their findings that B₁₅ was effective in retarding the aging process! Professor Shpirt of the City Clinical

Hospital No. 60 in Moscow concluded: "I believe the time will come when there will be calcium pangamate (B₁₅) next to the salt shaker on the table of every family with people past forty."¹

Doctors who wish to use vitamin B₁₅ in America have been forced to operate on the fringe of the law because their government has harassed its manufacturers and blocked its movement in commerce. As Dr. Krebs observed:

Our concern is with vitamin B₁₅—a natural constituent of natural foods, one that experimentation has shown to be of definite value in increasing resistance to disease and in maintaining healthy functioning of the body as well.

Pangamic acid is giving the people of Russia, Japan, Yugoslavia, France, Spain, and Germany a tremendous health and longevity advantage. But it is not available to us in the land in which it was first discovered.

Fortunately, there is some evidence that B₁₅ is finally becoming recognized by several of the more prestigious medical institutions in spite of government obstacles. Let us hope that the trend rapidly continues.

It is possible that B₁₅ will be recognized and accepted by orthodox medicine long before B₁₇. This is because there is less vested interest to overcome. There have been no broad derogatory pronouncements by the AMA and, hence, no reputations are at stake. But, in time, the sheer weight of the facts will force the acceptance of B₁₇ as well. And the men who now bear the brunt of controversy, professional ostracism, and social scorn, will emerge, not as quacks, but as the great medical pioneers of their day.

1. For a detailed analysis of these findings, see *Vitamin B₁₅ (Pangamic Acid); Properties, Functions, and Use*. (Moscow: Science Publishing House, 1965), translated and reprinted by McNaughton Foundation, Sausalito, Calif.

Chapter Nine

"UNPROVEN" CANCER CURES

Clinical evidence in support of the trophoblast thesis; laboratory experiments showing that Laetrile kills cancer cells; and case histories of terminal cancer patients who attribute their recovery to the effect of Laetrile.

The cyanide scare mentioned previously was but one small salvo in the continuing barrage of officialdom's attacks against Laetrile. The total weaponry runs the gamut from scare tactics to outright falsehoods. But mostly they take the form of scholarly pronouncements, cloaked in the cloth of apparent concern for the public welfare, that vitamin therapy may sound good in theory, but in practice, it simply does not work.

Dr. Ralph Weilerstein, Public Health Medical Officer of the California Food and Drug Administration has said flatly: "Nobody's come up with any reliable data that it is of any value."¹ The Federal FDA has proclaimed: "The Food and Drug Administration has seen no competent, scientific evidence that Laetrile is effective for the treatment of cancer."² And the American Cancer Society, in an impressive volume entitled *Unproven Methods of Cancer Management*, has stated:

After careful study of the literature and other information available to it, the American Cancer Society does not have evidence that treatment with Laetrile results in objective benefit in the treatment of cancer in human beings.³

Commenting on this statement, Dr. Dean Burk of the National Cancer Institute described it as:

-
1. "Food Additive Ban Likely," *San Jose Mercury* (Calif.), Sept. 9, 1972.
 2. *A Cancer Journal for Clinicians* (published by ACS) July/Aug., 1972.
 3. *Unproven Methods of Cancer Management*, 1971, p. 139.

... a statement with close to zero scientific worth, however much sheer propaganda value. The fact is ... there are few "Proven" methods operating on a large scale anywhere, so that the word "Unproved," as used by the ACS, is a highly and unjustifiedly weighted word."¹

As far as the general public is concerned, however, if the American Cancer Society classifies vitamin B₁₇ or Laetrile as an "unproven cancer cure," that's all they need to know. Consequently, official pronouncements from prestigious organizations such as these are hard to ignore. But so are the favorable findings of those clinicians who have used Laetrile on their own patients. *Somebody* is wrong!

In previous pages we examined the scientific integrity of the research projects upon which official opposition to Laetrile is based, and we saw that they are shockingly lacking on all counts. We discovered, also, that almost all of the cancer "experts" who have spoken out against Laetrile have done so, not out of personal experience or experimentation, but simply out of their complete faith in the scientific integrity of these discredited reports.

Showing that the case against Laetrile is fraudulent, however, does not constitute a case *for* Laetrile. It is necessary, therefore, to examine the evidence that vitamin B₁₇ actually *does* work in practice just as well as it does in theory.

The effectiveness of the trophoblast thesis as a basis of cancer therapy has been demonstrated both in the laboratory and in the clinic. In 1935, for example, long before the development of Laetrile, Dr. Isabella Perry of the Department of Pathology at the University of California Medical School conducted a series of experiments in which she subjected tumor-bearing rats to prolonged inhalation of cyanide fumes. Here is what she wrote:

A considerable percentage of the animals so treated showed complete regression of the tumor. Both regressing and growing tumors in treated animals had little capacity for transplantation.²

Perry observed that these experiments were probably of little value to humans because, in order to be effective, the level of

1. Letter from Dr. Dean Burk to Dr. Frank Rauscher, Director of the National Cancer Institute, dated April 20, 1973, reprinted in the *Cancer Control Journal*, Sept./Oct. 1993, p. 5.

2. "The Effects of Prolonged Cyanide Treatment on The Body and Tumor Growth in Rats," *American Journal of Cancer*, 1935, 25:592.

cyanide fumes had to be dangerously close to lethal—a problem that is not present when the cyanide is released only at the cancer cell, as it is in the action of vitamin B₁₇. Nevertheless, these rats showed, not only complete tumor regression, but, compared to the control group without cyanide, an average life extension in excess of three-hundred percent.

When we turn to the laboratory reports on *Laetrile*, the results are even more encouraging, especially since there is none of the danger connected with the inhalation of cyanide fumes. Dr. Dean Burk, Director of the Cytochemistry Section of the federal government's National Cancer Institute, reported that, in a series of tests on animal tissue, the B₁₇ had no harmful effect on normal cells, but released so much cyanide and benzaldehyde when it came in contact with cancer cells that not one of them could survive. He said, "When we add *Laetrile* to a cancer culture under the microscope, providing the enzyme glucosidase also is present, we can see the cancer cells dying off like flies."¹

While participating in the Seventh International Congress of Chemotherapy held in Prague in 1971, Dr. Burk declared:

Laetrile appears to work against many forms of cancer including lung cancer. And it is absolutely non-toxic....

In vitro tests with Ehrlich ascites carcinoma [a particular type of cancer culture] revealed that, where cyanide alone killed one percent of the cells and benzaldehyde alone killed twenty percent, a combination of the two was effective against all the cells. Amygdalin [*Laetrile*] with glucosidase [the "unlocking enzyme"] added also succeeded in killing 100 percent of the ascites tumor cells, due to the freeing of the same two chemicals.²

In another series of tests, Dr. Burk reported that *Laetrile* was responsible for prolonging the life of cancerous rats eighty-percent longer than those in the control group not inoculated.³

The man who made these findings was one of the foremost cancer specialists in the world. He was the recipient of the Gerhard Domagk Award for Cancer Research, the Hillebrand Award of the American Chemical Society, and the Commander

1. "Laetrile Ban May Be Lifted," *Twin Circle*, June 16, 1972, p. 11.

2. "Amygdalin Claimed Nontoxic Anti-Cancer Therapeutic Agent," *Infectious Diseases*, Oct. 15, 1971, pp. 1, 23.

3. Testimony in *Hearings* before the Subcommittee on Public Health and Environment, Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-Second Congress, quoted in *Cancer News Journal*, July-October, 1972, p. 48.

Knighthood Of The Medical Order of Bethlehem (Rome) founded in 1459 by Pope Pius the Eleventh. He held a Ph.D. in biochemistry earned at the University of California. He was a Fellow of the National Research Council at the University of London, of the Kaiser Wilhelm Institute for Biology, and also Harvard. He was senior chemist at the National Cancer Institute, which he helped establish, and in 1946 became Director of the Cytochemistry Section. He belonged to eleven scientific organizations, wrote three books relating to chemotherapy research in cancer, and was author or co-author of more than two-hundred scientific papers in the field of cell chemistry.

If Dr. Burk says Laetrile works, *it works!*

Dr. Burk is not a physician. He is a biochemist. His experiments have been with cancer cultures and with laboratory animals, not people. As we have seen, however, the health records of the Hunzakuts, and Eskimos, and other groups around the world are statistically conclusive that vitamin B₁₇—together with other substances associated with it in nature—does control cancer in human beings with an effectiveness approaching 100%. But what about cancer that already has started? Can B₁₇ restore a person to health *after* he has contracted the disease?

The answer is yes, *if* it is caught in time, and *if* the patient is not too badly damaged by prior X-ray treatment or toxic drugs. Unfortunately, most cancer victims start taking Laetrile only after their disease is so far advanced that they have been given up as hopeless by routine medical channels. Usually they have been told that they have only a few more months or weeks to live. And it is in this tragic state of near death that they turn to vitamin therapy as a last resort. If they die—and, indeed, many of them do—then they are counted as statistical failures for Laetrile. In reality, it is a victory for Laetrile that *any* of them should be saved at this stage. Once a deficiency disease has progressed so far, the damage it has done simply cannot be reversed.

It is known, for example, that a severe vitamin-A deficiency in a pregnant animal will result in an offspring that is completely blind. In fact, it will be born without orbits, retina, or even optical nerves. No amount of vitamin A administered at that late stage can cause the eyes to grow back.

Likewise, a child whose legs become bowed by rickets, a vitamin-D deficiency disease, can never achieve a normal bone structure again, no matter how much vitamin D he receives.

In cancer, the process is different. Instead of normal tissue *failing* to form or becoming *malformed*, it literally becomes destroyed. The cancerous growth invades and corrupts, leaving behind organs that cannot function because they are almost gone.

A man who has been shot with a gun can have the bullet removed but still die from the wound. Likewise, a patient can have his cancer deactivated by vitamin B₁₇ and still die from the irreversible damage already done to his vital organs.

And so, in view of this tremendous handicap, the number of terminal patients who *have* been restored to health is most impressive. In fact there literally are thousands of such case histories in the medical record. The American Cancer Society has tried to create the impression that the only ones who claim to have been saved by Laetrile are those who merely are hypochondriacs and who never really had cancer in the first place. But the record reveals quite a different story. Let's take a look at just a few examples.

DAVID EDMUNDS

Mr. David Edmunds of Pinole, California, was operated on in June of 1971 for cancer of the colon, which also had metastasized or spread to the bladder. When the surgeon opened him up, he found that the malignant tissue was so widespread it was almost impossible to remove it all. The blockage of the intestines was relieved by severing the colon and bringing the open end to the outside of his abdomen—a procedure known as a colostomy. Five months later, the cancer had worsened, and Mr. Edmunds was told that he had only a few more months to live.

Mrs. Edmunds, who is a Registered Nurse, had heard about Laetrile and decided to give it a try. Six months later, instead of lying on his deathbed, Mr. Edmunds surprised his doctors by feeling well enough to resume an almost normal routine.

An exploratory cystoscopy of the bladder revealed that the cancer had disappeared. At his own insistence, he was admitted to the hospital to see if his colon could be put back together again. In surgery, they found nothing even resembling cancer tissue. So they re-connected the colon and sent him home to recuperate. It was the first time in the history of the hospital that a *reverse* colostomy for this condition had been performed.¹

1. See "Cancer 'Miracle-Cure'," by Mark Trantwein, *Berkeley Daily Gazette*, July 27, 1972.

At the time of the author's last contact three years later, Mr. Edmunds was living a normal life of health and vigor.

JOANNE WILKINSON

In 1967 in Walnut Creek, California, Mrs. Joanne Wilkinson, mother of six, had a tumor removed from her left leg just below the thigh. Four months later there was a recurrence requiring additional surgery and the removal of muscle and bone.

A year later, a painful lump in the groin appeared and began to drain. A biopsy revealed that her cancer had returned and was spreading.

Her doctor told her that surgery would be necessary again, but this time they would have to amputate the leg, the hip, and probably the bladder and one of the kidneys as well. The plan was to open up her lungs first to see if cancer had located there. If it had, then they would not amputate, because there would be no chance of saving her anyway.

At the urging of her sister and of a mutual friend, Mrs. Wilkinson decided not to undergo surgery but to try Laetrile instead. Her doctor was greatly upset by this and told her that, if she did not have the surgery, she couldn't possibly live longer than twelve weeks. Mrs. Wilkinson describes in her own words what happened next:

That was Saturday, November 16, 1968. I'll never forget that day! The stitches from the biopsy were still in the leg.

Dr. Krebs¹ gave me an injection of Laetrile—and the tumor reacted. It got very large—from walnut size to the size of a small lemon—and there was bleeding four or five days. I went back on Monday, Wednesday, and Friday each week for five weeks to get injections, and the tumor then started getting smaller. Five weeks later I could no longer feel it.

An X-ray was taken the first Monday, and regularly after that to watch the progress. Injections were continued for six months—ten cc's three times a week and of course the diet: No dairy products, nothing made with white flour—no eggs—but white fish, chicken, turkey.

And I felt wonderful! In fact, in August, 1969, the doctor told me I needed no more injections. My X-rays were clear, showing that the tumor had shrunk, was apparently encased in scar tissue, and was not active.²

1. She is referring here to Byron Krebs, M.D., the brother of Dr. E.T. Krebs, Jr.

2. See "Laetrile—An Answer to Cancer?" *Prevention*, Dec. 1971, pp. 172–175.

Our last contact with Mrs. Williams was nine years after her doctor told her she couldn't possibly live longer than twelve weeks without surgery. She was living a healthy and productive life, and all that was left as a grim reminder of her narrow escape was a small scar from the biopsy.

JOE BOTELHO

Mr. Joe Botelho of San Pablo, California, underwent surgery (trans-urethral resection) and was told by his doctor that he had a prostate tumor that simply had to come out. His reaction?

I didn't let them take it out because I figured that would only spread it. The doctor told me I wouldn't last too long. He wanted to give me cobalt, and I wouldn't agree to that either.

At a health food store I heard about a doctor in San Francisco who used Laetrile. I went to see him, was told that the prostate was the size of a bar of soap. I got one injection every four days for several months.¹

Mr. Botelho, who was sixty-five at the time, also maintained a strict diet designed specifically not to use up the body's pancreatic enzyme, trypsin. When the author interviewed him three years later, his tumor was gone, and he even reported that his hair was turning dark again. He was not sure what was causing that, but attributed it to his better eating habits.

ALICIA BUTTONS

Alicia Buttons, the wife of the famous actor-comedian Red Buttons, is among the thousands of Americans who attribute their lives to the action of Laetrile. Speaking before a cancer convention in Los Angeles, Red Buttons declared:

Laetrile saved Alicia from cancer. Doctors here in the U.S. gave her only a few months to live last November. But now she is alive and well, a beautiful and vital wife and mother, thanks to God and to those wonderful men who have the courage to stand up for their science.²

Mrs. Buttons had been suffering from advanced cancer of the throat and was given up as terminal by practitioners of orthodox medicine. As a last resort, however, she went to West Germany to seek Laetrile therapy from Dr. Hans Nieper of the Silbersee Hospital in Hanover. Within a few months her cancer had

1. *Ibid.*, pp. 175, 176.

2. "Comedian Red Buttons Says 'Laetrile Saved My Wife From Death By Cancer,'" *The National Tattler*, Aug. 19, 1973, p. 5.

completely regressed, the pain had gone, her appetite had returned, and she was as healthy and strong as ever. Doctors in the United States verified the amazing recovery, but could not believe that a mere vitamin substance had been responsible. Alicia is still going strong twenty-three years later.

CAROL VENCIUS

The reluctance of many physicians to accept the reality of the vitamin concept of cancer was well described by Miss Carol Vencius, a former cancer victim from Marin County, California. After successful Laetrile treatment in Tijuana, Mexico, under the care of Dr. Ernesto Contreras, Miss Vencius returned home. Here is what she reported:

I went to another doctor who had treated me. He greeted me with "Well, what do they do down there? Do you crush the apricot pit, bathe in it? Do they light incense over you?"

I said to him, "Okay, enough with the jokes," and asked him to read the *College of Marin Times* article [which contained information about Laetrile]. He said his mind was closed on the matter. When I pressed, he finally said, "Carol, I guess you might be able to help me after all. You see, I have insomnia and I'm sure that if I read that article it would put me to sleep."¹

Miss Vencius' story, unfortunately, is not unique. She had begun to complain of feeling generally ill: night sweats, itching, fever, and headaches. After extensive tests in the hospital she was told that she had Hodgkins Disease (a form of cancer initially affecting the lymph nodes), Miss Vencius continued:

Only a couple of days after that, a friend came to visit and told me about vitamin therapy in Mexico called Laetrile. I never followed up on his advice, I was too frightened. And besides, at the time I had complete faith in my doctors....

The first thing they tried was cobalt radiation treatments. Soon after they began, my doctor told me, "Carol, of course you know this treatment will make you sterile." Hell no, I didn't know. Naturally I became pretty upset.... I went through menopause at the age of 28.

Other "side effects" were indescribable pain, loss of appetite, and temporary loss of hair. Six months after the treatments, her lungs and heart cavity began to fill with fluid. They tried draining

1. "Laetrile Works Through C.O.M. Times," *College of Marin Times*, April 12, 1972.

it with a hypodermic, but it continued to fill up. She was having minor heart attacks.

After six weeks and three heart-cavity taps, her physicians were still debating whether or not to remove the pericardium (the membrane enclosing the heart cavity). On November 28, 1970, it was removed.

By July, general fatigue, sleeplessness, and loss of appetite had returned and for several months grew worse until it was decided to try drugs.

The first injection left me with mild nausea. Two weeks later, I received two more injections which produced acute nausea and diarrhea followed by a week of intense pain in my jaw. It was so bad I couldn't eat. This was followed by a one-week migraine headache, followed by stomach cramps, followed by leg cramps. In all, the symptoms lasted four weeks.

For ten days following this, however, I felt great, better than I had in years. This positive response, I was told, was a sign that the disease was still active and that the drugs had done some good. Then it was downhill again, a return of pain, sleeplessness, fatigue, and all the rest. I decided then, whatever happened, I would not undergo chemotherapy again.

At this point, Miss Vencius concluded that it was hopeless anyway so there was no reason why she should not go to Mexico and try Laetrile after all. Dr. Contreras told her that Hodgkins Disease was slower to respond to vitamin therapy than many other cancers such as those of the lung, pancreas, liver, or colon, but that it certainly was worth a try. After just the third day on Laetrile, however, she reported that her pain had gone completely and that within only a week she was feeling almost normal again. Within a few months she had recovered her health and was continuing a routine maintenance dose of vitamin B₁₇.

The issue of maintenance doses is important. Once a person has contracted cancer and recovered, apparently the need for vitamin B₁₇ is considerably greater than for those who have not. Most physicians who have used Laetrile in cancer therapy have learned through experience that their patients, once recovered, can reduce their dosage levels of Laetrile, but if they eliminate it altogether, it is almost a certain invitation to a return of the cancer. It's for this reason that physicians using Laetrile never say that it *cures* cancer. They prefer the more accurate word *control*, implying a continuing process.

MARGARET DeGRIO

This fact was illustrated most dramatically and tragically in the case of Mrs. Margaret DeGrio, wife of a County Supervisor in Sierra County, California. After undergoing surgery twice, and with her cancer continuing to spread, she was told by three physicians that her case was hopeless and that there was nothing further that modern medical science could do. But Mike DeGrio had read about Laetrile and decided to take his wife to Mexico for treatment. It was the same old story: She began to improve immediately and, after four months of intensive treatment, she returned to her Northern California home with only minor symptoms of her original cancer. The rapid disappearance of her tumors was confirmed by her American doctor, although he could not explain why it happened.

Shortly afterward, however, Mrs. DeGrio contracted a serious respiratory infection and was hospitalized in San Francisco for pneumonia. While she was there for over three weeks, her physician and the hospital staff refused to allow her the maintenance dose of Laetrile because they feared it might be against the California anti-quackery law. The denial of this dose came at a critical time in the recovery and healing stage. Mrs. DeGrio succumbed to cancer on the night of October 17, 1963.¹

DALE DANNER

In 1972, Dr. Dale Danner, a podiatrist from Santa Paula, California, developed a pain in the right leg and a severe cough. X-rays revealed carcinoma of both lungs and what appeared to be massive secondary tumors in the leg. The cancer was inoperable and resistant to radio therapy. The prognosis was: incurable and fatal.

At the insistence of his mother, Dr. Danner agreed to try Laetrile, although he had no faith in its effectiveness. Primarily just to please her, he obtained a large supply in Mexico. But he was convinced from what he had read in medical journals that it was nothing but quackery and a fraud. "Perhaps it was even dangerous," he thought, for he noticed from the literature that it contained cyanide.

1. "The Laetrile Story," by Jim Dean and Frank Martinez, *The Santa Ana Register*, Sept., 1964. For an excellent portrayal of the futility and tragedy of orthodox cancer therapy, read Wynn Westover, *See the Patients Die*, (Sausalito, CA: Science Press International, 1974)

Within a few weeks the pain and the coughing had progressed to the point where no amount of medication could hold it back. Forced to crawl on his hands and knees, and unable to sleep for three days and nights, he became despondent and desperate. Groggy from the lack of sleep, from the drugs, and from the pain, finally he turned to his supply of Laetrile.

Giving himself one more massive dose of medication, hoping to bring on sleep, he proceeded to administer the Laetrile directly into an *artery*. Before losing consciousness, Dr. Danner had succeeded in taking at least an entire ten-day supply—and possibly as high as a twenty-day supply—all at once.

When he awoke thirty-six hours later, much to his amazement, not only was he still alive, but also the cough and pain were greatly reduced. His appetite had returned, and he was feeling better than he had in months. Reluctantly he had to admit that Laetrile was working. So he obtained an additional supply and began routine treatment with smaller doses. Three months later he was back at work.¹

WILLIAM SYKES

In the fall of 1975, William Sykes of Tampa, Florida, developed lymphocytic leukemia plus cancer of the spleen and liver. After removal of the spleen, he was told by his doctors that he had, at best, a few more months to live.

Although chemotherapy was recommended—not as a cure but merely to try to delay death a few more weeks—Mr. Sykes chose Laetrile instead. In his own words, this is what happened:

When we saw the doctor a few weeks later, he explained how and why Laetrile was helping many cancer patients, and suggested that I have intravenous shots of 30 cc's of Laetrile daily for the next three weeks. He also gave me enzymes and a diet to follow along with food supplements.

In a few days I was feeling better, but on our third visit the doctor said that he could no longer treat me. He had been told that his license would be revoked if he continued to use Laetrile. He showed my wife how to administer the Laetrile, sold us what he had, and gave us an address where more could be obtained.

The next week I continued on the program and was feeling better each day. One afternoon the doctor from Ann Arbor called to ask why I had not returned for the chemotherapy. He said I was playing "Russian Roulette" with my life. He finally persuaded me to

1. Story confirmed in tape-recorded interview by author.

return for chemotherapy, so I went to Ann Arbor and started the treatments. Each day I felt worse. My eyes burned, my stomach felt like it was on fire. In just a few days I was so weak I could hardly get out of bed.... The "cure" was killing me faster than the disease! I couldn't take it any longer, so I stopped the chemotherapy, returned to my supply of Laetrile and food supplements, and quickly started feeling better. It took longer this time as I was fighting the effects of the chemotherapy as well as the cancer....

In a short time I could again do all my push-ups and exercises without tiring. Now, at 75 years of age [20 years after they said I had only a few more months to live], I still play racquet ball twice a week.¹

In a letter to the author, dated June 19, 1996, Mrs. Hazel Sykes provides this additional insight:

After Bill had conquered cancer, a doctor came to him one day. (This was an M.D. who gave chemotherapy in a well-known hospital.) He wanted to know how Bill had conquered his cancer, because his wife was quite ill with cancer. Bill said: "Why don't you give her chemotherapy?" His answer was: "I would never give chemotherapy to any of my friends or family."! He was not the only doctor who came to Bill with the same question.²

BUD ROBINSON

The following letter from Bud Robinson in Phoenix, Arizona, needs no further comment. It was sent to Dr. Ernst Krebs, Jr.

Dear Dr. Krebs,

Thank you for giving me another birthday (May 17).

Please, again, remember November 15th, 1979, when my doctor and four other urologists gave me a maximum of four months to live with my prostate cancer, and they set up appointments for radiation and chemotherapy, which I knew would kill me if the cancer didn't, and refused their treatment.

Then on a Sunday afternoon I contacted you by telephone and went with your simple program.

I am 71 years old and am in my 13th year [of survival]. *Three* of the four urologists have died with prostate cancer, and forty or fifty people are alive today, and doing very well, because they followed my "Krebs" simple program.

Thanks again for giving me back my life.

Your friend,

H.M. "Bud" Robinson³

1. Open letter to "Dear Friends"; Griffin *Private Papers*, *op. cit.*

2. Letter to the author, June 19, 1996; Griffin, *Private Papers*, *op. cit.*

3. Letter from Bud Robinson to Ernst T. Krebs, Jr., May 18, 1992; Griffin, *Private Papers*, *op. cit.*

This letter was written in 1992. When the author contacted him in June of 1996, Mr. Robinson was still going strong. His age at that time was 75, not 71, and the number of cancer patients he had helped to recover was up to 90.

The use of amygdalin in the treatment of cancer is not new. The earliest recorded case was published in 1845 in the *Paris Medical Gazette*.¹ A young cancer patient was given 46,000 milligrams of amygdalin over a period of several months in 1842 and, reportedly, was still living at the time of the article three years later. A woman with extensive cancer throughout her body received varying amounts of amygdalin starting in 1834(!) and was still surviving at the time of the report eleven years later.

Since the publication of this first report, there have been literally *thousands* of similar case histories reported and documented. It is important to know that because, as demonstrated previously, spokesmen for orthodox medicine have stated authoritatively that there simply is no evidence that Laetrile works. The truth is that the evidence is *everywhere*.

When confronted with this evidence, some doctors, because of their professional bias against nutritional medicine, seek alternate explanations. Their favorite is that the cancer had a delayed response to previous treatment such as radiation or drugs. And when it occasionally happens that there has been no previous treatment except Laetrile, they then say that the patient probably didn't have cancer in the first place. And when it is demonstrated that the presence of cancer was proven by surgery or biopsy, they ultimately fall back on the claim that it was a *spontaneous remission*, meaning that it just went away on its own with no outside help.

It is true, of course, that, occasionally, there are cases in which cancers either stop spreading or disappear without medical treatment.² But such cases are rare. With certain cancer locations—such as testicular chorionepithelioma, for example—they are so rare as to defy statistical analysis. And when one comes up with a *series* of such cases, all of which involve proven cancers,

1. *Gazette Medical de Paris*, Vol. 13, pp. 577–582.

2. It would be interesting to examine such cases for a possible change in eating habits to see if there were any connection. My guess is that such a study would show a change in foods, either by selection or by a change in locale, that placed less of a demand upon the pancreas and/or provided a higher source of natural vitamin B₁₇.

and all of which have responded to B17, it is beyond reason to speak of spontaneous regressions.

In a banquet speech in San Francisco on November 19, 1967, Dr. Krebs reviewed *six* such cases. Then he added:

Now there is an advantage in not having had prior radiation, because if you have not received prior radiation that has failed, then you cannot enjoy the imagined benefits of the delayed effects of prior radiation. So this boy falls into the category of the "spontaneous regression...."

And when we look at this scientifically, we know that spontaneous regression occurs in fewer than one in 150,000 cases of cancer. The statistical possibility of spontaneous regression accounting for the complete resolution of six successive cases of testicular chorionepithelioma is far greater than the improbability of the sun not rising tomorrow morning.¹


With the passage of each year and the presence of a growing stream of patients who are living proof of their claim, it becomes increasingly difficult to ignore or dismiss these recoveries. If they are spontaneous remissions, then, indeed, it must be said in all fairness that Laetrile produces far more spontaneous remissions than all other forms of therapy put together!

1. Speech delivered before a meeting of the International Association of Cancer Victims and Friends at the Jack Tar Hotel, Nov. 19, 1967.




Photo from L.A. County Medical Bulletin

Photo from San Francisco Medical Society



Dr. Ian MacDonald (left) and Dr. Henry Garland (right) wrote the famous 1953 report of the California Medical Association that since has become the basis of almost all scientific opposition to Laetrile. It was learned later, however, that the findings in this report had been falsified. Both doctors defended cigarette smoking as a harmless pastime unrelated to lung cancer. Dr. MacDonald had publicly stated: "A pack a day keeps lung cancer away."



Photos © by Peter Chowka

Dr. Kanematsu Sugiura (left) was the senior laboratory researcher at the Sloan-Kettering Cancer Institute. He reported that, in his experiments with mice, Laetrile was more effective in the control of cancer than any substance he had ever tested. This was not acceptable to his superiors. Instead of being pleased at the possibility of a breakthrough, they brought in other researchers to duplicate Sugiura's experiments and to prove that they were faulty. Instead, the follow-up studies confirmed Sugiura. Undaunted, his superiors called for new experiments over and over again, following procedures designed to make the tests fail. Eventually they did fail, and it was that failure that was announced to the world.

Ralph Moss (right) was the Assistant Director of Public Affairs at Sloan-Kettering at the time of the Laetrile tests. When he was ordered by his superiors to release false information about the results of those tests, he resigned in protest.



The elders of Hunza, typically ninety years or older.

The Hunzakuts are world renowned for their amazing longevity and good health. There is no cancer in Hunza. The native diet contains over two-hundred times more vitamin B₁₇ than found in the average diet of industrialized societies.

(Photos courtesy of Dr. J. Milton Hoffman.)



In Hunza, the apricot and its seed are the most prized of all foods.




Photo by author




Photo from Internat'l Assoc. Cancer Victims & Friends





Photo from author

John A. Richardson, M.D., (above left) shares his scrapbook of newspaper clippings with the author. Dr. Richardson was in the forefront of the legal battle for the right of a physician to administer Laetrile.

Dr. Ernst T. Krebs, Jr. (opposite page, left), the biochemist who pioneered Laetrile and the vitamin concept of cancer, likely will be acknowledged in history as the Louis Pasteur of our day.

Dr. Ernesto Contreras (opposite page, right), one of Mexico's most distinguished medical figures, established the world's first hospital specializing in Laetrile as the treatment of choice for cancer.

Shown at left are (from left to right) Dr. Dean Burk, head of the Cytochemistry section of the National Cancer Institute, Dr. Krebs, and Dr. Hans Nieper, famous cancer specialist from Hanover, Germany. Drs. Burk and Nieper are among the many prominent supporters of Dr. Krebs and his work with Laetrile.




Photo by

Photo by author



Dr. Dale Danner (left), a terminal cancer victim himself, at first had no faith in Laetrile. On the brink of death he self-administered a massive dose as a last resort and was amazed to experience a release from pain and a return of appetite. Three months later he was able to return to work.

In 1967, cancer victim Joanne Wilkinson (bottom left) was told that it would be necessary to remove her leg, hip, bladder, and one of her kidneys. When she chose Laetrile instead, her irate physicians warned her that she could not possibly live longer than twelve weeks. This photo was taken many years afterward. Mrs. Wilkinson has enjoyed a healthy and productive life.

Alicia Buttons, wife of the famous actor-comedian Red Buttons (below), had been given up as hopeless by practitioners of orthodox medicine. After a few months of Laetrile therapy, however, her cancer had completely disappeared. The couple is shown here at the 1973 Cancer Control Convention in Los Angeles. Alicia was still going strong twenty-three years later.

Photo from *The Tattler*






Photo from Sykes family




Photo from V

Bill Sykes (left) was given up as hopeless when he developed Stage-4 Lymphocytic Leukemia and cancerous tumors in his spleen and liver. He was told that chemotherapy might prolong his life a few months but no more. Instead, he turned to Laetrile and enzyme therapy. That was over 20 years ago. Bill is now 74 and plays racquet ball twice a week.

X-rays (right) are known to cause cancer, not to cure it. The patient often dies from X-ray damage rather than cancer. Those who receive no treatment at all live just as long—or longer—than those who undergo radiology or chemotherapy. Orthodox cancer therapies treat the symptom (the tumor) rather than the cause.

Chapter Ten

"PROVEN" CANCER CURES

The effects of surgery and radiation in the treatment of cancer; a comparison showing that those who receive no treatment at all live just as long, if not longer, than those who are treated.

The advocates of Laetrile therapy have always emphasized that there is no *cure*, as such, for cancer. Since it is essentially a deficiency disease, one can only speak of *prevention* or *control* but not *cure*. Among the advocates of orthodox therapies, however, there is no such restraint. Official spokesmen for the cancer industry tell the American public, without batting an eyelash, that they have *proven cures* for cancer, and that anyone who resorts to such nostrums as Laetrile is merely wasting valuable time in which he would be far better off availing himself of these proven cures. What are these cures? They are surgery, radiation, and drugs.

The following report carried in a Los Angeles paper is typical:

Warnings of a mounting scale of cancer quackery activity affecting the San Fernando Valley were issued today by the American Cancer Society.

Mrs. Stanley Grushesky, Education Chairman of the Society's Valley area, said she is concerned over the possibility that some local residents have been deceived in recent weeks by propaganda issued on behalf of unorthodox practitioners with claims of unproven cancer "cures"... which could easily lure unsuspecting victims into a quackery mill....

Mrs. Grushesky said that ... "Cancer quackery kills many unsuspecting patients because time wasted on phony devices and treatments delays effective treatment until it is too late to save the patient's life."¹

1. "Amer. Cancer Soc. Warns of Valley Quacks," *The Valley News* (Van Nuys, Calif.), Dec. 10, 1972.

Echoing the same theme, Dr. Ralph Weilerstein of the California Department of Public Health declared:

The use of Laetrile in early cancer cases to the exclusion of conventional treatment might well be dangerous since treatment with acceptable, modern curative methods—surgery or radiation—would thereby be delayed potentially until such time as metastases had occurred and the cancer, therefore, might no longer be curable.¹

Public Library references on cancer often contain bookmarks distributed by the American Cancer Society. One of these depicts an ace of spades along with the slogan: THE UNPROVEN CANCER CURE. DON'T BET YOUR LIFE ON IT. On the back it says: "For more information on proven cancer cures, write or phone the American Cancer Society." In response, the author sent a letter expressing surprise at the assertion that any cancer therapy is successful enough to warrant being called a proven cure. This is the reply:

To Mr. G. Edward Griffin:

Thank you for your note. There *are* proven cures—if detected in time—surgery and/or radiation and, more and more, chemotherapy is playing its part.²

By 1996, the American Cancer Society was claiming *millions* of cures. In their release of statistics for that year we find this:

It is estimated that over 10 million Americans alive today have a history of cancer, 7 million diagnosed five or more years ago. Most of these 7 million can be considered cured.³

This is the position of orthodox medicine. Therefore, let us take a look at the results and benefits of the so-called cures obtained through surgery, radiation, and chemotherapy.

Surgery is the least harmful of the three. It can be life-saving, particularly where intestinal blockages must be relieved to prevent death from secondary complications. Surgery also has the psychological advantage of visibly removing the tumor and offering the temporary comfort of hope. However, the degree to which surgery is useful is the same degree to which the tumor is *not* malignant. The greater the proportion of cancer cells in that tumor, the less likely it is that surgery will help. The most malignant tumors of all generally are considered inoperable.

1. As quoted in *College of Marin Times* (Kentfield, Calif.), April 26, 1972.

2. Letter from Mabel Burnett dated Dec. 18, 1972; Griffin, *Private Papers*, *op. cit.*

3. *Cancer Facts & Figures*—1996, p. 1.

A further complication of surgery is that cutting into the tumor—even for a biopsy—does two things that can aggravate the condition. First, it causes trauma to the area. That triggers the healing process which, in turn, brings more trophoblast cells into being as a by-product of that process. (See Chapter IV.) The other effect is that, if not all the malignant tissue is removed, what remains may become encased in scar tissue from the surgery. Consequently, the cancer tends to become insulated from the action of the pancreatic enzymes which are essential for exposing trophoblast cells to the surveillant action of the white blood cells.

Perhaps the greatest indictment against surgery is the fact that, statistically, there is no solid evidence that patients who submit to surgery have any greater life expectancy, on the average, than those who do not. The first statistical analysis of this question was compiled in 1844 by Dr. Leroy d'Etoilles and published by the French Academy of Science. It is, to date, the most extensive study of its kind ever released. Over a period of thirty years, case histories of 2,781 patients were submitted by 174 physicians. The average survival after surgery was only one year and five months—not much different than the average today.

Dr. Leroy d'Etoilles separated his statistics according to whether the patient submitted to surgery or caustics, or refused such treatment. His findings were electric:

The net value of surgery or caustics was in prolonging life two months for men and six months for women. But that was only in the first few years after the initial diagnosis. After that period, those who had not accepted treatment had the greater survival potential by about fifty percent.¹

Recent surveys have produced similar results. Patients with breast cancer used to have, not only their tumor removed, but the entire breast and the lymph nodes as well. The procedure often removed the ovaries also because cancer is stimulated by the hormones they produce. Finally, in 1961, a large-scale survey was begun, called the National Surgical Adjuvant Breast Project. After seven-and-a-half years of statistical analysis, the results were conclusive: There was no significant difference between the percentage of patients remaining alive who had received the smaller operation and those who had received the larger.

1. Walter H. Walshe, *The Anatomy, Physiology, Pathology and Treatment of Cancer*, (Boston: Ticknor & Co., 1844).

It was to be expected that an effort would be made to discredit this study. Teams of auditors combed over the records of 5,000 physicians at the 484 medical centers which participated. In 1991 it was announced that the study was not reliable. Why? Because one of the doctors (out of 5,000) had falsified his data and two of the medical centers (out of 484) could no longer locate all their patients' lab tests or consent forms.¹

But the evidence could not be buried. At the University of California-Irvine College of Medicine, a similar study conducted between 1984 and 1990 produced this conclusion: "All other factors being equal, there is no difference between BCS [breast-conserving surgery] and total mastectomy in either disease-free or overall survival."²

One of the nation's top statisticians in the field of cancer is Hardin B. Jones, Ph.D., former professor of medical physics and physiology at the University of California at Berkeley. After years of analyzing clinical records, this is the report he delivered at a convention of the American Cancer Society:

In regard to surgery, no relationship between intensity of surgical treatment and duration of survival has been found in verified malignancies. On the contrary, simple excision of cancers has produced essentially the same survival as radical excision and dissection of the lymphatic drainage.³

That data, of course, related to surgery of the breast. Turning his attention to surgery in general, Dr. Jones continued:

Although there is a dearth of untreated cases for statistical comparison with the treated, it is surprising that the death risks of the two groups remain so similar. In the comparisons it has been assumed that the treated and untreated cases are independent of each other. In fact, that assumption is incorrect. Initially, all cases are untreated. With the passage of time, some receive treatment, and the likelihood of treatment increases with the length of time since origin

1. See Ravdin, R.G., *et.al.*, "Results of a Clinical Trial Concerning The Worth of Prophylactic Oophorectomy for Breast Carcinoma," *Surgery, Gynecology & Obstetrics*, 131:1055, Dec., 1970. Also "Breast Cancer Excision Less with Selection," *Medical Tribune*, Oct. 6, 1971, p. 1. Also "Breast Cancer Research on Trial," *Science News*, April 30, 1994, pp. 277, 282, 283, 286.

2. "Treatment Differences and Other Prognostic Factors Related to Breast Cancer Survival: Delivery Systems and Medical Outcomes," by Anna Lee-Feldstein, Hoda Anton-Culver, and Paul J. Feldstein, *Journal of the American Medical Association*, ISSN:0098-7484, April 20, 1994.

3. Hardin B. Jones, Ph.D., "A Report on Cancer," paper delivered to the ACS's 11th Annual Science Writers Conference, New Orleans, Mar. 7, 1969.

of the disease. Thus, those cases in which the neoplastic process progresses slowly [and thus automatically favors a long-term survival] are more likely to become "treated" cases. For the same reason, however, those individuals are likely to enjoy longer survival, whether treated or not. Life tables truly representative of untreated cancer patients must be adjusted for the fact that the inherently longer-lived cases are more likely to be transferred to the "treated" category than to remain in the "untreated until death."

The apparent life expectancy of untreated cases of cancer after such adjustment in the table seems to be greater than that of the treated cases.
[Emphasis added]

What, then, is the statistical chance for long-term survival of five years or more after surgery? That, we are told, depends on the location of the cancer, how fast it is growing, and whether it has spread to a secondary point. For example, two of the most common forms of cancer requiring surgery are of the breast and the lung. With breast cancer, only sixteen percent will respond favorably to surgery or X-ray therapy. With lung cancer, the percentage of patients who will survive five years after surgery is somewhere between five and ten percent.¹ And these are optimistic figures when compared to survival expectations for some other types of cancers such as testicular chorionepitheliomas.

When we turn to cancers which have metastasized to secondary locations, the picture becomes virtually hopeless—surgery or no surgery. As one cancer specialist summarized it bluntly:

A patient who has clinically detectable distant metastases when first seen has virtually a hopeless prognosis, as do patients who were apparently free of distant metastases at that time but who subsequently return with distant metastases.²

An objective appraisal, therefore, is that the statistical rate of long-term survival after surgery is, on the average *at best*, only ten or fifteen percent. And once the cancer has metastasized to a second location, surgery has almost *no* survival value. The reason

1. See "Results of Treatment of Carcinoma of the Breast Based on Pathological Staging," by F.R.C. Johnstone, M.D., *Surgery, Gynecology & Obstetrics*, 134:211, 1972. Also "Consultant's Comment," by George Crile, Jr., M.D., *Calif. Medical Digest*, Aug., 1972, p. 839. Also "Project Aims at Better Lung Cancer Survival," *Medical Tribune*, Oct. 20, 1971. Also statement by Dr. Lewis A. Leone, Director of the Department of Oncology at Rhode Island Hospital in Providence, as quoted in "Cancer Controls Still Unsuccessful," *L.A. Herald Examiner*, June 6, 1972, p. C-12.

2. Johnstone, "Results of Treatment of Carcinoma of the Breast," *op. cit.*

is that, like the other therapies approved by orthodox medicine, surgery removes only the tumor. It does not remove the cause.

The rationale behind X-ray therapy is the same as with surgery. The objective is to remove the tumor, but to do so by burning it away rather than cutting it out. Here, also, it is primarily the non-cancer cell that is destroyed. The more malignant the tumor, the more resistant it is to radio therapy. If this were not so, then X-ray therapy would have a high degree of success—which, of course, it does not.

If the average tumor is composed of both cancer and non-cancer cells, and if radiation is more destructive to non-cancer cells than to cancer cells, then it would be logical to expect the results to be a *reduction* of tumor size, but also an *increase* in the *percentage of malignancy*. This is, in fact, exactly what happens.

Commenting on this mechanism, Dr. John Richardson explained it this way:

Radiation and/or radiomimetic poisons *will* reduce palpable, gross or measurable tumefaction. Often this reduction may amount to seventy-five percent or more of the mass of the growth. These agents have a selective effect—radiation and poisons. They selectively kill everything except the definitively neoplastic [cancer] cells.

For example, a benign uterine myoma will usually melt away under radiation like snow in the sun. If there be neoplastic cells in such tumor, these will remain. The size of the tumor may thus be decreased by ninety percent while the relative concentration of definitively neoplastic cells is thereby increased by ninety percent.

As all experienced clinicians know—or at least should know—after radiation or poisons have reduced the gross tumefaction of the lesion the patient's general well-being does not substantially improve. To the contrary, there is often an explosive or fulminating increase in the biological malignancy of his lesion. This is marked by the appearance of diffuse metastasis and a rapid deterioration in general vitality followed shortly by death.¹

And so we see that X-ray therapy is cursed with the same drawbacks of surgery. But it has one more: It actually increases the likelihood that cancer will develop in other parts of the body!

Excessive exposure to radioactivity is an effective way to induce cancer. This was first demonstrated by observing the increased cancer incidence among the survivors of Hiroshima, but it has been corroborated by many independent studies since then. For example, a recent headline in a national-circulation

1. Open letter to interested doctors, Nov., 1972; Griffin, *Private Papers*, *op. cit.*

newspaper tells us: FIND 'ALARMING' NUMBER OF CANCER CASES IN PEOPLE WHO HAD X-RAY THERAPY 20 YEARS AGO.¹

The *Textbook of Medical Surgical Nursing*, a standard reference for Registered Nurses, is most emphatic on this point. It says:

This is an area of public health concern because it may involve large numbers of people who may be exposed to low levels of radiation over a long period of time. The classic example is of the women employed in the early 1920's to paint watch and clock dials with luminizing (radium containing) paints. Years later, bone sarcomas resulted from the carcinogenic effect of the radium. Similarly, leukemia occurs more frequently in radiologists than other physicians. Another example is the Hiroshima survivors who have shown the effects of low levels of radiation....

Among the most serious of the late consequences of irradiation damage is the increased susceptibility to malignant metaplasia and the development of cancer at sites of earlier irradiation. Evidence cited in support of this relationship refers to the increased incidence of carcinoma of skin, bone, and lung after latent periods of 20 years and longer following irradiation of those sites. Further support has been adduced from the relatively high incidence of carcinoma of the thyroid 7 years and longer following low-dosage irradiation of the thymus in childhood, and from the increased incidence of leukemia following total body irradiation at any age.²

In 1971, a research team at the University of Buffalo, under the direction of Dr. Robert W. Gibson, reported that less than a dozen routine medical X-rays to the same part of the body increases the risk of leukemia in males by at least sixty percent.³ Other scientists have become increasingly concerned about the growing American infatuation with X-rays and have urged a stop to the madness, even calling for an end to the mobile chest X-ray units for the detection of TB.⁴ And these "routine" X-rays are harmlessly mild compared to the intense radiation beamed into the bodies of cancer patients today.

X-rays induce cancer because of at least two factors. First, they do physical damage to the body which triggers the production of trophoblast cells as part of the healing process. Second, they

1. *National Enquirer*, Oct. 7, 1973, p. 29.

2. Brunner, Emerson, Ferguson, and Doris Suddarth, *Textbook of Medical-Surgical Nursing*, (Philadelphia: J.B. Lippincott Co., 1970) 2nd Edition, p. 198.

3. "Too Many X-Rays Increase Risk of Leukemia, Study Indicates," *National Enquirer*, Dec. 5, 1971, p. 11.

4. "Top FDA Officials Warn: Chest X-Rays in Mobile Vans Are Dangerous and Must Be Stopped," *National Enquirer*, Sept. 10, 1972, p. 8.

weaken or destroy the production of white blood cells which, as we have seen, constitute the immunological defense mechanism, the body's front-line defense against cancer.

When it comes to statistics, there is little or no evidence that radiation actually improves the patient's chances for survival. The National Surgical Adjuvant Breast Project, previously mentioned in connection with surgery, also conducted studies on the effect of irradiation, and here is a summary of their findings:

... the use of post-operative irradiation has provided no discernible advantage to patients so treated in terms of increasing the proportion who were free of disease for as long as five years.¹

In August of 1998, *Science News* published a review of over 30 years of data and reported that radiation can actually *reduce* a patient's chances for survival:

Data from nine studies ... show that radiation treatments after surgery actually hurt the survival chances of many patients, particularly those whose cancer hadn't spread initially. The findings appear in the July 25 *Lancet*.... The survival rate 2 years after surgery was 48 percent for those getting radiation treatments and 55 percent for surgery-only patients.²

This is an embarrassing fact for radiologists to face, for it brings into question the justification for their existence in the medical fraternity. Consequently, one does not expect to hear these issues being discussed by radiologists or those whose livelihood depends on the construction, sale, use, or maintenance of the multi-million-dollar linear accelerators. It comes as a surprise, therefore, to hear these truths spoken frankly by three radiologists sharing the same platform at the same medical convention. They were William Powers, M.D., Director of the Division of Radiation Therapy at the Washington University School of Medicine, Phillip Rubin, M.D., Chief of the Division of Radiotherapy at the University of Rochester Medical School, and Vera Peters, M.D., of the Princess Margaret Hospital in Toronto, Canada. Dr. Powers stated:

Although preoperative and postoperative radiation therapy have been used extensively and for decades, it is still not possible to prove unequivocal clinical benefit from this combined treatment.... Even if the rate of cure does improve with a combination of radiation and therapy, it is necessary to establish the *cost* in

1. Fisher, B., et. al., "Postoperative Radiotherapy in the Treatment of Breast Cancer; Results of the NSAPP Clinical Trial," *Annals of Surgery*, 172, No. 4, Oct. 1970.

2. "Lung Cancer Radiation Questioned," *Science News*, August 1, 1998, p. 68.

increased morbidity which may occur in patients without favorable response to the additional therapy.¹

What Dr. Powers means when he says "increased morbidity" is that radiation makes people ill. In a study at Oxford University, it was found that many women who received radiation died of heart attacks because their hearts had been weakened by the treatment.² Radiation also weakens the immune system which can lead to death from secondary causes such as pneumonia. Many patients whose death certificates state heart failure or pulmonary pneumonia or respiratory failure really die from cancer—or, to be more exact—from their cancer *treatment*. Cancer statistics—based as they are on data from death certificates—conceal the truth about the failure of orthodox cancer therapy.

At the convention of radiologists previously mentioned, Dr. Phillip Rubin reviewed the cancer-survival statistics published in the *Journal of the American Medical Association*. Then he concluded:

The clinical evidence and statistical data in numerous reviews are cited to illustrate that no increase in survival has been achieved by the addition of irradiation.

To which Dr. Peters added:

In carcinoma of the breast, the mortality rate still parallels the incidence rate, thus proving that there has been no true improvement in the successful treatment of the disease over the past thirty years, even though there has been technical improvement in both surgery and radiotherapy during that time.

In spite of the almost universal experience of physicians to the contrary, the American Cancer Society still prattles to the public that *their* statistics show a higher recovery rate for treated patients as compared to untreated patients. After all, if this were not the case, why would anyone spend the money or accept the pain and disfigurement associated with these orthodox treatments? But how can they get away with such outright lies?

The answer is that they are not really lying—just bending the truth a little. In other words, they merely adjust the method of gathering and evaluating statistics so as to guarantee the desired results. In the words of Dr. Hardin Jones:

1. "Preoperative and Postoperative Radiation Therapy for Cancer," speech before the Sixth National Cancer Conference, sponsored by the Amer. Cancer Society and The National Cancer Institute, Denver, Colorado, Sept. 18-20, 1968.
 2. Breast Cancer Update/Q & A, by Ridgely Ochs, *Newsday*, December 19, 1995, p. B23.

Evaluation of the clinical response of cancer to treatment by surgery and radiation, separately or in combination, leads to the following findings:

The evidence for greater survival of treated groups in comparison with untreated is biased by the method of defining the groups. All reported studies pick up cases at the time of origin of the disease and follow them to death or end of the study interval. If persons in the untreated or control group die *at any time* in the study interval, they are reported as deaths in the control group. In the treated group, however, deaths which occur before completion of the treatment are rejected from the data, since these patients do not then meet the criteria established by definition of the term "treated." The longer it takes for completion of the treatment, as in multiple step therapy, for example, the worse the error....

With this effect stripped out, the common malignancies show a remarkably similar rate of demise, whether treated or untreated.¹

Such statistical error is significant, but it is doubtful if it could account for the American Cancer Society's favorite claim that "there are on record a million and a half people cured of cancer through the efforts of the medical profession and the American Cancer Society with the help of the FDA."²

The answer lies in the fact that there are some forms of cancer, such as skin cancer, that respond very well to treatment. Often they are arrested or disappear even without treatment. Seldom are they fatal. But they affect large numbers of people—enough to change the statistical tabulations *drastically*. In the beginning, skin cancers were not included in the national tabulations. Also, in those days, very few people sought medical treatment for their skin disorders, preferring to treat them with home remedies, many of which, incidentally seem to have worked just as well as some of the more scientifically acceptable techniques today.

At any rate, as doctors became more plentiful, as people became more affluent and able to seek out professional medical help, and as the old-time remedies increasingly fell into disrepute, the number of *reported* skin cancers gradually increased until it is now listed by the ACS as a "major site." So, all they had to do to produce most of those million-and-a-half "cures," was to change their statistics to include skin cancers—*presto-chango!*

1. Jones, "A Report on Cancer," *op. cit.*

2. Letter from Mrs. Glenn E. Baker, Executive Director, Southern District, ACS, addressed to Mr. T.G. Kent, reprinted in *Cancer News Journal*, Jan./Feb., 1972, p. 22.

As Dr. Hardin Jones revealed:

Beginning in 1940, through redefinition of terms, various questionable grades of malignancy were classed as cancer. After that date, the proportion of "cancer" cures having "normal" life expectancy increased rapidly, corresponding to the fraction of questionable diagnoses included.¹

The American Cancer Society claims that patients are now surviving longer, thanks to orthodox therapy. But people are *not* living longer after they *get* cancer; they are living longer after they are *diagnosed* with cancer. With modern diagnostic techniques, cancer can be detected at an earlier stage. The time between diagnosis and death *is* longer, but the length of life itself has not increased at all.² This is merely another statistical deception.

When X-ray therapy is used, the body's white blood cell count is reduced which leaves the patient susceptible to infections and other diseases as well. It is common for such patients to succumb to pneumonia, for instance, rather than cancer. And, as stated previously, that is what appears on the death certificate—as well as in the statistics. As Dr. Richardson has observed:

I have seen patients who have been paralyzed by cobalt spine radiation, and after vitamin treatment their HCG test is faintly positive. We got their cancer, but the radiogenic manipulation is such that they can't walk.... It's the cobalt that will kill, not the cancer.³

There is an old joke about the doctor who told the recent widow: "You will be happy to know we cured your husband's disease just before he died." The death of U.S. Senator Paul Tsongas in January of 1997 was proof that this is no joke. His obituary stated: "Hospitalized Jan. 3 with a liver problem because of cancer treatments, Tsongas was cancer-free at his death."

If the patient is strong enough to survive radiation, then he still faces a closed door. Once the cancer has metastasized to a second location, there is practically no chance that the patient will live. In addition to an almost zero survival value, radio therapy has the extra distinction of also spreading the very cancer it is supposed to combat.

1. Jones, "A Report on Cancer," *op.cit.*

2. Robert N. Proctor, *Cancer Wars: How Politics Shapes What We Know and Don't Know About Cancer* (New York: Basic Books, 1995), p. 4.

3. Letter from John Richardson, M.D., to G. Edward Griffin, dated Dec. 2, 1972; Griffin, *Private Papers*, *op. cit.*

One of the most publicized claims by The American Cancer Society is that early diagnosis and treatment increases the chance of survival. This is one of those slogans that drives millions of people into their doctors' offices for that mystical experience called the annual checkup. "A check and a checkup" may be an effective stimulus for revenue to the cancer industry but its medical value is not as proven as the hype would suggest. As Dr. Hardin Jones stated emphatically:

In the matter of duration of malignant tumors before treatment, no studies have established the much talked about relationship between early detection and favorable survival after treatment.... Serious attempts to relate prompt treatment with chance of cure have been unsuccessful. In some types of cancer, the opposite of the expected association of short duration of symptoms with a high chance of being "cured" has been observed. A long duration of symptoms before treatment in a few cancers of the breast and cervix is associated with longer than usual survival.... Neither the timing nor the extent of treatment of the true malignancies has appreciably altered the average course of the disease. The possibility exists that treatment makes the average situation worse.¹

In view of all this, it is exasperating to find spokesmen for orthodox medicine continually warning the public against using Laetrile on the grounds that it will prevent cancer patients from benefiting from "proven" cures. The pronouncement by Dr. Ralph Weilerstein of the California Department of Public Health cited at the opening of this chapter is typical. But Dr. Weilerstein is vulnerable on two points. First, it is very rare to find any patient seeking Laetrile therapy who hasn't already been subjected to the so-called "modern curative methods" of surgery and radiation. In fact, most of them have been pronounced hopeless after these methods have failed, and it is only then that these people turn to vitamin therapy as a last resort. So Dr. Weilerstein has set up a straw-man objection on that score. But, more important than that is the fact that the Weilersteinian treatments simply *do not work*.

Battling as a lone warrior within the enemy stronghold, Dr. Dean Burk of the National Cancer Institute repeatedly has laid it on the line. In a letter to his boss, Dr. Frank Rauscher, he said:

In spite of the foregoing evidence,... officials of the American Cancer Society and even of the National Cancer Institute, have continued to set forth to the public that about one in every four

1. Jones, "A Report on Cancer," *op. cit.*

cancer cases is now "cured" or "controlled," but seldom if ever backed up with the requisite statistical or epidemiological support for such a statement to be scientifically meaningful, however effective for fund gathering. Such a statement is highly misleading, since it hides the fact that, with systemic or metastatic cancers, the actual rate of control in terms of the conventional five-year survival is scarcely more than one in twenty....¹

One may well ask Dr. Weilerstein where are all the modern curative methods to which he, the California Cancer Advisory Council, and indeed so many administrators so glibly refer?... No, disseminated cancer, in its various forms and kinds remains, by and large, as "incurable" as at the time of the Kefauver Amendment ten years ago.²

The statistics of the ACS are fascinating. They constitute many pages of tables and charts showing cancer by location, sex, age, and geography. But when it comes to hard numbers about those "proven cures," there is nothing. There is only the unsupported statement: "One out of three patients is being saved today as against one out of five a generation ago." This may or may not be true, depending on one's definition of the word *saved*. But even if we do not challenge it, we must keep in mind that there also is a corresponding gain in the number of those who are *getting* cancer. Why is that? Here is the official explanation:

Major factors are the increasing age and size of the population. Science has conquered many diseases, and the average life span of Americans has been extended. Longer life brings man to the age in which cancer most often strikes—from the fifth decade on.

All of which sounds plausible—until one examines the facts:

First, the increasing size of the population has nothing to do with it. The statistics of "one out of three" and "one out of five" are *proportional* rather than *numerical*. They represent *ratios* that apply regardless of the population size.

Second, the average life expectancy of the population has been extended less than three years between 1980 to 1996. That could not possibly account for the drastic increase of the cancer death rate within that time.

And third, increasing age need not be a factor, anyway—as the cancer-free Hunzakuts and Abkhazians prove quite conclusively.

1. Letter from Dean Burk to Frank Rauscher; Griffin, *Private Papers*, op. cit., p. 3.

2. Letter from Dean Burk to Congressman Frey; Griffin, *Private Papers*, op. cit., p. 5.

In May of 1986, the clouds of propaganda parted and a sun-ray of truth broke through into the medical media. The *New England Journal of Medicine* published a report by John C. Bailar, III, and Elaine M. Smith. Dr. Bailar was with the Department of Biostatistics at Harvard School of Public Health; Dr. Smith was with the University of Iowa Medical Center. Their report was brutal in its honesty:

Some measures of efforts to control cancer appear to show substantial progress, some show substantial losses, and some show little change. By making deliberate choices among these measures, one can convey any impression from overwhelming success against cancer to disaster.

Our choice for the single best measure of progress against cancer is the mortality rate for all forms of cancer combined, age adjusted to the U.S. 1980 standard. This measure removes the effects of changes in the size and age composition of the population, prevents the selective reporting of data to support particular views, minimizes the effects of changes in diagnostic criteria related to recent advances in screening and detection, and directly measures the outcome of greatest concern—death....

Age-adjusted mortality rates have shown a slow and steady increase over several decades, and there is no evidence of a recent downward trend. In this clinical sense we are losing the war against cancer.... The main conclusion we draw is that some 35 years of intense effort focused on improving treatment must be judged a qualified failure.¹

In a follow-up report released eleven years later, Dr. Bailar revealed that the dismal picture had not improved. He said: "We have given it our best effort for decades: billions of dollars of support, the best scientific talent available. It hasn't paid off."²

It is clear that the American Cancer Society—or at least someone very high within it—is trying to give the American people a good old-fashioned snow job. The truth of the matter is—ACS statistics notwithstanding—orthodox medicine does *not* have "proven cancer cures," and what it *does* have is pitifully inadequate considering the prestige it enjoys, the money it collects, and the snobbish scorn it heaps upon those who do not wish to subscribe to its treatments.

1. "Progress Against Cancer?" *New England Journal of Medicine*, May 8, 1986, p. 1231.

2. "\$30 billion 'War on Cancer' a bust?" *USA Today*, May 29, 1997, p. 1.

Chapter Eleven

A NEW DIMENSION OF MURDER

Anti-cancer drugs shown to be ineffective and cancer-causing; FDA-approved experiments on humans resulting in death from drugs rather than from cancer.

The following article appeared in the *Los Angeles Times* on August 18, 1973, under the heading: CANCER "CURE" LAETRILE HIT:

Los Angeles (UPI)—The manufacturers and distributors of the drug Laetrile were called "purveyors of deceit and outright quackery" Wednesday by the president of the California division of the American Cancer Society.

Helene Brown ... said the FDA has tested Laetrile at regular intervals, obtained negative results, and prohibited its use as a cancer remedy.

Cancer quackery is "a new dimension of murder," according to Mrs. Brown who said ... there are now 10 kinds of cancer which can be cured or controlled by chemotherapy—the treatment of disease by drugs.

Less than a month later, while speaking at an ACS national conference on cancer nursing, Mrs. Brown said flatly: "Present medical knowledge makes it possible to cure seventy percent of all cancers, if they are detected early."¹

Spokesmen for the American Cancer Society never tire of perpetuating the myth of "proven cures." But they seldom look quite so foolish in the eyes of those who know anything about true survival statistics as they do when they speak of cures by *chemotherapy*.

We briefly have viewed the miserable results obtained by orthodox surgery and radiation. However, the record of so-called

1. "Cancer Quacks Deadly," (AP) *The Clarion Ledger*, (Miss.), Sept. 13, 1973.

anti-cancer *drugs* is even worse. The primary reason for this is that most of them currently in use are highly poisonous, not just to cancer but to the rest of the body as well. Generally they are *more* deadly to healthy tissue than they are to the malignant cell.

All substances can be toxic if taken in sufficient quantity. This is true of aspirin, sugar, Laetrile, or even water. But, unlike those, the anti-cancer drugs are poisonous, not as a result of an overdose or as a *side-effect*, but as a *primary* effect. In other words, their poisonous nature is not tolerated merely as a necessary price to pay in order to achieve some desired effect, *it is* the desired effect.

These chemicals are selected because they are capable of differentiating between types of cells and, consequently, of poisoning some types more than others. But don't jump to the conclusion that they differentiate between cancer and non-cancer cells, killing only the cancer cells, because they do not.

The cellular poisons used in orthodox cancer therapy today cannot distinguish between cancer and non-cancer cells. They act instead to differentiate between cells that are fast-growing and those that are slow-growing or not growing at all. Cells that are actively dividing are the targets. Consequently, they kill, not only the cancer cells that are dividing, but also a multitude of normal cells all over the body that also are caught in the act of dividing.

Theoretically, those cancers that are dividing more rapidly than normal cells will be killed before the patient is, but it is nip and tuck all the way. In the case of a cancer that is dividing at the same rate or even slower than normal cells, there isn't even a *theoretical* chance of success.

In either event, poisoning the system is the objective of these drugs, and the resulting pain and illness often is a torment worse than the disease itself. The toxins catch the blood cells in the act of dividing and cause blood poisoning. The gastrointestinal system is thrown into convulsion causing nausea, diarrhea, loss of appetite, cramps, and progressive weakness. Hair cells are fast-growing, so the hair falls out during treatment. Reproductive organs are affected causing sterility. The brain becomes fatigued. Eyesight and hearing are impaired. Every conceivable function is disrupted with such agony for the patient that many of them elect to die of the cancer rather than to continue treatment.

It is ironic that the personnel who administer these drugs to cancer patients take great precautions to be sure they themselves

are not exposed to them. The *Handbook of Cancer Chemotherapy*, a standard reference for medical personnel, offers this warning:

The potential risks involved in handling cytotoxic agents have become a concern for health care workers. The literature reports various symptoms such as eye, membrane, and skin irritation, as well as dizziness, nausea, and headache experienced by health care workers not using safe handling precautions. In addition, increased concerns regarding the mutagenesis and teratogenesis [deformed babies] continue to be investigated. *Many chemotherapy agents, the alkylating agents in particular, are known to be carcinogenic [cancer-causing] in therapeutic doses.* [Emphasis added.]¹

Because these drugs are so dangerous, the *Chemotherapy Handbook* lists sixteen OSHA safety procedures for medical personnel who work around them. They include wearing disposable masks and gowns, eye goggles, and *double* latex gloves. The procedure for disposing needles and other equipment used with these drugs is regulated by the Environmental Protection Agency under the category of "hazardous waste." Yet, these same substances are injected directly into the bloodstream of hapless cancer patients supposedly to *cure* their cancer!

Most of these drugs are described as *radiomimetic*, which means they mimic or produce the same effect as radiation. Consequently, they also suppress the immune system, and that is one of the reasons they help spread the cancer to other areas. But whereas X-rays usually are directed at only one or two locations, these chemicals do their deadly work on every cell in the body. As Dr. John Richardson has pointed out:

Both radiation therapy and attempts to "poison out" result in a profound hostal immunosuppression that greatly increases the susceptibility to metastasis. How irrational it would be to attempt to treat cancer immunologically and/or physiologically, and at the same time administer immunosuppressants in the form of radiation of any kind, methotrexate, 5-FU, Cytosin, or similarly useless and dangerous *general* cellular poisons. All of these modalities, as we know, have been used to depress the rejection phenomena associated with organ transplantation. The entire physiological objective in rational cancer therapy is to *increase* the rejection phenomena.²

1. Roland T. Skeel, M.D., and Neil A. Lachant, M.D., *Handbook of Cancer Chemotherapy; Fourth Edition* (New York: Little, Brown and Company, 1995), p. 677.

2. Open letter to interested doctors, Nov., 1972; Griffin, *Private Papers*, *op. cit.*

The view that toxic "anti-cancer" drugs usually accomplish just the opposite of their intent is not restricted to the advocates of Laetrile. It is a fact of life (or shall we say death?) that has become widely acknowledged even by those who use these drugs. Dr. John Trelford, for instance, of the Department of Obstetrics and Gynecology at Ohio State University Hospital has said:

At the present time, chemotherapy of gynecological tumors does not appear to have increased life expectancy except in sporadic cases.... The problem of blind chemotherapy means not only a loss of the effect of the drugs, but *also a lowering of the patient's resistance to the cancer cells* owing to the toxicity of these agents [Emphasis added.]¹

Dr. Trelford is not alone in his observation. A report from the Southern Research Institute, dated April 13, 1972, based upon research conducted for the National Cancer Institute, indicated that most of the accepted drugs in the American Cancer Society's "proven cure" category produced cancer in laboratory animals that previously had been healthy!²

In a courageous letter to Dr. Frank Rauscher, his boss at the National Cancer Institute, Dr. Dean Burk condemned the Institute's policy of continuing to endorse these drugs when everyone *knew* that they caused cancer. He argued:

Ironically, virtually all of the chemotherapeutic anti-cancer agents now approved by the Food and Drug Administration for use or testing in human cancer patients are (1) highly or variously *toxic* at applied dosages; (2) markedly *immunosuppressive*, that is, destructive of the patient's native resistance to a variety of diseases, including cancer; and (3) usually highly *carcinogenic* [cancer-causing].... These now well established facts have been reported in numerous publications from the National Cancer Institute itself, as well as from throughout the United States and, indeed, the world. Furthermore, what has just been said of the FDA-approved anti-cancer chemotherapeutic drugs is true, though perhaps less conspicuously, of radiological and surgical treatments of human cancer....

In your answer to my discussion on March 19, you readily acknowledged that the FDA-approved anti-cancer drugs were indeed toxic, immunosuppressive, and carcinogenic, as indicated.

1. "A Discussion of the Results of Chemotherapy of Cancer and the Host's Immune Response," Sixth National Cancer Conference proceedings, *op. cit.*

2. NCI research contract PH-43-68-998. Information contained in letter from Dean Burk to Congressman Lou Frey, Jr., May 30, 1972; Griffin, *Private Papers*, *op. cit.*, p. 5.

But then, even in the face of the evidence, including your own White House statement of May 5, 1972, all pointing to the pitifully small effectiveness of such drugs, you went on to say quite paradoxically it seems to me, "I think the Cancer Chemotherapy program is one of the best program components that the NCI has ever had."... One may ask, parenthetically, surely this does not speak well of the "other program areas?"...

Frankly, I fail to follow you here. I submit that a program and series of the FDA-approved compounds that yield only 5-10% "effectiveness" can scarcely be described as "excellent," the more so since it represents the total production of a thirty-year effort on the part of all of us in the cancer therapy field.¹

There is little evidence for long-term survival with chemotherapy. Here is just a sampling of the negative verdict handed down by physicians, many of whom *still continue to prescribe it*:

Dr. B. Fisher, writing in the September 1968 issue of *Annals of Surgery*, stated:

As a result of its severe toxicity and its lack of therapeutic effect, further use of 5-FU as an adjuvant to breast surgery in the regimen employed is unwarranted.²

Dr. Saul A. Rosenberg, Associate Professor of Medicine and Radiology at Stanford University School of Medicine:

Worthwhile palliation is achieved in many patients. However, there will be the inevitable relapse of the malignant lymphoma, and, either because of drug resistance or drug intolerance, the disease will recur, requiring modifications of the chemotherapy program and eventually failure to control the disease process.³

Dr. Charles Moertal of the Mayo Clinic:

Our most effective regimens are fraught with risks and side-effects and practical problems; and after this price is paid by all the patients we have treated, only a small fraction are rewarded with a transient period of usually incomplete tumor regressions....

Our accepted and traditional curative efforts, therefore, yield a failure rate of 85%.... Some patients with gastrointestinal cancer can have very long survival *with no treatment whatsoever*. [Emphasis added.]⁴

1. Letter to Frank Rauscher, dated April 20, 1973; Griffin, *Private Papers*, *op. cit.*

2. "Surgical Adjuvant Chemotherapy in Cancer of the Breast: Results of A Decade of Cooperative Investigation," *Annals of Surgery*, 168, No. 3, Sept., 1968.

3. "The Indications for Chemotherapy in the Lymphomas," Sixth National Cancer Conference proceedings, *op. cit.*

4. Speech made at the National Cancer Institute Clinical Center Auditorium, May 18, 1972.

Dr. Robert D. Sullivan, Department of Cancer Research at the Lahey Clinic Foundation:

There has been an enormous undertaking of cancer research to develop anti-cancer drugs for use in the management of neoplastic diseases in man. However, progress has been slow, and no chemical agents capable of inducing a general curative effect on disseminated forms of cancer have yet been developed.¹

If it is true that Orthodox chemotherapy is (1) toxic, (2) immunosuppressant, (3) carcinogenic, and (4) futile, then why would doctors continue to use it? The answer is that they don't know what else to do. Patients usually are not scheduled into chemotherapy unless their condition seems so hopeless that the loss of life appears to be inevitable anyway. Some doctors refer to this stage, not as *therapy*, but *experimentation*, which, frankly, is a more honest description.

Another reason for using drugs in the treatment of cancer is that the doctor does not like to tell the patient there is no hope. In his own mind he knows there is none, but he also knows that the patient does not want to hear that and will seek another physician who will continue some kind of treatment, no matter how useless. So he solves the problem by continuing the treatment himself.

In his book *The Wayward Cell, Cancer*, Dr. Victor Richards made it clear that chemotherapy is used primarily just to keep the patient returning for treatment and to build his morale while he dies. But there is more! He said:

Nevertheless, chemotherapy serves an extremely valuable role in keeping patients oriented toward proper medical therapy, and prevents the feeling of being abandoned by the physician in patients with late and hopeless cancers. *Judicious employment and screening of potentially useful drugs may also prevent the spread of cancer quackery.*²
[Emphasis added.]

Heaven forbid that anyone should forsake the nauseating, pain-racking, cancer-spreading, admittedly ineffective "proven cures" for such "quackery" as Laetrile!

Here, at last, is revealed the true goal of much of the so-called "educational" programs of orthodox medicine—psychologically

1. "Ambulatory Arterial Infusion in the Treatment of Primary and Secondary Skin Cancer," Sixth National Cancer Conference proceedings, *op. cit.*

2. Victor Richards, *The Wayward Cell, Cancer; Its Origins, Nature, and Treatment*, (Berkeley: The University of California Press, 1972), pp. 215-16.

to condition people not to try any other forms of therapy. That is why they perpetuate the myth of "proven cures."

The American Cancer Society, in its *Unproven Methods of Cancer Management*, stated:

When one realizes that 1,500,000 Americans are alive today because they went to their doctors in time, and that the proven treatments of radiation and surgery are responsible for these cures, he is less likely to take a chance with a questionable practitioner or an unproven treatment.¹

Before leaving the subject of cancer therapy and moving on to the field of cancer *research*, let us clarify and summarize our findings so far. Here is a brief outline of the four optional modes of cancer therapy:

SURGERY: Least harmful. Sometimes a life-saving, stop-gap measure. No evidence that patients who receive radical or extensive surgical options live any longer than those who receive the most conservative options, or, for that matter, those who receive none at all. Believed to increase the likelihood of disseminating cancer to other locations.

When dealing with internal tumors affecting reproductive or vital organs, the statistical rate of long-term survival is, on the average, 10–15%. After metastasis, the statistical chances for long-term survival are close to zero.

RADIOLOGY: Very harmful in many ways. Spreads the cancer and weakens the patient's resistance to other diseases. Serious and painful side-effects, including heart failure. No evidence that treated patients live any longer, on the average, than those not treated. Statistical rate of long-term survival after metastasis is close to zero.

CHEMOTHERAPY: Also spreads the cancer through weakening of immunological defense mechanism plus general toxicity. Leaves patient susceptible to other diseases and infections, often leading to death from these causes. Extremely serious side-effects. No evidence that treated patients live any longer, on the average, than untreated patients. Statistical rate of long-term survival after metastasis is close to zero.

VITAMIN THERAPY: Non-toxic. Side effects include increased appetite, weight gain, lowered blood pressure, increased hemoglobin and red-blood cell count. Eliminates or sharply reduces pain without narcotics. Builds up body's resistance to other diseases. Is a natural substance found in foods and is compatible with human biological experience. Destroys cancer cells while nourishing non-cancer cells.

1. *Unproven Methods of Cancer Management*, op. cit., pp. 17, 18.

Considering that most patients begin vitamin therapy only after they have been cut, burned, or poisoned by orthodox treatments and have been told that there no longer is any hope, the number of patients who have been brought back to normal health on a long-term survival basis (15%) is most encouraging. For those who turn to vitamin therapy *first*, the long-term survival rate is greater than 80%! (See next chapter for statistical breakdown.)

Turning, at last, to the question of cancer *research*, we find that it is plagued with the same frustrations and self-induced failures as cancer *therapy*. Almost all current research projects are preoccupied with the question of how to *cure* cancer rather than what *is* cancer. Consequently, the basic problem of cancer research today remains one of *fundamental* rather than *applied* science.

The 1926, Thirteenth Edition of the *Encyclopedia Britannica* says this of cancer theories:

The very number and variety of hypotheses show that none are established. Most of them attempt to explain the growth but not the origin of the disease.

When applied to orthodox medicine, that statement is just as true today as it was in 1926. As a result, researchers have come up with an ever-lengthening list of things that supposedly "cause" cancer—everything from smog in the air to insecticides on our raw fruits and vegetables, to a multitude of obscure viruses. Not recognizing that all of these merely act as trigger mechanisms for the *real* cause—an enzyme and vitamin deficiency—they then run off in all directions at once trying to find a thousand separate "cures," each designed specifically to filter out the smog, to eliminate the insecticide, to destroy the virus, and so on. The more they research, the more "causes" they discover, and the more hopeless becomes their task.

In spite of this continuum of failure, almost daily we can read in our press encouraging stories about how we are on the very brink of a cancer breakthrough. On September 23, 1972, the *Los Angeles Herald-Examiner* even announced to the world in bold front-page headlines: CANCER CURE FOUND! And respected researchers from the nation's most prestigious medical institutions parade routinely before television cameras telling us how their latest findings have, at last, brought the solution to the cancer puzzle within their grasp. We have been "on the verge of a great breakthrough" for decades!

The reason for this is simple. These men are the beneficiaries of research grants from the federal government, tax-exempt foundations, and the American Cancer Society. They *must* claim to be making encouraging progress or their funding will disappear. If they reported honestly that they have worked for over four decades, employed thousands of researchers, consumed millions of man-hours, and spent billions of dollars to produce nothing of consequence—well, one can imagine what would happen to the future funding of their research projects. The cancer-research pie now is reaching out to the multi-billion-dollar mark annually. The ones who get the biggest slice of that pie are the ones who claim to be “on the verge of a great breakthrough,” for who would want to be responsible for cutting funds just when the cure was so close?

In the meantime, researchers are busying themselves, not in trying to understand what cancer is, but in finding a substance or a treatment to get rid of it. And it seems that, the more wild the theory, the better chance it has of getting federal money.

When research grants are reported in the press, they often carry headlines that tell the whole story: SEA SQUIRTS HELP SUPPRESS MICE CANCER, (*L.A. Times*); EXPERTS HUNT MYSTERIOUS CANCER AGENT, (*L.A. Times*); RAT POISON HELPS TERMINAL CANCER PATIENTS LIVE LONGER, CLAIMS TEAM OF DOCTORS, (*National Enquirer*); WAITING IN THE WINGS? (*Medical World News*).

This last headline perhaps needs expansion. The article began:

On an educated hunch that insects synthesize compounds that can inhibit cell growth, chemist George R. Pettit of the University of Arizona in Tempe has spent six years and some \$100,000 extracting chemicals from a quarter of a million butterflies ... part of a National Cancer Institute program. To get his ... butterflies, Dr. Pettit enlisted the help of 500 collectors in Taiwan.

And so the search goes on—rat poison, jet fuel, butterfly wings, sea squirts—everything except the natural foods of man.

It is significant that the only time orthodox research produces useful information is when it is in conformity with the trophoblast thesis of cancer. Or, stated another way, there is nothing in the realm of solid scientific knowledge gained through recent research that does not conform to the trophoblast thesis of cancer. This is true of a wide range of research projects.

For example, the excitement over the possibility of BCG acting as an anti-cancer agent is in conformity with the fact that

the white blood cells are a front-line defense mechanism against cancer, as theorized by Dr. John Beard almost a century ago.

Dr. Robert Good, former president of the Sloan-Kettering Institute, while previously serving as chairman of the Pathology Department of the University of Minnesota, discovered that altering the protein content of the diet in mice appears to have an effect on increasing their resistance to cancer. He said: "The work raises questions about the role of diet in human cancer."¹

His studies were sparked after observing that the aborigines of Australia consumed a low protein diet and showed an excellent immunity to cancer. The good Doctor Good was on the right track, but it was a track he never followed. A low-protein diet cannot be patented.

Dr. J.N. Davis, Professor of Pathology at Albany Medical College, also stumbled across a part of the solution when he noticed that there was a staggering increase in cancer of the esophagus in Kenya, Africa, in recent years, while there was practically none in neighboring Uganda. He noticed, also, that there appears to be some kind of relationship between cancer of the colon and diet. He asked, "Why should there be a low incidence of colon cancer in poor countries where food is scanty?"

For those familiar with the traditionally high nitriloside content of unrefined foods in poor countries, the answer is obvious. If Dr. Davis keeps asking the right questions, sooner or later he is bound to find the right answers. And then he will have the whole medical establishment to fight. In the meantime, he has come to the conclusion that the reason for the difference may be found in the types of beer drunk in these two countries—which may not be too far off, for the different beers are made out of different grains such as maize, sorghum, and millet, all of which have varying concentrations of vitamin B₁₇.² But as long as Dr. Davis theorizes only about the beer and not the vitamin, he will retain the respect of his colleagues and probably will continue to receive funding for his research program.

And so it goes. Over and over again, the trophoblast thesis (fact) of cancer is confirmed by independent researchers who,

1. "Protein Study—Diet Linked to Cancer Control," *San Francisco Chronicle*, October 21, 1971. Also, "American College of Surgeons, A New Cancer Link; Gene-Pool Pollution," *Modern Medicine*, Nov. 29, 1971, p. 13.

2. See "Seek Clues to Dramatic Rise of Throat Cancer in Kenya," *Infectious Diseases*, July 2, 1972.

unfortunately, have no inkling of the significance of their discoveries. Some of them, however, eventually do begin to grasp the picture. Dr. Bruce Halstead, for instance, Director and founder of the World Life Research Institute of Colton, California, travelled to the Soviet Union and discovered that scientists there were studying natural non-toxic compounds as early as the 1960s and appeared to be way ahead of the United States in this field. He spoke glowingly of one such compound called Eleuterococcus which, from his description, sounds suspiciously like pangamic acid or vitamin B₁₅ discovered by Dr. Krebs.

At any rate, Dr. Halstead was unsuccessful in getting the FDA to approve experimentation with this compound. He complained:

I've tried everywhere. I can't get any pharmaceutical company to support it because of the FDA's regulations which are for specifics. This is where the whole field of medicine is in conflict.

Dr. Halstead also was on the right track, which undoubtedly is why he ran up against a stone wall of resistance from the Medical and Political Establishment. After noting that Congress had just authorized 1.6 billion dollars for cancer research, he said that, in his opinion, it would not produce results because it all would be spent for research into exotic and toxic artificial drugs rather than in the investigation of natural non-toxic compounds. Then he added:

I predict that cures for cancer can be expected out of the natural products field. Someday we'll discover that some native population had the cancer cure product and was using it. They may not have been using it intentionally for this reason, but we'll find out that they were using it, and the results were bona fide.

I believe that if we could really do a thorough study of all the natural occurring materials used by primitive tribes on a world scale, we (the U.S.) could become a highly-productive area of cancer research.¹

But this is not the approach of the cancer industry. Instead, infatuated with their newly acquired skills in creating artificial compounds, they scorn nature and plunge billions of tax dollars into their poisonous concoctions. And, as scores of these drugs are developed each year, cancer patients become the human guinea pigs upon which they are tested.

1. "Russia, U.S. Join Ranks in Cancer Battle Project," *L.A. Herald Examiner*, Feb. 20, 1972, p. A-18.

Not all testing is in an attempt to cure cancer. Much of it is done just because the researchers have at their disposal large numbers of patients who, as they reason, are going to die anyway, so why not use their bodies while they still have some life. If that sounds like too harsh a judgment, then consider the research project funded by the federal government at the Maryland Psychiatric Research Center in Cantonville. The project was headed by Dr. Stanislav Grof, a Czechoslovakian-born psychiatrist who specializes in the use of psychedelic drugs, particularly LSD.

The story here is so bizarre that many persons will find it hard to believe. So let us examine the eye-witness account of a special reporter to the *Washington Post* who visited the research center and observed video-tapes of some of the experiments. The reporter, by the way, was extremely sympathetic to the entire experimental program and presented it in the most favorable light possible. But even in spite of this bias, the report is a shocking exposé of the total disregard that these men have for the human "specimens" given to them for experimentation:

On the morning of his session, the patient is given a single red rose in a vase. The center's music therapist has selected a program intended to heighten the experience—Vivaldi, Beethoven, Bach, Wagner, Simon and Garfunkel, the Balinese Rarnazana Monkey Chant, and others....

Here is an example of one session preserved on video-tape: The cancer patient, a laborer in his late forties who was depressed and afraid of his imminent death, was apprehensive as he sat on the couch talking with Grof and the nurse.

"It hurts so bad," he said in a choked voice. "I never cry, I mean I can't help it, but I've got to let it come out sooner or later." He sobbed, and Grof comforted him.

The nurse injected him intravenously with a single high dose of LSD, and he waited the ten to thirty minutes for it to start to take effect. When it did, he reacted with fear. "I don't know what to do," he cried, and he moaned and eventually vomited into a pan.... Grof soothed him with a few words then slipped a stereophonic headset over his ears. The patient was overcome with the mighty sound of the Mormon Tabernacle Choir singing "The Lord's Prayer."

He lay motionless.... After a long while the patient started uttering words:

"Like a ball of fire. Everything was dumped into this that I can remember. Everything was destroyed in a final way. It had all disappeared. I don't remember, but whoever it was said they was set

free. Somebody was free. I don't know who it was. I don't know who it was, but he was free.

Grof asked the patient if it was he who was set free, and the man replied, "Yes, yes."¹

The next day, the patient was convinced he had had a religious experience. The staff was pleased because, as they explained it, they had helped the patient find "meaning in his life and to enjoy his last months more fully."

Four days later, the man died from cancer.

It is shocking to learn that, under the code of ethics followed by the FDA and the medical profession it now controls, it is not necessary to advise a patient that he or she is being experimented upon. This is an ominous fact, not only in regard to the patient who is receiving the experimental drug, but also to the patient who expects medical help but instead is placed into the control group and, thus, receives placebos—no help at all. Robert N. Veatch, a specialist in medical ethics, told a Senate Health Subcommittee in 1973 that, in just one typical research project, ninety-one children acting as controls in a study of treatment for asthma "received ineffective treatment for periods lasting up to fourteen years." He confirmed also that "no mother or child in the study knew any sort of study was underway."²

As of 1970, there were over 100,000 cancer patients who had been used in experiments without either their knowledge or consent.³

In a report prepared for the Chairman of a Senate Subcommittee, and published in the Congressional Record of October 5, 1966, Dr. Miles H. Robinson revealed:

An undetermined number of cancer patients with an otherwise substantial expectation of life have died in these tests, according to reports in NCI's *Cancer Chemotherapy Reports*. The full extent of mortality and morbidity is difficult to estimate, since the journal's editor told me only the "best" investigations are published.⁴

The following statements are taken from just a few of these "best" official *Chemotherapy Reports*:

1. "LSD Therapy: Quiet Revolution in Medicine," *L.A. Times*, Dec. 15, 1972, Part VII, pp. 10, 11.

2. "Unethical Experiments Hit," *Prevention*, July, 1973, p. 97.

3. Omar Garrison, *The Dictocrats*, (Chicago, London, Melbourne: Books for Today, Ltd., 1970), p. 271.

4. *Ibid.*, p. 273.

An effort was made to choose patients who were well enough to withstand the anticipated toxicity.... Unexpectedly, early death of two of the first five patients treated caused a reduction to 8.0 mg/kg/day. No significant anti-tumor benefit of any duration was observed....

In this study, six of the eight patients [children] died.... No therapeutic effect was observed. Toxic clinical manifestations consisted of vomiting, hypotension, changes in oral mucus membranes, and diarrhea, in that order of frequency. Renal damage and cerebral edema were observed at postmortem examination in each of the six patients who died while receiving this drug....

The death of two patients was unequivocally caused by drug toxicity.... Eight of the fourteen patients who survived their initial courses of therapy showed rapid general deterioration and died within ten weeks after therapy began. It was our opinion that drug toxicity contributed to the rapid demise of these patients....

Because of severe toxicity, which led to the death of a number of the forty patients initially treated with the full five-day "priming doses" used by the Wisconsin workers, investigators in the Eastern group voted to omit the fifth "priming" doses of each course.¹

It is a fact that many of these experiments are carried out, *not* to see if the drug is effective against cancer, but only to determine how much of it can be administered before the patient becomes ill from its toxic effect.

It is difficult for the average person to fathom the depth of these legalized tortures and murders committed on unsuspecting victims in the name of science. And it is a sad commentary that so many people in and near the medical profession accept them without protest. It is insult added to injury when the FDA finances and encourages the wider use of these killer-drugs while at the same time forbidding doctors to experiment with Laetrile—which is known to be at least a thousand times less toxic—on the absurd contention that it has not yet been proven to be *safe*! None of the FDA-approved cancer drugs has been proven to be safe, and most of them, quite to the contrary, have been proven to be extremely *unsafe*. And the American Cancer Society has the gall to label the use of Laetrile as "a new dimension of murder," when, in reality, it is they and their worthless, unproven nostrums that truly have earned that epithet.

1. *Ibid.*, pp. 273, 274.

Chapter Twelve

A STATISTICAL COMPARISON

The inherent weaknesses of all cancer statistics; the need for statistical comparisons in spite of those weaknesses; a comparison of the results obtained by orthodox and Laetrile physicians; and the consequences of consensus medicine.

A substantial part of the resources of the American Cancer Society and the National Cancer Institute is spent on gathering statistics. Each year the records of thousands of physicians and hospitals are combed through to produce cancer statistics by geography, age, sex, site, extent, type of treatment, and length of survival. It is a mammoth task consuming hundreds of thousands of man-hours and millions of dollars. This activity is about as important to victory over cancer as is a body count in time of war. The experts know all about who *has* cancer but nothing about how to cure it.

Unlike the proponents of orthodox medicine who publish reams of statistics on just about everything, the proponents of vitamin therapy are extremely reluctant to speak in these terms. At first this may appear as a lack of confidence on their part or, even worse, as an indication that they really don't have any solid evidence to back up their claims. Their reluctance, however, is well-founded.

The first reason is that, in order to have statistics from which meaningful comparisons can be made, there has to be a control group. In other words, it would be necessary for those who believe in vitamin therapy to accept cancer patients but then not to treat some of them or to treat them with orthodox therapies. This, of course, to the physicians involved would be tantamount to murder, and they could not participate in it. These men have already witnessed the tragic results of orthodox therapies on

patients who come to them as a last resort. To ask these physicians to assign some of their patients to a continuation of those treatments would be like asking them to place a hot poker on human flesh to see if it would cause burns and pain. And yet, not to set up such control groups would leave an opening for the claim that, if the patient recovers, it could be due to other causes such as "spontaneous regression" or "delayed response of the orthodox treatments."

Another fact is that, even if control groups were to be set up, it would be impossible to make sure that they were meaningful. There are so many variables in such factors as location of cancer, degree of metastasis, dietary background, hereditary characteristics, emotional state, age, sex, general health, medical history, environment, and so on. Almost any of these variables could be claimed as reasons for invalidating the statistics.

Whenever the proponents of vitamin therapy have attempted to offer surveys of their clinical results, the proponents of orthodox medicine have condemned them because their studies did not have adequate control groups, or that their results could be explained by some other factors, or that their follow-up records were inadequate. In most cases, these have been legitimate objections. But exactly these same weaknesses are present in most of the statistical studies of orthodox medicine as well. The primary difference is that orthodox studies are *presumed* to be accurate and, therefore, seldom challenged.

The truth of the matter is that, because of the many variables previously mentioned, there is no field of medicine in which statistics are more confusing and meaningless than in the field of cancer. In fact, there are many times when pathologists will disagree among themselves as to whether or not a particular tissue even *is* cancer.

So it is not just the nutritional therapist whose statistics are open to challenge. But it is only the nutritional therapist who, generally speaking, honestly recognizes these problems and, consequently, is reluctant to speak in terms of hard numbers or ratios. Dr. Krebs, for example, repeatedly has refused to quote statistics because he thinks they are meaningless from a scientific point of view and cannot prove the reality of his theory. Anyone who insists on numbers, he says, reveals his lack of understanding of the scientific concept involved. It would be like trying to prove the value of oxygen by collecting case histories of people

who claim that breathing saved their lives. Of *course*, it saved their lives. But anyone who didn't believe it could find a hundred plausible explanations as to why something *other* than oxygen was responsible for their being alive.

Dr. Richardson also advised strongly against using statistics, and then added:

But this is a vitamin and enzyme deficiency disease. We dare not talk about five-year survivals when we are really talking about 100% survival with prophylaxis [prevention]. When you start killing people with radiomimetic insults to their bodies—you're talking about radiation deaths, not deaths from cancer.

There are several other reasons for not using their false and misleading yardstick. One is that this yardstick is not applied to vitamin deficiency diseases. Later on when B17 is accepted ... we may appear the fool by having cheapened our presentation by acquiescing in the use of the yardstick. Anyone who begins to see the vitamin aspect soon realizes that it is like measuring water and steel with the same clumsy apparatus.¹

The reluctance to deal in statistics on the part of proponents of vitamin therapy is based upon a respect for scientific truth. In spite of this, the public clamors for a statistical comparison, and few people will take the trouble to study the problems deeply enough to understand why such comparisons are not to be trusted. The result is that orthodox medicine, with its mountains of statistical charts and tables, easily wins the race for public opinion, while the nutrition oriented doctors are condemned as quacks, charlatans, and murderers.

Let us make it an honest race. Without defending the value of such statistics, let us at least see what they tell us, such as they are. Let us acknowledge that one should view all cancer statistics with reservation, but let us give the nutritional therapists the same right to use them that their critics have enjoyed.

The statistics of the American Cancer Society indicate that, at present rates, cancer will strike two out of every three families. Of every five deaths from all causes, one is from cancer. Of every five persons who get cancer, two will be saved and three will die.² Two out of five, therefore, represents an ACS "cure rate" of approximately forty percent.

1. Letter from John Richardson, M.D., to G. Edward Griffin, December 2, 1972; Griffin, *Private Papers*, *op. cit.*

2. All data taken from *Cancer Facts and Figures—1996*, ACS, p. 1. Also *California Cancer Facts & Figures—1997*, ACS, p. 3.

These figures are heavily weighted to present the most favorable picture possible. As mentioned previously, they include the relatively non-fatal cancers such as skin cancer, and they do not include those patients who die from cancer before they have completed their prescribed course of treatment—which is a *substantial* number—and they do not include the multitude of deaths from the complications of cancer *treatment*, such as heart failure and pneumonia.

Now let us attempt to break this down into three categories:

METASTATIC OR "TERMINAL"—Those whose cancer has spread to two or more distant locations, who have not responded to surgery, radiation, or drugs, and who have been told by their doctor that there no longer is any hope.

PRIMARY—Those whose cancer is confined to a single area with perhaps a few adjacent lymph nodes involved. It has been detected before metastasis to a distant location and appears sufficiently limited or slow-growing to offer some hope of successful control by orthodox treatments. Skin cancer is not included in this category.

PRESENTLY HEALTHY—Those who are in reasonably good health and who have no clinical cancer or symptoms.

Admittedly, these categories are not absolute. They are rightly subject to all the criticisms of any such statistical categorization. The first two are especially dependent upon the subjective evaluation of the physician, since no one can point out a clear dividing line between them. But, whatever errors might be generated by these problems will work randomly and equally on behalf of both orthodox and nutritional therapies. Neither group will have an advantage.

The chances of a metastatic (terminal) cancer patient surviving five years after the point at which he has been classified as such are so small as to defy statistical statement. Most physicians will say that there isn't one chance out of ten-thousand. Some will say one out of a thousand. Let's not quibble. We shall use the more favorable figure which is one-tenth of one percent.

When it comes to "primary" cancers, it is difficult to know what figures to use. An unofficial poll conducted by the author and directed to a random group of Southern California doctors, produced an "opinion" of approximately fifteen percent long-term survival in this category. The American Cancer Society was unable to produce either statistics or opinion. But a letter was received from the National Cancer Institute which claims that

"regional spread" (the same category as "primary") cancer patients can anticipate a five-year survival of a whopping twenty-eight percent!¹ Frankly, that is difficult to believe, even allowing for all the built-in enhancement factors. But, following our practice of taking these statistics as we find them, let us accept this one also, even if it is with a very large grain of salt.

For those who are presently healthy with no cancer at all, we return to the American Cancer Society's statement that one out of three (33%) Americans will get cancer and that, of those, 40% will survive five years. That means that 60% will die. Out of 100 people who are "presently healthy," 33 will develop cancer and 13 of those will survive 5 years or longer. Add those 13 to the 67 who will not develop cancer in the first place, and we see that 80 of the original 100 will survive under orthodox therapy. That's an average survival rate of 80%.

Now let's turn to the record of Laetrile therapy. Almost all of the patients who seek Laetrile do so only after they have moved into the metastasized or "terminal" category. The fact that most of them do not survive five years after beginning vitamin and enzyme therapy is not surprising. What is surprising is that *any* of them should be saved at that stage. Yet, Doctors Contreras, Richardson, and Binzel have all reported that approximately 15% of their patients have survived five years or longer. Fifteen percent, of course, is not good. But, considering that less than one-tenth of one percent survive under orthodox therapy, that record is truly amazing.


Those whose cancer has not yet metastasized to secondary locations and who, therefore, fall into the localized or "primary" category can look forward to approximately an 80% long-term survival in response to Laetrile therapy. Doctors Richardson and Binzel have found the response to be as high as eighty-five percent, providing the vital organs have not been too badly damaged by surgical, X-ray, or chemical intervention during prior treatment.²

1. Letter from Marvin A. Schneiderman, Ph.D., Associate Scientific Director for Demography, NCI, to G. Edward Griffin, dated March 21, 1973. See Griffin, *Private Papers*, *op. cit.*

2. 80% survival was reported by the McNaughton Foundation in its IND-6734 application for Phase-One testing of Laetrile. See *Cancer News Journal*, Jan./Apr., 1971, p. 12. Dr. Richardson's data are contained in his letter to the author, Dec. 2, 1972; Griffin, *Private Papers*, *op. cit.* Dr. Binzel's record was published in his book *Alive and Well*, *op. cit.*

Of those who presently are healthy with no clinical cancer at all, close to one-hundred percent can expect to be free from cancer as long as they routinely obtain adequate amounts of vitamin B₁₇, and presuming they are not subject to some rare pancreas malfunction or subjected to an unnatural exposure to carcinogenic agents such as massive radiation. Fortunately, the "control group" for this category already has been provided through the existence of the Hunzakuts, the Abkhazians, the Eskimos, the Hopi and Navajo Indians, and other similar populations around the world.

Putting the two groups of statistics together, here is the story they tell:



It bears repeating that *all* cancer statistics are subject to a host of unseen and undefined premises and are useful only for the most general reference purpose. These, in particular, because they attempt to present a *composite* picture, can be misleading when it comes to applying them to any *particular* person with a *particular* condition. The data that go into these figures vary with age, sex, cancer location, and degree of malignancy. Also, the categories are somewhat arbitrary when it comes to separating moderately spread cancers from those that are far advanced, for often there is a gray area between the two. Nevertheless, for those who simply must have statistics, these are as accurate as any such tabulation

can be and, especially considering that they have given the proponents of orthodox treatments every conceivable advantage, they tell an impressive story that cannot be brushed aside.

As physicians become aware of these facts and begin to experiment with the nutritional approach to cancer therapy, they soon find themselves the victims of something called *consensus medicine*. Consensus medicine is the tangible result of the belief that doctors need to be policed in order to prevent them from injuring or cheating their patients, and that the best people to police doctors are other doctors acting through professional organizations, hospital staffs, and government agencies. The result of this seemingly proper arrangement is that, no matter how useless or even harmful current practices may be, consensus medicine demands that they be used by every physician. Regardless of how many patients are lost, the doctor's professional standing is upheld, because those who pass judgment through "peer review" are using the same treatments and getting the same tragic results. On the other hand, if a doctor deviates from this pattern and dares to apply nutrition as the basis of his treatment, even if he attains a high degree of success, he is condemned as a quack. He loses his hospital privileges, is denied malpractice insurance, and even becomes subject to arrest.

The result of this is that many physicians are just as afraid of cancer as their patients—afraid that they may miss a diagnosis or cause a month delay before surgery. They may know in their own mind that the extra month really makes little difference in the survival of the patient, but they know it will make a great difference in their reputations. It requires great courage for a doctor not to operate or not to recommend radiation or drugs. This is especially true if he knows that, if the patient dies anyway, relatives of the deceased could easily institute a malpractice suit against him on the grounds that he did not do all that he could have done. And, in light of the present abysmal ignorance about the true nature of cancer, it would be next to impossible for the doctor to convince either the judge or the jury that the patient would have died anyway, even without the "benefit" of surgery, radiation, or drugs. This is especially true if a spokesman for the American Cancer Society were called to the witness stand and unleashed the "statistic" of a million-and-a-half who, supposedly, are now alive only because of such treatments.

And so the physician cannot follow his own judgment or his conscience. He gets into far more trouble by prescribing a few non-toxic vitamins than by prescribing the most radical surgery or violent chemical poisons. All but the very brave toe the line. *That* is consensus medicine.

Consensus or no consensus, statistics or no statistics—cancer is a disease for which orthodox medicine does *not* have either a cure or control worthy of being called such. And the rate of cancer deaths continues to climb every year in spite of billions of dollars and millions of man-hours spent annually in search for even a clue. It is ironic that those who have failed to find the answer themselves spend so much of their time and energy condemning and harassing others who merely want the freedom to be able to choose an alternate approach.

Dr. Krebs often commented that using a Chinese prayer wheel would produce just as good or possibly better results than orthodox treatment. And that was not said in jest. To those of us in the West, the use of such a device would be viewed as the same as no treatment at all. But no treatment at all would at least spare us the deadly side-effects of radiation and chemical poisoning. In that sense, the medical results of a prayer wheel would compare quite favorably to those produced at the Mayo Clinic.

"Cancer," said Dr. Krebs, "is properly described as one of the last outposts of mysticism in medical science." He was referring to the great wall of ignorance and vested interest that still prevents large numbers of present-day scientists from objectively viewing the evidence around them. If they did so, many of them would have to admit that they have been wrong. It is a humbling experience for a man who has spent a lifetime learning complex surgical procedures, concocting elaborate chemical structures, or mastering monster ray machines to accept in the end that during all these years the answer was right under his nose—not as the product of his intelligence or technical skills—but in the form of a simple food factor found in the lowly apple seed. So he persists in his quest for the *complex* answer.

Just as we are amused today at the primitive medical practices of history—the trepanning of skulls, the bloodletting, the medicinal elixirs of dog hair, goose grease, or lizard blood—future generations will look back at our own era and cringe at the senseless cutting, burning, and poisoning that now passes for medical science.



National Health Federation

Part Two

THE POLITICS OF CANCER THERAPY

Chapter Thirteen

CARTELS — ESCAPE FROM COMPETITION

A review of the science of cancer therapy; a summary of the politics of cancer therapy; the early history of the I.G. Farben chemical and pharmaceutical cartel; the cartel's early success in the United States; and its "marriage" with DuPont, Standard Oil, and Ford.

In Part One we presented the science of cancer therapy. Before proceeding with Part Two, the *politics* of cancer therapy, let's review briefly the major points previously covered.

As we have seen, cancer is the unnatural and unchecked growth of trophoblast cells which, themselves, are a normal and vital part of the life process.

Trophoblast cells are produced in the body as a result of a chain reaction involving the hormone estrogen. Estrogen always is present in large quantities at the site of damaged tissue, possibly serving as an organizer or catalyst for body repair.

Cancer, therefore, can be triggered by any prolonged stress or damage to the body—whether it be smoking, or chemical additives to our food, or even certain viruses—for these are what trigger the production of estrogen as part of the normal healing process.

Nature, fortunately, has provided a metabolic barrier—a complex mechanism to limit and control the growth of these trophoblast cells. Many factors are involved, but the most direct-acting of them appear to be the pancreatic enzymes and the food factor known as a nitriloside or vitamin B₁₇, a unique compound that destroys cancer cells while nourishing and sustaining all others.

The answer to cancer, therefore, is to avoid excessive damage or stress to the body, to minimize foods that preempt the pancreatic enzymes for their digestion, and to maintain a diet rich in *all* minerals and vitamins—especially vitamin B₁₇.

Opposition to the nutritional concept of cancer is strong and vocal. This concept has been branded as fraud and quackery by the Food and Drug Administration, the American Cancer Society, and the American Medical Association.

It is important to stress again, however, that the average physician is not part of this opposition—except, perhaps, to the extent to which he trustingly accepts the official pronouncements of these prestigious bodies. Most doctors, however, would be more inclined to give Laetrile a try before passing final judgment. As a result, an increasing number of physicians all around the world now are testing and proving the value of vitamin therapy in their own clinics. Doctors in the United States, however, are forbidden both by law and by the pressure of peer review from experimenting with unorthodox therapies. Consequently, they are not able to find out if Laetrile works, only if it is *said* to work.

Meanwhile, with the evidence continuing to mount in favor of vitamin therapy, the opposition and the controversy also continue to grow. The reason is both simple and unpleasant. Cancer, in the United States at least, has become a multi-billion dollar business. Not only are fortunes made in the fields of research, drugs, and X-ray, but political careers are enhanced by promising ever larger tax-supported programs and government grants.

It is an ominous fact that, each year, there are more people making a living from cancer than are dying from it. If the riddle were to be solved by a simple vitamin found abundantly and inexpensively in nature, this gigantic commercial and political industry could be wiped out overnight. It is not unexpected, therefore, that vested interest should play an important role in clouding the scientific facts.

This does not mean that the surgeons, the radiologists, the druggists, the researchers, or the thousands of people who supply and support them would consciously withhold a control for cancer. They are, for the most part, highly motivated and conscientious individuals who would like nothing better than to put an end to human suffering. Furthermore, they and their families succumb to cancer the same as the rest of the population. Obviously, they are not keeping any secret cures to themselves.

But does it necessarily follow that *all* opposition is innocent? Are we to believe that personal gain or vested interest is not a factor *anywhere* along the line? The purpose of the second half of this presentation is to provide the answers to those questions. It will be demonstrated that, at the top of the economic and political pyramid of power there is a grouping of financial, industrial, and political interests that, by the nature of their goals, are the natural enemies of the nutritional approach to health. It will be shown that they have created a climate of bias that makes scientific objectivity almost an impossibility, and that they, themselves, often become the victims of their own bias.

It will be shown that these forces wield tremendous influence over the medical profession, the medical schools, and the medical journals; and that the average doctor is the last to suspect that much of his knowledge and outlook have been shaped subtly by these non-medical interests.

It will be shown, also, that this elite group can move long levers of political power that activate government agencies in their behalf; and that these agencies, which supposedly are the servants and protectors of the people, have become the mechanism of vested interest.

These are serious indictments. They are not made lightly, nor should they be accepted without challenge. So let us turn now to the record to see what evidence there is to support them.

The information that follows is taken primarily from government hearings and reports published by various Senate and House committees from 1928 to 1946. Principal among these are the House Subcommittee to Investigate Nazi Propaganda in 1934, the Special Senate Committee Investigating the Munitions Industry in 1935, the report on cartels released by the House Temporary National Economic Committee in 1941, the Senate Special Committee Investigating the National Defense Program in 1942, the report of the Senate Patents Committee in 1942, and the Senate Subcommittee on War Mobilization in 1946.

Other sources include the Senate Lobby Investigating Committee, the Senate Committee on Banking and Currency, court records of the Nuremberg trials, and dozens of volumes found as standard references in any large library. In other words, although the story that follows is not widely known, it is, nevertheless, part of the public record and can be verified by anyone. This is that story.

In the years prior to World War II, there came into existence an international cartel, centered in Germany, that dominated the world's chemical and drug industries. It had spread its operations to ninety-three countries and was a powerful economic and political force on all continents. It was known as I.G. Farben.

I.G. stands for *Interessen Gemeinschaft*, which means "community of interests" or, more simply, "cartel." Farben means "dyes," which, because the modern chemical industry had its origin in the development of dyestuffs, now is a deceptively innocent sounding category that, in reality, encompasses the entire field of chemistry, including munitions and drugs.

Munitions and drugs can be powerful human motivators. One offers the promise of health and prolonged life, while the other can be the carrier of death and destruction. There can be no greater earthly desire for men than to have the first but to avoid the second. He who controls munitions and drugs, therefore, holds the ultimate carrot and stick.

The basic ingredient for almost all chemicals—including those that wound as well as those that heal—is coal tar or crude oil. With the advent of the internal combustion engine, the value of these raw materials as the precursor of gasoline has given those who control their chemical conversions a degree of power over the affairs of the world that is frightening to contemplate. In other words, the present movement of civilization is driven by the engine of chemistry. But the fuel of chemistry is oil. Whereas gold once was the key to world power, now it is oil. And it has come to pass that it is the same men who now control both.

Howard Ambruster, author of *Treason's Peace*, summarizes:

I.G. Farben is usually discussed as a huge German cartel which controls chemical industries throughout the world and from which profits flow back to the headquarters in Frankfurt. Farben, however, is no mere industrial enterprise conducted by Germans for the extraction of profits at home and abroad. Rather, it is and must be recognized as a cabalistic organization which, through foreign subsidiaries and by secret tie-ups, operates a far-flung and highly efficient espionage machine—the ultimate purpose being world conquest—and a world superstate directed by Farben.¹

Much of the earlier scientific knowledge that made it possible for German industry to assume world leadership in the field of organic chemistry was the result of the pioneering genius of the

1. Howard Ambruster, *Treason's Peace*, (New York: Beechhurst Press, 1947), p. vii.

well known chemist, Justus von Leibig. It is an interesting coincidence that Leibig, shortly after he completed his university training in 1824, first attracted attention within the scientific community by publishing a paper on the chemical properties of the bitter almond, a substance rich in vitamin B₁₇. He identified the presence of benzaldehyde, an ingredient that acts against cancer cells, but there is no indication that he ever followed up these studies with particular application to cancer therapy.¹

I.G. Farben was created in 1926 by the dual genius of a German industrialist by the name of Hermann Schmitz and a Swiss banker by the name of Eduard Greutert.² Greutert's stock in trade was keeping "loose books" and creating financial mazes to conceal Farben ownership of companies. Schmitz was a director of the great Deutsche Reichsbank and of the Bank of International Settlements headquartered in Switzerland. And so, from the beginning, the leaders of I.G. Farben had been a part of the international banking structure.

By the beginning of World War II, I.G. Farben had become the largest industrial enterprise in Europe, the largest chemical company in the world, and part of the most powerful cartel in history.³ It would take over an hour just to read aloud the names of the companies around the world with which it had interlocking cartel agreements. There were, in fact, over 2,000 of them.⁴ When the list is narrowed to include just those companies which it owned or controlled *outright*, it still would fill many pages in a book. Here are just a few of the better known:

Inside Germany, the cartel included the top six chemical firms and extended to virtually all of heavy industry as well, especially the steel industry. Hermann Schmitz was a dominant figure in the Krupp Steel Works and was on its board of directors as well as on the board of the major steel combine, Vereinigte Stahlwerke.

1. Richard Sasuly, *I.G. Farben*, (New York: Boni & Gaer, 1947), p. 21.

2. Greutert was a German national also. His bank was located in Basel and was known as Greutert & Cie.

3. This was the opinion of the U.S. Department of Justice as expressed in *U.S. vs. Allied Chemical & Dye Corp. et. al.*, U.S. District Court of New Jersey, May 14, 1942.

4. General Eisenhower, as Supreme Commander in the American Zone of Occupation, reported that I.G. had stock interests in 613 corporations, including 173 in foreign countries, piled up assets of 6 billion Reichsmarks, and "operated with varying degrees of power in more than 2,000 cartels." See *New York Times*, Oct. 21, 1945, Sec. 1, pp. 1, 12.

All-in-all, more than 380 German firms were controlled by the cartel.

Elsewhere in Europe, I.G. Farben dominated such industrial giants as Imperial Chemical in Great Britain, Kuhlmann in France, and Allied Chemical in Belgium. Leslie Waller, in his *The Swiss Bank Connection*, provides this modest description:

Through the Basel connection, I.G. Farben spread out across the face of the globe widening its grasp of the chemical business by establishing thoroughly concealed interests in companies in Belgium, England, France, Greece, Holland, Hungary, Norway, Poland, Romania, various nations of South America, Sweden and the United States.¹

In the United States the cartel had established important agreements with a wide spectrum of American industry including Abbott Laboratories, Alcoa, Anaconda, Atlantic Oil, Bell and Howell, the Borden Company, the Carnation Company, Ciba-Geigy, Dow Chemical, DuPont, Eastman Kodak, Firestone Rubber, Ford Motor, General Drug Company, General Electric, General Mills, General Motors, General Tire, Glidden Paint, Goodyear Rubber, Gulf Oil, the M.W. Kellogg Company, Monsanto Chemical, National Lead, Nestle's, Owl Drug Company, Parke-Davis and Company, Pet Milk, Pittsburgh Glass, Proctor and Gamble, Pure Oil, Remington Arms, Richfield Oil, Shell Oil, Sinclair Oil, Socony Oil, Standard Oil, Texaco, Union Oil, U.S. Rubber, and hundreds more.

The list of companies which it owned outright or in which it had (or eventually would have) a dominant financial interest is equally impressive. It includes the Bayer Co. (makers of aspirin), American I.G. Chemical Corporation (manufacturers of photographic film and supplies), Lederle Laboratories, the Sterling Drug Company,, the J.T. Baker Chemical Company, Winthrop Chemical, Metz Laboratories, Hoffman-LaRoche Laboratories Whitehall Laboratories, Frederick Stearns and Company, the Nyal Company, Dern and Mitchell Laboratories, Chef-Boy-Ar-Dee Foods, Breck Inc., Heyden Anti-biotics, MacGregor Instrument Company, Antrol Laboratories, the International Vitamin Corp., Cardinal Laboratories, Van Ess Laboratories, the William S. Merrill Company, the Jensen Salsberry Laboratories, Loesser Laboratories, Taylor Chemical, the Ozalid Corporation,

1. Leslie Waller, *The Swiss Bank Connection*, (New York: Signet Books, New American Library, Inc., 1972), p. 162.

Alba Pharmaceutical, Bristol Meyers, Drug, Inc., Vegex, Inc., Squibb and Sons Pharmaceutical, and scores of others, many of which were large enough to be holding companies which, in turn, owned numerous smaller companies—and some not-so-small—as well.¹

By 1929, I.G. Farben had concluded a series of limited cartel agreements with its largest American competitor, the DuPont Company. DuPont was a major power in itself and it always had been reluctant to enter into cooperative ventures with Farben which usually insisted on being the dominant partner. Consequently, many of the agreements were made indirectly through Farben's subsidiary, Winthrop Chemical, through Imperial Chemical (its cartel partner in Great Britain), and through Mitsui, its cartel partner in Japan. By 1937, American I.G. had substantial stock holdings in both DuPont and Eastman Kodak. The Olin Corporation, a Farben holding, entered into the manufacture of cellophane under a DuPont license.

The primary reason that such an industrial giant as DuPont finally relented and entered into cartel agreements with I.G. is that Standard Oil of New Jersey had just done so. The combination of these two Goliaths presented DuPont with a serious potential of domestic competition. DuPont might have been able to stand firmly against I.G. alone, but it could not hope to take on both I.G. *and* the great Rockefeller empire as well. Standard Oil, therefore, was the decisive factor that brought together the ultimate "community of interest"—I.G., Standard Oil, Imperial Chemical, DuPont, and as we shall see, Shell Oil.

The agreement between I.G., Standard, and Shell was consummated in 1929. How it came about is a fascinating story and sheds considerable light on the behind-the-scenes maneuvers of companies that, in the public eye, are perceived as competitors.

One of the factors leading to Germany's defeat in World War I was its lack of petroleum. German leaders resolved never again to be dependent upon the outside world for gasoline. Germany may not have had oil deposits within its territory, but it did have

1. The listing of these firms does not imply illegality or impropriety. It is merely to establish the historical facts of either cartel contractual interlock or outright control. These facts can be verified by consulting back issues of standard business references such as *Standard and Poor's Corporation Records* and *Moody's Industrial Manual*. See also the findings of previous researchers in this field such as *Cartels in Action*, by Stocking and Watkins; *Treason's Peace*, by Ambruster; and *The Devil's Chemist*, by DuBois; all mentioned elsewhere in this study.

abundant reserves of coal. One of the first goals of German chemists after the war, therefore, was to find a way to convert coal into gasoline.

By 1920, Dr. Bergius had discovered ways to make large quantities of hydrogen and to force it, under great pressure, at high temperatures, and in the presence of specific catalysts, into liquid coal products. The final steps into refined gasoline were then assured. It was only a matter of perfecting the hydrogenation process. I.G. suddenly was in the oil business.

One might assume that the cartel would have eagerly gone into production. But the plan, instead, was to interest existing oil producers in their process and to use their patents as leverage to gain concessions and business advantages in other areas. This was to be the bait to ensnare Standard Oil which, in turn, would bring in DuPont. And it worked exactly as planned.

Frank Howard of Standard Oil was invited to visit the great Baldische plant at Ludwigshafen in March of 1926. What he saw was astounding—gasoline from coal! In a near state of shock, he wrote to Walter Teagle, president of Standard Oil:

Based upon my observations and discussions today, I think that this matter is the most important which has ever faced the company....

The Baldische can make high-grade motor oil fuel from lignite and other low-quality coals in amounts up to half the weight of the coal. This means absolutely the independence of Europe on the matter of gasoline supply. Straight price competition is all that is left....

I shall not attempt to cover any details, but I think this will be evidence of my state of mind.¹

The following three years were devoted to negotiation. The cartel agreement was signed on November 9, 1929 and it accomplished several important objectives: First, it granted Standard Oil one-half of all rights to the hydrogenation process in all countries of the world except Germany. This assured Standard that it would control, or at least profit from, its own competition in this field. In return, Standard gave I.G. 546,000 shares of its stock valued at more than \$30,000,000. The two parties also agreed not to compete with each other in the fields of chemistry and petroleum products. In the future, if Standard Oil wished to enter the field of industrial chemicals or drugs, it would do so

1. Sasuly, *I.G. Farben*, *op. cit.*, pp. 144–145.

only as a partner of Farben. Farben, in turn, agreed not to enter the field of petroleum except as a joint venture with Standard. Each party disavowed "any plan or policy" of "expanding its existing business in the direction of the other party's industry as to become a serious competitor of that other party."¹

As Frank Howard of Standard Oil phrased it:

The I.G. may be said to be our general partner in the chemical business.... The desire and intention of both parties is to avoid competing with one another.²

To facilitate the implementation of this agreement, several jointly owned companies were formed. One of these was the International Hydrogenation Patents Company (I.H.P.). Shell Oil also became a partner in this venture. Its purpose was *not* to promote the international use of the hydrogenation process, but to keep the lid on it as much as possible. An official Standard memorandum declared:

I.H.P. should keep in close touch with developments in all countries where it has patents, and should be fully informed with regard to the interest being shown in hydrogenation and the prospect of its introduction.... It should not, however, attempt to stir up interest in countries where none exists.³

The other jointly-owned company was created in 1930 and was known as Jasco, Inc. Its purpose was to allow each company to share in any future new chemical developments of the other. Under the agreement, whenever I.G. or Standard developed a new chemical process, it would offer to the other party an option to obtain one-third interest in the patent. Jasco then would exploit the marketing of that process throughout the world.

Here, then, was a perfect example of how two giant industrial empires came together, a step at a time, until eventually, in large areas of their activity, they were moving in unison as one. The goal of each simply was to remove all marketplace competition between themselves and assure that each had a secure guarantee of future growth and profit. Dr. Carl Bosch, head of I.G. at the time, was not merely being picturesque when he said that I.G. and Standard had "married." He was describing quite accurately the philosophical essence of all major cartel agreements.

1. George Stocking and Myron Watkins, *Cartels in Action*, (New York: The Twentieth Century Fund, 1946), p. 93.

2. As quoted by Ambruster, *Treason's Peace*, *op. cit.*, p. 52.

3. *Ibid.*, pp. 492, 493.

Space does not permit a detailed chronicle of all of I.G. Farben's polygamous marriages with other major U.S. firms, but at least two more should be mentioned in passing. On October 23, 1931, I.G. and Alcoa signed an accord, known as the Alig Agreement, in which the two companies pooled all their patents and technical knowledge on the production of magnesium. The other industrial giant that became part of the international web was none other than the Ford Motor Company.

When Henry Ford established a branch of his company in Germany, I.G. Farben immediately purchased most of the forty percent of the stock which was offered for sale. The marriage was completed when Carl Bosch, I.G.'s president, and Carl Krauch, I.G.'s chairman of the board, both joined the board of directors of the German Ford Company. In the United States, Edsel Ford joined the board of directors of the American I.G. Chemical Company, as did Walter Teagle, president of Standard Oil, Charles E. Mitchell, president of Rockefeller's National City Bank of New York, and Paul M. Warburg, brother of Max Warburg who was a director of the parent company in Germany.

Paul Warburg was one of the architects of the Federal Reserve System which placed control of the American monetary system into the hands of the same banking circles he represented. According to the memoirs of Frank Vanderlip, this scheme was hatched at a secret meeting on Jekyll Island in Georgia attended by Vanderlip himself, Senator Aldrich (both representing Rockefeller), Henry Davison, Charles Norton, and Benjamin Strong (representing J.P. Morgan), Abraham Piatt Andrew (from the Treasury), and Paul Warburg (representing the Rothschilds in England and France). Warburg's brother, Felix, married Frieda Schiff, the daughter of Jacob Schiff who headed the banking firm of Kuhn, Loeb, and Company.¹ Years later, according to his grandson John, Jacob Schiff had given twenty million dollars to Trotsky for use in establishing a Soviet Dictatorship in Russia.²

1. For the complete story of how the Federal Reserve System operates as a banking cartel under the guise of a government agency, read G. Edward Griffin's *The Creature from Jekyll Island; A Second Look at The Federal Reserve System* (Westlake Village, CA: American Media, 1995)

2. The comments by John Schiff first appeared in the Charlie Knickerbocker column of the *New York Journal American*, Feb. 3, 1949. See also the exclusive interview with Alexander Kerensky, leader of the Russian revolution, *U.S. News & World Report*, Mar. 13, 1967, p. 68.

There is much more of significance known about these men, but the bottom line is that they were more than mere businessmen looking for a means of expanding markets and securing profits. They were part of that special breed whose vision extends far beyond profit-and-loss ledgers to the horizons of international intrigue and politics.

To fully understand that aspect of their careers, it is necessary first to understand the nature of cartels. A cartel is a grouping of companies that are bound together by contracts or agreements designed to promote inter-company cooperation and, thereby, reduce competition between them. Some of these agreements may deal with such harmless subjects as industry standards and nomenclature. But most of them involve the exchange of patent rights, the dividing of regional markets, the setting of prices, and agreements not to enter into product competition within specific categories. Generally, a cartel is a means of escaping the rigors of competition in the open free-enterprise market. The result always is higher prices and fewer products from which to choose. Cartels and monopolies, therefore, are not the result of free enterprise, but the escape *from* it.

The motivation for businessmen to make cartel agreements is similar to that which leads laborers and skilled workers into trade unions and professional associations. They reason that by lowering the price on their product or their labor they might be able to attract a greater share of the existing market. But that is only true if others do not follow their example. It is reasonable to assume, however, that the competition *will* lower its prices also in order to avoid losing patronage. A price cut by one tends to lower the prices of all. A person is encouraged, therefore, to join with other firms or other workers and agree not to follow competitive policies that will impoverish all.

This does not mean that cartel members always succeeded in eliminating all conflict or competition. Occasionally a party to an agreement will decide that the terms of the agreement no longer are acceptable and it will break away and attempt to go it alone. Price wars and fierce contests for markets periodically erupt with all the overtones of military war itself. But, just as in the case of war between nations, eventually they come to an end. One party either is vanquished or, as is more often the case in business wars, one party clearly emerges with the dominant position, and then a

"truce" and a new negotiated cartel agreement is worked out on the basis of the new balance of power.

Stocking and Watkins, writing in *Cartels in Action*, describe this process succinctly:

"Price wars" broke out, were terminated by "armistices," recurrently flamed up again, and finally settled into a long siege....

Chemical companies usually decide who shall sell what, where, how much, and on what terms in foreign markets, by negotiation rather than by competition, because they believe that cooperation "pays." They reach their decisions by driving hard-headed bargains. Each party tries to obtain the best terms for itself. Thus these decisions reflect the relative bargaining power of the parties involved. This depends on many factors including the efficiency of their processes, strength of their patent positions, quality of their products, extent of their financial resources, and support of their governments. In the final analysis, the issue turns on the comparative readiness of the several parties for a competitive "war" if negotiations break down.

This kind of business rivalry differs from effective competition in that the bulk of its benefits are likely to go to the cartel members rather than to the consumers.¹

This is an accurate description of the hidden reality behind most of the world's major products today. Stocking and Watkins made extensive calculations of pre-war trade and proved quite convincingly that, in the United States, in the year 1939, cartels controlled eighty-seven percent of the mineral products sold, sixty percent of agricultural products, and forty-two percent of all manufactured products. Needless to say, the trend has greatly accelerated since 1939, so one can well imagine what the situation is like today. The chemical industry—and that includes pharmaceuticals—is completely cartelized. Even as far back as 1937, this fact was so obvious that *Fortune* magazine editorialized:

The chemical industry, despite its slowly lowering curve of real prices, is an "orderly" industry. It was practicing "cooperation" long before General Johnson invented it in 1933. It has seldom been bedeviled by over production, has had no private depression of its own, and has not often involved itself in long or bloody price wars.... By and large, the chemical industry has regulated itself in a manner that would please even a Soviet Commissar.... The industry ... is ... the practitioner of one definite sort of planned economy.²

1. Watkins, *op. cit.*, pp. 398, 420.

2. "Chemical Industry," *Fortune*, Dec., 1937, pp. 157, 162.

This is reminiscent of the sentiments expressed in 1973 by the United States Tariff Commission. In its report to the Senate, it said:

In the largest and most sophisticated multinational corporations, planning and subsequent monitoring of plan fulfillment have reached a scope and level of detail that, ironically, resemble more than superficially the national planning procedures of Communist countries.¹

The comments about resembling the planned economy of a Soviet Commissar in a Communist country are quite "on target." They shed a great deal of light on the inherent philosophy of cartels. If it is true that cartels and monopolies are not the result of free enterprise but the escape *from* it, then it follows that the best way to escape free enterprise is to destroy it altogether. This is why cartels and collectivist governments inevitably work together as a team. They have a common enemy and share a common objective: the destruction of free enterprise.

A million dollars put into politics to bring about the passage of a protective tariff law, a so-called fair-trade law, or an anti-quackery law, is a tremendous bargain for those who benefit. Even though these laws are masqueraded as being for the benefit of the people, in reality they are a means of putting the machinery of government into motion against cartel competitors. They produce a return on the original investment many times over. Big government, therefore, with its capacity to regulate every facet of economic life, is the natural friend and ally of cartels and monopolies.

Cartels and monopolies, without the help of government, would be hard-pressed to exist, at least at the level they do now. Look at any of the major world markets—in sugar, tea, chocolate, rubber, steel, petroleum, automobiles, food—*any* of them, and one will find a mountain of government restrictions, quotas, and price supports. And scampering all over this mountain, there is an army of lobbyists, representing special interests, applying pressures on politicians who, in turn, endorse the laws that, supposedly, are designed to protect the people.

Cartels are not alone in this racket. Organized labor sought the escape from free-market competition when it demanded

1. Report entitled *Implications of Multinational Firms for World Trade and Investment for U.S. Trade and Labor*, Feb. 1973, p. 159.

government-enforced minimum wage laws and the closed shop. Farmers did the same with price supports and subsidies. It seems that, increasingly of late, almost everyone wants the government to step in and "protect" him from the rigors of open and honest competition. The cartels are no different in this except that they were ahead of most of the others, have more money to spend, and have perfected the art to its ultimate state.

It is not merely a question of prestige, therefore, but a matter of pure necessity that large multinational corporations often have prominent political figures on their boards. ITT, for example, has displayed on its main board in New York such significant names as Eugene Black, former head of the World Bank, and John McCone, former director of the Central Intelligence Agency. In Europe it has had such figures as Trygve Lie, first Secretary-General of the United Nations, Paul-Henri Spock of Belgium, and Lord Caccia of Britain. There was even an attempt to recruit Prime Minister Harold McMillan.¹

It is no coincidence that all of the above-named individuals are self-classified either as socialists or, at the very least, political liberals. None of them would be caught dead advocating the free enterprise system. They know that the road to wealth now is traveled, not by the carriage of industrial expertise, but by the sport car of political influence. Government is where the action is.

The consequences can be seen everywhere—especially in the world of international finance. The situation was aptly described in the January 1973 *Monthly Review* of the Bank of Hawaii:

There appears to be no ready answer to the complex interrelated domestic and international developments. Those standing to lose the most include the individuals who seek to establish their own business and those independent domestic firms seeking to compete in the traditional open market place. They face increasing regimentation through bureaucratic red tape and preempted markets by federally subsidized competition.

Virtually immune are the multi-national corporations whose massive investments abroad, and effective lobbying positions, and allegiance to a world market unobstructed by local government and competition, place them in a position to not only straddle these developments but to encourage them.

1. Anthony Sampson, *The Sovereign State of ITT*, (New York: Stein & Day, 1973), pp. 113, 114.

Ferdinand Lundberg, in his book, *The Rich and the Super Rich*, put aside his Leftist clichés about the “exploitation of the working class,” and his outspoken apologies for the Soviet system long enough to recognize certain truths, or half-truths at least, about the American system. He wrote, almost with glee:

The restriction of free enterprise has also come principally from businessmen who have constantly sought to increase government regulation in their own interest, as in the case of tariffs, subsidies, and prohibition of price-cutting on trademarked items.

In fact, the interests of businessmen have changed to a considerable extent from efficiency in production, to efficiency in public manipulation, including manipulation of the government for attainment of preferential advantages....

As everything thus far inquired into has obviously flowed under the benign providence of government, it is evident that, government and politics have more than a little to do with the gaudy blooms of extreme wealth and poverty in the feverish American realm.¹

All of which is true; but it is not all that is true. There are two traps that can ensnare the unwary observer of these trends. The first is the hasty conclusion that cartels and monopolies are an expression of capitalism or free enterprise, and that the solution to the problem lies in the replacement of capitalism with some other kind of system. As we have emphasized, however, cartels and monopolies are just the opposite of competitive capitalism and free enterprise.

The second trap is the conclusion that the solution for the abuses of cartels and monopolies is to be found in the increase of government regulations and controls. But that is precisely the problem already. It simply is not humanly possible to draw up a new law or combination of laws granting increased power to government, supposedly to regulate commerce and to *prevent* monopoly and their political puppets, without accomplishing just the opposite of its stated objective.

Current anti-trust laws are a perfect example. More often than not, they end up merely being the instruments whereby one business group uses the power of government to suppress or hinder its less politically influential competitors. *Bigger and stronger government is not the solution, it is the problem!*

1. Ferdinand Lundberg, *The Rich and the Super-Rich*, (New York: Bantam, 1968), pp. 153, 154, 584.

Lundberg, like many other writers in this field, fell victim to both traps. He recognized that monopoly was not free enterprise. He even saw that government was the inseparable partner of monopoly. But, having done so, he then turned around and opened the door for a move into bigger government, and even a "forward" step into Communism itself:

We cannot go back to competition. We must go forward to some new system, perhaps Communism, perhaps cooperativism, perhaps much more complete governmental regulation than we now have. I don't know what lies ahead and I am not particularly concerned....¹

There, in a nutshell, is the likely reason that Mr. Lundberg's amazingly dull and oversized book (1009 pages) has been pushed into the bestseller list by the very Establishment which, on the surface at least, he supposedly condemns. If men like Lundberg would only stop to wonder why they are hired to teach at Establishment universities, and why their books are eagerly sought by Establishment publishers, and why they are in demand for TV and radio appearances on Establishment networks, and why they receive generous financial grants from Establishment foundations, they might begin to catch on. The "super-rich" do not particularly care if their vast wealth and power is exposed so long as nothing practical is done to weaken that power.

If anyone has to be publicly recognized as a crusader against them, how much better it is to have someone like Lundberg, rather than an individual who *also* is a foe of big government. There is a phalanx of government-worshipping intellectuals now leading the American people in their struggle against the increasingly oppressive Establishment. Yet, the Establishment calmly tolerates them and even sponsors them in their efforts. As long as they can view "much more complete government regulation" or even Communism as a step "forward," they are no threat. To the contrary, the continued concentration of government power into the hands of a few—until it is *total* power—is exactly what the world's "super-rich" are determined to achieve.

1. *Ibid.*, p. 154.

Chapter Fourteen

THE ULTIMATE MONOPOLY

Early examples of cartel support for totalitarian regimes; I.G. Farben's role in lifting Hitler out of political oblivion and converting the Nazi state into an instrument of cartel power.

At this point in our survey, the reader may wonder what all of this has to do with the politics of cancer therapy. The answer—as will become evident further along—is that it has *everything* to do with it. The politics of cartels and monopolies can be likened to a football game with specific goals and rules. If one who had never heard of football before came across two teams playing on the field, and if he knew nothing at all about the sport, he would be totally confused as to what was going on. Likewise, we can look at the actions of giant corporations and government agencies but, if we are unaware of the rules that determine the play, we will never be able to understand why things happen as they do, or even be able to tell what is happening in the first place.

As outlined in the previous chapter, cartels and monopolies result from an effort to escape the rigors of free enterprise. In the long run, the best way to do that is to enlist the aid of government, to seek the passage of laws that will put the regulatory power of the state on the side of the business venture and against its competition.

An individual or a corporation can succeed in breaking the cartels if they are determined and talented enough and can raise the necessary capital. The capital is relatively easy if the promise of profits is great—as it *will* be if the cartel's marketing and pricing policies are far out of line. If they are not out of line, then the harm they do is relatively small and there is no pressing need to disrupt them.

It follows, therefore, that cartels and monopolies could not flourish as they do if they existed in a political environment of limited government. Conversely, the more extensive the power of government, and the more it is accepted by its citizens as the proper regulator of commerce, then the more fertile is the ground for the nourishment and growth of monopolies and cartels.

It follows, also, that if *big* government is good for cartels, then *bigger* government is better, and *total* government is best. It is for this reason that, throughout their entire history, cartels have been found to be the behind-the-scenes promoters of every conceivable form of totalitarianism. They supported the Nazis in Germany; they embraced the Fascists in Italy; they financed the Bolsheviks in Russia. And they are the driving force behind that nameless totalitarianism that increasingly becomes a grim reality in the United States of America.

At first glance, it seems to be a paradox that the "super rich" so often are found in support of socialism or socialist measures. It would appear that these would be the people with the most to lose. But, under socialism—or any other form of big government—there is no competition and there is no free enterprise. This is a desirable environment if one is operating a cartelized industry and also has powerful political influence "at the top." That way, one can make larger profits and be part of the ruling class as well. These people do not fear the progressive taxation scheme that oppresses the middle class. Their political influence enables them to set up elaborate tax-exempt foundations to preserve and multiply their great wealth with virtually no tax at all. This is why monopolists can never be true capitalists.

In the narrow sense of the word, a capitalist merely is a person who believes in the concept of private ownership of property. But that is not an adequate definition for a clear understanding of the ideological conflicts between the term capitalism, as it generally is used, and opposing concepts such as socialism or communism. In many primitive tribes there supposedly is no such thing as private property. Theoretically, all things are held by the chief on behalf of his followers. The net result, though, is that the property belongs to the chief, because he can do with it whatever he pleases. Freedom of use is the test of ownership. If you think you own a piece of property but cannot use it without permission from someone else, then you do not own it, *he* does. The extent to which you do not have control over

your own property is the extent to which someone else has a share of ownership in it. So the chief owns all the property, and that theory about holding it on behalf of his followers is just a ruse to keep them more or less content with the situation.

Likewise, our own TVA (Tennessee Valley Authority) and the national parks supposedly are owned by "the people." If you really think you own a part of them, however, just try to sell your share. The TVA, the national parks, and all the other "public" property is owned by those who determine how it is to be used. Which means they are owned by the politicians and the bureaucrats—and the people who hold financial power over them.

In communist and socialist countries, almost all property supposedly is owned by "the people"—which means by the three percent who are members of the ruling elite. In the final analysis, *everyone* is a capitalist. All desirable property is owned by someone. And some of the world's greatest wealth is very privately owned by communists and socialists who loudly condemn the "evil" doctrine of capitalism.

So just owning property does not make one a capitalist. The more classical and correct use of the word should include the additional concept of free enterprise, the open marketplace with an absence or a minimum of government intervention. It is with this connotation that the word *capitalist* is used here.

Returning to our point of departure, monopolists never can be free-enterprise capitalists. Without exception, they embrace either socialism or some other form of collectivism, because these represent the ultimate monopoly. These government-sponsored monopolies are tolerated by their citizens because they assume that, by the magic of the democratic process and the power of their vote, somehow, it is they who are the benefactors. This might be true *if* they took the trouble to become informed on such matters, and *if* they had independent and honest candidates from which to choose, and *if* the political parties were not dominated by the super-rich, and *if* it were possible for men to win elections without vast sums of campaign money. In other words, these monopolies theoretically could work to the advantage of the common man on some other planet, with some other life form responding to some other motives, and under some other political system. As for us Earthlings, forget it.

The reality, therefore, is that government becomes the tool of the very forces that, supposedly, it is regulating. The regulations,

upon close examination, almost always turn out to be what the cartels have agreed upon beforehand, except that now they have the police power of the state to enforce them. And it makes it possible for these financial and political interests to become secure from the threat of competition. About the only time that these regulations are used to the actual detriment of any of the multi-national companies or financial institutions is when they are part of the internal struggle of one group maneuvering for position or attempting to discipline another group. The "people" are *never* the benefactors.

One of the earliest examples of cartel support for totalitarian regimes occurred in Germany even before World War I. Those cartels which, later, were to join together into the I.G. Farben, supported Bismarck because they saw in his collectivist philosophy of government an excellent opportunity to gain favoritism in the name of patriotism.

Bismarck was the first to introduce socialized medicine as we know it in the modern world. He recognized that its appeal among the masses would make it an ideal opening wedge leading to more control over the rest of the economy later on. It was his view that socialized medicine would lead the way to a socialized nation. It was a pilot program studied and imitated by all the world's totalitarians in succeeding years.¹ And fascism was no exception.

In 1916, while still under the regime of Kaiser Wilhelm, an official of I.G. Farben, named Werner Daitz, wrote an essay that was printed and widely distributed by the cartel. In it he said:

A new type of state socialism is appearing, totally different from that which any of us have dreamed or thought of. Private economic initiative and the private capitalist economy will not be crippled, but will be regimented from the points of view of state socialism in that capital will be concentrated in the national economy and will be directed outward with uniform impetus.... This change in capitalism demands with natural peremptoriness a reconstruction of a former counterpoise, international socialism. It breaks this up into *national socialism*.²

1. For background on Bismarck's first government health insurance program and its ultimate incorporation into the programs of the International Labor Organization (ILO), see Marjorie Shearon's *Wilbur J. Cohen: The Pursuit of Power*, (Shearon Legislative Service, 8801 Jones Mill Rd., Chevy Chase, MD., 20015, 1967), pp. 3-8.

2. Sasuly, *I.G. Farben*, *op. cit.*, p. 53.

Here is a rare glimpse into the cartel mind. Note that, in the "new" socialism, there will be no conflict with economic initiative (for the cartels) and no threat to a "private capitalist economy" (meaning the private ownership of wealth, *not* the free enterprise system). Capital will be "regimented" and "concentrated in the national economy and directed outward with uniform impetus" (controlled by government according to cartel priorities). The change will require a "reconstruction of a former counterpoise, international socialism" (an acceptance of certain features of Marxian communism which the cartels previously opposed). And we must not only embrace the *international* socialism of Marx, but we must apply it differently to each country on the basis of *national* socialism (Nazism, fascism, or any other purely national manifestation of socialism).

Eighteen years later, the theoretical stratagem had become the reality. On September 30, 1934, Farben issued a report that declared: "A phase of development is now complete which conforms to the basic principles of national socialist economics."¹

The encyclopedia reminds us that national socialism is the term used in Germany to identify the goals of the Nazi party. In fact, the party's complete name was the National Socialist German Workers' Party (NSDAP). But Nazism was also identified with the fascism of Mussolini, and the two terms have come to be interchangeable. Although the two did differ in some minor respects, they both were merely local manifestations of *national* socialism, and were, consequently, totalitarian regimes regardless of the labels.

The dictionary definition of fascism is government control over the means of production with ownership held in private hands. That definition may satisfy the average college exam in political science, but falls far short of telling the whole story. In reality, the twentieth century fascism of Germany was private monopolist *control over the government* which then *did* control industry, but in such a way as to favor the monopolists and to prevent competition.

The American economist, Robert Brady, has correctly described the German fascist state as "a dictatorship of monopoly capitalism. Its 'fascism' is that of business enterprise organized on

1. *Scientific and Technical Mobilization*, Hearings before the Kilgore Subcommittee of the Senate Committee on Military Affairs, Pt. XVI, p. 1971.

a monopoly basis and in full command of all the military, police, legal and propaganda power of the state."¹

Stocking and Watkins summed it up this way:

The German chemical industries came as close to complete cartelization as the combined efforts and organizational talents of German business and a Nazi state could achieve—and that was close, indeed. Even before 1933, industrial syndicalization had progressed far, perhaps farthest of all in chemicals. Fascism merely completed the program and integrated the entire structure.... In the cartels which the Nazi state set up over German industry, it was often hard to determine where state control ended and cartel control began. Totalitarianism ultimately involved almost complete unification of business and state.²

This unification did not happen as a result of blind, natural forces. It came about as a result of long and patient efforts on the part of cartel leaders, plus the corruptibility of politicians, plus the abysmal naiveté of the voters. Long before Hitler became a national figure, the cartel had been the dominant force, behind the scenes, in a long succession of German governments. Farben's president, Hermann Schmitz, had been a personal advisor to Chancellor Bruening. Dr. Karl Duisberg, I.G.'s first chairman, (also founder of the American Bayer Co.) and Carl Bosch, Schmitz's predecessor as president of I.G., created a secret four-man Political Committee for the purpose of forcing a controlling link with *each* of Germany's political parties. At the Nuremberg trials, Baron von Schnitzler testified that I.G. did not hesitate to use plenty of hard cash in its role of hidden political manipulator. He estimated that each election cost the cartel about 400,000 marks—which in the 1930's was a considerable expenditure. But in this way, the cartel was protected no matter who was victorious in the political arena.³

As early as 1925, the cartel was setting the pace for German politics. In a speech to the central organization of industry, the Reichsverband der Deutschen, Karl Duisberg explained:

1. Sasuly, I. G. Farben, *op. cit.*, p. 128.

2. Stocking and Watkins, *Cartels in Action*, *op. cit.*, pp. 411, 501.

3. A parallel to the hidden manipulation of American political parties is both obvious and ominous. For the author's analysis of this situation, see his *The Capitalist Conspiracy*, (Westlake Village, CA: American Media, 1971). Also see his *The Creature from Jekyll Island; A Second Look at The Federal Reserve*, from American Media, 1995.

Be united, united, united! This should be the uninterrupted call to the parties in the ... Reichstag.... We hope that our words of today will work, and will find the strong man who will finally bring everyone under one umbrella for he [the strong man] is always necessary for us Germans, as we have seen in the case of Bismarck.¹

At first, the cartel was not convinced that Hitler was the "strong man" that would best serve their purposes. But his program of national socialism and his ability to motivate large crowds through oratory singled him out for close watching and cautious funding. Although certain leading members of the trust had cast their lot with Hitler as early as 1928, it wasn't until 1931 that the cartel officially began to make sizable contributions to the Nazi war chest. Max Ilgner, a nephew of Hermann Schmitz, was the first to establish a close and personal contact with Hitler. Ilgner generally was referred to as I.G.'s "Director of Finance." His real function, however, was as head of the organization's international spy network. Originally conceived as a means of gathering information about competitive business ventures, it expanded rapidly into a politically oriented operation that seldom has been equalled even by the efficient intelligence agencies of modern governments. As Sasuly observed:

So complete was the coverage of every important aspect of conditions in foreign countries, that Farben became one of the main props of both Wehrmacht and Nazi Party intelligence.... What is remarkable is the fact that the Supreme Command of the Army, which boasted of having the most highly-developed staff in the world, should call on a private business concern to do this work for it. Even more remarkable is Ilgner's own admission that *relations with the OKW [Army Supreme Command] began as far back as 1928*.²

In the following years, even closer ties were to be established by an I.G. official named Gattineau. Gattineau had been the personal assistant of Duisberg and, later, of Bosch. He also acted as I.G.'s public-relations director.

In the fall of 1932, the Nazi Party began to lose ground badly. Yet, out of all the contesting groups, the Nazis were most suitable to Duisberg's plans. So, at the crucial moment, the entire weight of the cartel was thrown in Hitler's direction. The initial financial contribution was three million marks! And much more was to follow.

1. Sasuly, *I. G. Farben, op. cit.* p. 65.

2. *Ibid.*, pp. 97, 98.

As Sasuly described it:

Hitler received backing more powerful than he had ever dared hope for. The industrial and financial leaders of Germany, with I.G. Farben in the lead, closed ranks and gave Hitler their full support.... With that backing, he quickly established a blood-thirsty fascist state.¹

Not only did the money arrive in what seemed like unlimited quantities, but many of the leading German newspapers, which were either owned by or beholden to the cartel because of its advertising accounts, also lined up behind Hitler. In this way, they created that necessary image of universal popularity that, in turn, conditioned the German people to accept him as *the* great leader. Germany's strong man had suddenly appeared.

Even in the United States this same heavy-handed tactic was used. If an American newspaper was unfriendly to the Nazi regime, I.G. withheld its advertising—which was a tremendous economic lever. In 1938, I.G. sent a letter to Sterling Products, one of its American subsidiaries, directing that, in the future, all advertising contracts must contain "... a legal clause whereby the contract is immediately cancelled if overnight the attitude of the paper toward Germany should be changed."²

As previously stated, Schmitz had been the personal advisor to Chancellor Bruening. After Hitler came to power, he became an honorary member of the Reichstag and also a *Geheimrat*, a secret or confidential counselor. Another Farben official, Carl Krauch, became Goering's trusted advisor in carrying out the Four-Year Plan. But, as a matter of policy, the leaders of the cartel avoided taking official government positions for themselves, even though they could have had almost any post they desired. In keeping with this policy, Schmitz repeatedly had declined the offer to be named as the "Commissar of German Industry."

The Nazi regime was the Frankenstein monster created by Farben. But Farben was, at all times, the master, in spite of shrewd efforts on its part to make it look to outsiders as though it had become the helpless victim of its own creation. This was extremely wise, as was demonstrated later at the Nuremberg trials. Almost all of these men were deeply involved with the determination of Nazi policies throughout the war—and even

1. *Ibid.*, pp. 63, 69.

2. *Ibid.*, p. 106.

had coordinated the operation of such concentration camps as Auschwitz, Bitterfeld, Walfen, Hoechst, Agfa, Ludwigshafen, and Buchenwald for the value of the slave labor they provided. They built the world's largest poison-gas industry and used the product experimentally on untold thousands who perished in those camps.¹

In May of 1941, Richard Krebs, who had been first a Communist and then a Nazi (and subsequently turned against both),² testified before the House Committee on Un-American Activities and said:

The I.G. Farbenindustrie, I know from personal experience, was already in 1934 completely in the hands of the Gestapo. They went so far as to have their own Gestapo prison on the factory grounds of their large works at Leuna and ... began, particularly after Hitler's ascent to power, to branch out in the foreign field through subsidiary factories.³

At the Nuremberg trials, however, the leaders of Farben were dismissed by the judges, not as Nazi war criminals like their underlings who wore the uniforms, but as over-zealous businessmen merely in pursuit of profits. At the conclusion of the trials, a few were given light sentences, but most of them walked out of the courtroom scot-free. Yes, their strategy of remaining behind the scenes was wise, indeed.

One cannot help drawing parallels to political realities in the United States. More and more, we are learning that the men who wield the greatest power in America are, not those whose names appear on our ballots, but those whose signatures appear on the bottoms of checks—particularly when those checks are for campaign expenditures.

From time to time, the operations of these *finpols* (financier-politicians) are exposed to public view, and, for a fleeting second, we see their presence in every sphere of government activity. Time and again we have learned of some private sector wielding undue influence in foreign policy, monetary decisions, farm

1. For an excellent account of Farben's role in administering these camps, see *The Devil's Chemists*, by Josiah E. DuBois, Jr., legal counsel and investigator for the prosecution at the trial of I.G. Farben's leaders at Nuremberg, (Boston: Beacon Press, 1952).

2. See Krebs' own personal account, written under the pen name of Jan Valtin, entitled *Out of the Night* (New York: Alliance Book Corp., 1941). Richard Krebs is not related to Dr. Ernst T. Krebs, Jr.

3. As quoted by Ambruster, *Treason's Peace*, *op. cit.*, p. 273.

programs, labor laws, tariffs, tax reform, military contracts, and, yes, even cancer research. We are assured, however, that these manipulators are just businessmen. They are not politically motivated for, otherwise, they would run for office or would accept appointments to important public posts. If they have any political ideology at all, undoubtedly, they must oppose socialism because, see, they are rich capitalists! They may be guilty of greed and a little graft, but nothing more serious than that.

Let us hope that the memory of Auschwitz and Buchenwald will dispel such nonsense while there still is time.